Optimising measures of endothelial function to assess the effects of lifestyle interventions by Greyling, J.C.A.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/161239
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.

Optimising measures of endothelial 
function to assess the effects of 
lifestyle interventions 
 
 
 
Arno Greyling 
  
  
 
 
 
 
 
 
 
 
 
 
ISBN 
978-94-028-0407-2 
Cover artwork, design & layout 
Arno Greyling 
 
Print 
Ipskamp Printing, Nijmegen 
 
The work presented in this thesis was financially supported by Unilever Research and 
Development Vlaardingen. Mr. Greyling and Dr. Zock are employees of Unilever. 
 
© 2016, J.C.A. Greyling  
Optimising measures of endothelial 
function to assess the effects of 
lifestyle interventions 
 
 
Proefschrift 
ter verkrijging van de graad van doctor  
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,  
volgens besluit van het college van decanen  
in het openbaar te verdedigen op maandag 12 december 2016  
om 12.30 uur precies 
 
door 
Johannes Cornelis Arnoldus Greyling 
geboren op 8 oktober 1981 
te Groblersdal, Zuid-Afrika  
Promotoren 
Prof. dr. D.H.J. Thijssen (Liverpool John Moores University, Verenigd Koninkrijk) 
Prof. dr. M.T.E. Hopman 
 
Copromotor 
Dr. P.L. Zock (Unilever Research and Development, Vlaardingen) 
 
Manuscriptcommissie 
Prof. dr. G.A.P.J.M. Rongen 
Prof. dr. ir. C.L. de Korte 
Prof. dr. J.M. Geleijnse (Wageningen University & Research)  
Table of Contents 
Chapter 1 General introduction and outline of this thesis 7 
Chapter 2a Time for reference values and high-quality measurement to assess 
endothelial function?  International journal of clinical practice. 
2016;70:292 
33 
Chapter 2b Adherence to guidelines strongly improves reproducibility of 
brachial artery flow-mediated dilation.  Atherosclerosis. 
2016;248:196-202 
39 
Chapter 2c Assessing the perceived quality of brachial artery Flow Mediated 
Dilation studies for inclusion in meta-analyses and systematic 
reviews: Description of data employed in the development of a 
scoring; tool based on currently accepted guidelines.  Data in brief. 
2016;8:73-77 
59 
Chapter 3 Impact of volunteer-related and methodology-related factors on the 
reproducibility of brachial artery flow-mediated vasodilation: 
Analysis of 672 individual repeated measurements.  Journal of 
hypertension. 2016;34:1738-1745 
67 
Chapter 4 Elevation in blood flow and shear rate prevents hyperglycemia-
induced endothelial dysfunction in healthy subjects and those with 
type 2 diabetes.  Journal of applied physiology. 2015;118:579-585 
91 
Chapter 5 The effect of black tea on blood pressure: a systematic review with 
meta-analysis of randomized controlled trials.  PLoS One. 2014 Jul 
31;9(7):e103247 
113 
Chapter 6 The acute effect of black tea consumption on resistance artery 
endothelial function in healthy subjects.  Submitted 
133 
Chapter 7 Effects of wine and grape polyphenols on blood pressure, 
endothelial function and sympathetic nervous system activity in 
treated hypertensive subjects.  J Funct Foods. Accepted 
153 
Chapter 8 General discussion 181 
 English Summary / Nederlandse Samenvatting 203 
 Acknowledgements (Dankwoord) 213 
 List of publications / Curriculum Vitae 217 
 
 
  
 Chapter 1 
General introduction and outline of this thesis 
Published as a book chapter in adapted form as: 
Arno Greyling, Maria T. Hopman and Dick H.J. Thijssen. Chapter 12: Endothelial function in health and disease.  
(in Berbari, A and Mancia, G, Arterial Disorders: Definition, Clinical Manifestations, Mechanisms and 
Therapeutic Approaches, Springer International Publishing, 2015) 
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General Introduction 
“It has been said that one is as old as one’s arteries.  In view of the supreme importance of 
endothelium in arterial function I would like to modify, or rather simplify, this statement by saying 
that one is as old as one’s endothelium.” 1 
Dr. Rudolf Altschul prefaced his book “Endothelium: Its Development, Morphology, Function 
and Pathology” with this statement. Embedded in our current knowledge, this statement 
seems like an open door. However, it was made in 1954, a time during which relatively little 
was known on the subject. This contrasts with contemporary interest in the endothelium, 
supported by the publication of approximately ten thousand publications by 2014.  
Since the discovery of the endothelium by Friedrich von Recklinghausen in mid-1800, 
appreciation of the morphology and functions of the endothelium saw slow progress. 
Notable milestones include the definition of Starling’s "Law of capillary exchange" which 
established the endothelium as a selectively permeable barrier,2 and the use of electron 
microscopy which enabled assessment of the endothelium’s ultrastructure. Only recently, 
has it been found that the endothelium produces vasoactive substances. Prostacyclin was 
discovered in in 19763 and followed by the Nobel-prize winning work from Robert Furchgott 
who discovered the endothelium’s ability to produce nitric oxide in 1980.4 
We now know that the deceptively simple appearance of this single layer of cells belies the 
fact that it is ‘the largest endocrine gland in the body’5 with myriad of complex functions that 
play an integral part in vascular homeostasis. In this chapter, I will first focus on the role of 
the vascular endothelium in physiology and pathological processes. Secondly, I will provide 
an overview of the outline of this thesis, with a description of the various techniques 
employed. 
Physiological functions of the endothelium 
The endothelium forms a barrier between blood-borne cells and macro-molecules and the 
underlying artery wall. Its permeability and integrity is regulated by transcellular (through 
endothelial cells) and paracellular (between endothelial cells) passage mechanisms. 
Transcellular transport takes place via transport vesicles (e.g. caveolae and vesiculo-
vacuolar organelles) and is the primary means by which albumin, lipids, steroid hormones, 
and fat-soluble vitamins cross the endothelium. Transport vesicles can also fuse into 
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channels that traverse single cells, allowing the passage of leukocytes and solutes.6 
Furthermore, specialised fenestrae are present that control transcellular permeability to 
water and solutes. Paracellular transport occurs through the coordinated opening and 
closure of endothelial cell-cell junctions. Endothelial cell junctions also regulate contact-
induced inhibition of cell growth, apoptosis, gene expression and new vessel formation.7 The 
importance of controlling permeability is highlighted by the observation that increases in 
the permeability of the endothelium, which is linked to endothelial dysfunction, aids in the 
formation and progression of atherosclerosis.8 
In addition to the ‘barrier function’, the endothelium controls maintenance of vascular 
homeostasis. Through the autocrine secretion of substances, it exerts bi-directional control 
to form a finely-balanced interdependent system (Figure 1).9 The most important functions 
of the endothelium include: 1. regulation of vascular tone, 2. control of thrombosis and 
haemostasis, 3. immune and inflammatory responses, and 4. facilitation of vascular growth, 
repair and remodelling. These functions of the endothelium are discussed below. 
Regulation of vascular tone 
Nitric Oxide   
The endothelium regulates vascular tone through the rapid synthesis of vasodilators and 
vasoconstrictors (Figure 1). Nitric oxide (NO) is an important and powerful vasodilator, 
produced by the endothelium as a soluble gas with a short half-life (6-30 s in the artery wall 
and a few seconds in blood). Its production involves a two-step oxidation of L-arginine to L-
citrulline, with concomitant production of NO. This reaction is catalysed by NO-synthases 
(NOS) with the aid of cofactors, including tetrahydrobiopterin and nicotinamide adenine 
dinucleotide phosphate (NADPH) (Figure 1). The NOS family plays a central role in the 
production of NO and consists of three different isoforms named after the tissues in which 
they were first identified: the neuronal (nNOS), inducible- (iNOS) and endothelial (eNOS) 
isoforms. Many tissues can express more than one isoform and all three may be constitutive 
or inducible.10 Nonetheless, eNOS is the predominant form in endothelial cells and is the 
main source of endothelium-derived NO. eNOS is constitutively expressed and continuously 
produces small amounts of NO. eNOS can be stimulated by various hormones as well as 
hemodynamic factors. These stimuli induce an increase in intercellular Ca2+ that displaces 
the inhibitor caveolin from calmodulin to activate eNOS.  
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Figure 1. The endothelium is responsible for a number of physiological functions, including: 1) 
regulation of vascular tone; 2) control of blood fluidity and coagulation; and 3) regulation of 
inflammatory processes (derived from9). cAMP = cyclic adenosine monophosphate; cGMP = cyclic 
guanosine monophosphate; COX = cyclooxygenase; BH4 = tetrahydrobiopterin; IL = interleukin; TNF 
= tumor necrosis factor; L-arg = L-arginine; L-cit = L-citrulline; NO = nitric oxide; NOS = nitric oxide 
synthase; O2− = superoxide. 
After production, NO diffuses to vascular smooth muscle cells (VSMCs) and activates 
guanylate cyclase, causing an increase in intracellular cyclic guanosine monophosphate 
(cGMP). This action leads to relaxation of the VSMCs and subsequent vasodilation. The 
importance of NO is supported by experimental work where inactivation of eNOS results in 
vasoconstriction and elevation in arterial blood pressure.11 NO also exerts inhibitory effects 
on platelet aggregation, leukocyte adhesion and VSMC migration and proliferation, 
highlighting the importance of this hormone for vascular homeostasis.10 
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Prostacyclin   
The endothelium produces a family of prostaglandins through the catabolism of arachidonic 
acid by cyclooxygenases in response to mechanical and humoral stimuli. Prostacyclin (PGI2) 
is a major member of this family and acts as a paracrine signalling molecule and to activate 
the prostacyclin receptors on VSMC and platelets. This stimulates adenylate cyclase and 
with a consequent increase in intracellular levels of cyclic adenosine monophosphate 
(cAMP), ultimately resulting in VSMC relaxation and inhibition of platelet activation.12 The 
action of PGI2 is closely related to that of NO since PGI2 potentiates NO release (and vice 
versa). Nonetheless, PGI2 seems less important for vascular control than NO, but plays a 
central role in the coagulation pathway (see “Control of blood fluidity and coagulation”). 
Endothelium-Derived Hyperpolarizing Factor   
Some of the endothelium-dependent vasodilation has generally been associated with 
hyperpolarization of the VSMCs and referred to a non-characterised factor called 
endothelium-dependent hyperpolarizing factor (EDHF).13 A number of candidate EDHFs 
have been suggested, including arachidonic acid metabolites, gaseous mediators (e.g. NO, 
hydrogen sulfide & carbon monoxide), reactive oxygen species, vasoactive peptides, 
potassium ions and adenosine. Irrespective of its exact nature, EDHF plays an important 
role in regulating vascular tone. 
Endothelin   
Endothelins are a family of potent vasoconstrictor peptides. Endothelin-1 (ET-1) is the 
predominant isoform and is primarily secreted by the endothelium in response to a variety 
of humoral and physical stimuli. After the production of ET-1 by the endothelium, it binds to 
the ETA and ETB-receptors on VSMCs resulting in a sustained vasoconstriction. Endothelial 
cells also express ETB-receptors whose stimulation results in the release of NO and PGI2, 
leading to vasodilation (and therefore serves as a feedback mechanism to partially oppose 
the vasoconstrictive effects of VSMC-located ETA/B-receptors). ET-1 also induces VSMC 
proliferation and growth in a dose-dependent manner, suggesting an important role for ET-
1 to contribute to the atherosclerotic process.14 
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Angiotensin   
After cleavage of angiotensinogen to angiotensin (Ang) I via renin, this peptide is cleaved by 
the angiotensin converting enzyme (produced by pulmonary and systemic vascular 
endothelium) into Ang-II. The smooth muscle cell-localised AT1 receptor subtype mediates 
the predominant action of Ang-II: vasoconstriction. These vasoactive actions are partly 
counteracted by the AT2 receptor, which causes vasodilatation.15 Besides the vasoactive 
effects, Ang II leads to proliferation and growth of the VSMCs through activation of the AT1 
receptor. Similarly to ET-1, the vasoconstrictive effects of ATII are, at least partly, 
counterbalanced by a negative feedback loop in the vascular wall.  
Thromboxane A2   
Thromboxane A2 (TXA2) is an end product of arachidonic acid metabolism and is produced 
by TXA2-synthase. TXA2 is primarily produced by platelets, but also by the endothelium. The 
primary physiological role of TXA2 is platelet aggregation, but it has also been demonstrated 
to contribute to vasoconstriction.16 
Prostaglandin H2   
In contrast to most members of the prostaglandin-family, prostaglandin H2 (PGH2) is a 
vasoconstrictor substance. PGH2 is closely related to TXA2 as both are formed during 
arachidonic acid metabolism. Furthermore, PGH2 is the precursor of TXA2 and exerts its 
vascular effects through the same receptors.17 
Control of thrombosis and haemostasis 
The endothelium actively maintains an anticoagulant and antithrombotic surface through 
several mechanisms (Figure 1). First, the endothelium keeps circulating platelets in a 
quiescent state, mainly through release of NO and PGI2 which synergistically increase cAMP 
content in platelets to repress activation and aggregation. Endothelial expression of 
ectonucleotidases also contributes to this process by converting ADP (a powerful trigger of 
platelet activation) to AMP and then adenosine. If platelet aggregation occurs, the release 
of serotonin and ADP from aggregating platelets will stimulate NO- and PGI2-production to 
inhibit platelet aggregation and limit thrombus formation. Furthermore, vasodilation in 
response to NO and PGI2 serve to mechanically impede the progression of the coagulation 
process.18  
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Figure 2. Anticoagulant and procoagulant properties of the endothelium. The endothelium maintains 
blood fluidity through a balance between factors that either inhibit (left) or promote (right) (1) platelet 
activation, aggregation, and (2) coagulation, and inhibit (left) or promote (right) (3) fibrinolysis. NO = 
nitric oxide; PGI2 = prostacyclin; PC = protein C; PS = protein S; TF = tissue factor; TFPI = tissue factor 
pathway inhibitor; tPA = tissue-type plasminogen activator; PAI-1 = plasminogen activator inhibitor 
1. 
Secondly, endothelial cells promote the activity of anticoagulant pathways (Figure 2). 
Anticoagulation is achieved through expression of thrombomodulin which interacts with 
thrombin. This forms a complex that prevents activation of platelets or the conversion of 
fibrinogen to fibrin, a key step in the coagulation cascade. This complex also activates 
protein C, which works in combination with protein S to inactivate two essential cofactors 
for blood coagulation; VIIIa and Va. The endothelial surface layer (glycocalyx) contains 
heparan sulfate proteoglycans which bind and activate anti-thrombin III to inactivate 
thrombin and factors IXa, Xa and XIa. Finally, endothelial cells regulate initiation of 
coagulation by inhibiting the activation of factor X.19 In addition to the strong anti-coagulation 
effects, the endothelium can also contribute to coagulation. Endothelial expression of tissue 
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factor (TF) enhances the activity of factor VII, which ultimately activates thrombin to facilitate 
activation of platelets and release of the von Willebrand factor (vWF) to further promote 
platelet aggregation.  
A third step in the coagulation pathway is the ability of the endothelium to influence 
fibrinolysis (Figure 2) by the production of tissue-type plasminogen activator (t-PA) and 
urokinase-type plasminogen activator (uPA). These factors activate the liver-derived 
plasminogen into plasmin which then degrades fibrin. It is important to note that this activity 
is inhibited through the (endothelial) production of plasminogen activator inhibitor (PAI)-1.19 
Immune and inflammatory responses 
Under non-inflammatory conditions, interaction of endothelial cells with leukocytes is 
suppressed by inhibiting the endothelium-dependent production of adhesion molecules 
(Figure 1). Also NO production inhibits the fusion of Weibel-Palade bodies with the surface 
of the endothelial cell and leukocyte activation. However, during inflammation, a rapid 
response to infectious microbes or injured tissues occurs, involving local recruitment and 
activation of leukocytes. The purpose of the inflammatory response is to kill microbes and 
remove cellular debris. Endothelial cell activation in response to inflammation can be 
divided into rapid responses (type I) and slower responses (type II). 
Type I responses are rapid (<10-20 min), transient, and independent of protein synthesis. 
These responses generally initiate a signalling cascade that increases intracellular Ca2+-
levels to serve a number of purposes. First, this response facilitates increased NO and PGI2 
production, contributing to an increased blood flow and delivery of leukocytes. Secondly, 
increased Ca2+-levels enhance survival and migration of invading leukocytes and cause 
contraction of endothelial cells, which opens gaps between adjacent endothelial cells and 
increase permeability for leukocytes. Finally, expression of P-selectin and platelet 
activating factor (PAF) is initiated which promotes the binding and activation of leukocytes.20 
Type II activation of endothelial cells involves a more persistent form of activation. During 
sustained inflammation, leukocytes produce inflammatory cytokines (e.g tumour necrosis 
factor-α (TNF-α) and interleukin-1 (IL-1)), resulting in the increased transcription of genes 
responsible for expression of a pro-adhesive and prothrombotic endothelial cell phenotype 
(IL-8 and adhesion molecules). Increased expression of these factors contributes to further 
leukocyte migration, adhesion and extravasation into the inflamed tissue. Inflammatory 
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cytokines also induce leakage of plasma proteins into the affected tissue. Since these 
responses require transcription and translation of new proteins, type II activation is slower 
in onset but has more sustained effects than type I activation (i.e. hours-days). Accordingly, 
endothelial cells contribute to restoration of normal tissue architecture or form a connective 
tissue scar in response to inflammation.21 
Facilitation of vascular growth, repair and remodelling 
Remodelling or adaptation of the vasculature refers to a basic compensatory response 
intended to maintain the functional integrity of the vessel in the presence of (potentially 
harmful) haemodynamic, metabolic, and inflammatory stimuli. Sustained exposure to such 
stimuli, especially in conjunction with CVD risk factors, eventually transforms the initial 
(protective) response into a self-perpetuating and pathogenic process that contributes to 
the development of atherosclerosis (Figure 3).22  
Remodelling   
Straight sections of arteries are associated with laminar shear, which produces an 
atheroprotective genotype that mitigates the effects of risk factors. However, at flow 
dividers, disturbed flow impedes such atheroprotective functions and initiates increased 
expression of pro-atherogenic genes/proteins and (chronic) inflammatory responses. As a 
lesion forms and grows, matrix remodelling takes place, paving the way for abluminal 
expansion or outward growth of the growing atheroma that preserves the lumen of the 
artery and maintains blood flow. Ultimately, plaque growth can outstrip this compensatory 
enlargement of the artery wall, allowing the atheroma to encroach on the lumen and cause 
stenosis (Figure 3). Smaller arterioles resist the atherosclerotic lesion formation. However, 
due to increases in pressure, these smaller vessels develop medial hypertrophy and intimal 
thickening, which sustains and aggravates hypertension.22  
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Figure 3. Arterial remodelling influences the clinical consequences of atherosclerosis. Normal 
laminar shear stress maintains normal arterial calibre and properties (A). Disturbed flow 
characterised by a non-laminar, oscillatory flow promotes the up-regulation of pro-atherogenic 
genes and recruitment of monocytes, as depicted to the right in the enlarged nascent plaque (B). 
Monocyte/macrophage accumulation yields a thin-capped, lipid-rich inflamed plaque (C), which can 
rupture and cause a thrombus (D), leading to myocardial infarction (central bottom). Alternatively the 
plaque in (E) can undergo constrictive remodelling to promote flow-limiting stenosis that can cause 
demand ischaemia and angina pectoris. Less commonly, superficial erosion (bottom right) can cause 
myocardial infarction (derived from22). 
Endothelial cells play a pivotal role in the process of remodelling. For example, early animal 
studies found that the presence of the endothelium is essential for arteries to adapt in 
luminal size.23 When the endothelium is removed from an artery, exposure to elevations in 
shear stress does not induce a change in diameter. The adaptive response is therefore 
dependent on the endothelium, and more specifically, dependent on gene expression of 
eNOS and suppression of the bioavailability of ET-1.24 Also, immediate changes in vessel 
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diameter in response to elevations in shear stress are dependent on an intact endothelium 
that releases vasoactive substances.25 This highlights the importance of the endothelium to 
respond (acutely and chronically) to changes in shear.  
Repair   
During the past decade, evidence supported the presence of repair mechanisms of damaged 
or ‘old’ endothelial cells by bone marrow-derived cells; endothelial progenitor cells (EPCs). 
These immature cells have the capacity to maintain endothelial integrity and function by 
differentiating into mature endothelial cells, replacing damaged endothelial cells, and 
initiate neovascularisation.26 Vascular injury mobilizes circulating EPCs, which localize at 
the site of damage where they divide, proliferate, and adhere to the sub-endothelium 
promoting growth of new endothelium. Endothelial injury causes a cytokine-mediated 
release of stromal-derived factor-1 (SDF-1) which, in turn, determines recruitment and 
proliferation of EPCs. Intact NO bioavailability is linked to efficient mobilization and 
functionality of EPCs, which may explain why the number of CVD risk factors is inversely 
related to the number and migratory activity of circulating EPCs. Impairment in the ability 
and/or efficacy of repair mechanisms of the endothelium logically follows the presence of 
CVD risk factors and progression of atherosclerosis.27 
Hemodynamic forces affecting the endothelium 
Shear Stress   
Blood imparts a tangential frictional force on the endothelial surface, typically referred to 
as shear stress. Endothelial cells’ ability to detect shear stress and other hemodynamic 
forces is mediated by different sensing mechanisms, including ion channels, caveolae, G-
protein-coupled receptors, tyrosine kinase receptors, cell adhesion molecules, glycocalyx, 
primary cilia and the cell cytoskeleton and the lipid bilayer of the cell membrane.28 
Mechano-activation of the signalling pathways results in the activation of transcription 
factors, leading to modulation of gene expressions in endothelial cells. Importantly, 
responses to shear stress are not simply linked to the absolute level of thereof, but also the 
type (i.e. laminar or oscillatory).  
Straight sections of arteries are exposed to a steady, laminar shear stress. Sustained 
elevation of such types of shear stress generates an atheroprotective phenotype. This is 
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highlighted by the expression of approximately 3000 cultured endothelial cell genes after 
exposure to elevations in laminar shear stress.29 Expression of genes that are upregulated 
in this regard involve growth factors (e.g. FGF, TGF-β), vasodilators (e.g. NO, PGI2), anti-
thrombotic components (e.g. TPA, thrombomodulin, COX-2), and endogenous antioxidants, 
whilst down-regulation is observed of genes for adhesion molecules (e.g. VCAM-1), 
vasoconstrictors (e.g. ET-1) and coagulation factors (e.g. PAI-1).28 Conversely, regions of 
disturbed blood flow (e.g. branch points, curvatures, post-stenotic regions), typically include 
periods of reciprocating flow reversal that create oscillating wall shear stress. Experimental 
studies suggest that oscillating shear stress patterns produce a proatherogenic endothelial 
cell phenotype, characterised with decreased eNOS mRNA and increased VCAM-1, ICAM-1, 
MCP-1, ET-1, and NADPH oxidase 4.28, 30   
The impact of elevation in shear stress is well-established from animal and human 
experiments. Subjects exposed to 8-week repeated exposure to elevated shear stress via 
handgrip training demonstrate improvement in vascular function and structure, whilst such 
adaptations were not present when the exercise-induced elevation in shear stress was 
artificially attenuated.31 Furthermore, the detrimental effect of oscillatory shear stress is 
confirmed in humans in vivo as this leads to a dose‐dependent decline in endothelial 
function.32 These observations highlight the importance of the magnitude and pattern of 
shear stress for endothelial function and vascular structure. 
Transmural Pressure and Cyclic Strain   
Elevations in blood pressure expose endothelial cells to an increased transmural force and 
increased cyclic strain, both of which are signals that can alter endothelial cell phenotype. 
High transmural pressure directly affects endothelial cell NO production.33 Both in vitro and 
in vivo experiments in animals and humans demonstrate that exposure of arteries to short 
term increases in transmural pressure depresses endothelium-dependent vasodilation by 
activating ROS-dependent mechanisms. More specifically, elevation in transmural pressure 
increases intracellular Ca2+ concentrations and protein kinase C activation, which ultimately 
results in NADPH oxidase activation and cause an increase in ROS production.34 The 
increased oxidative stress contributes to a proatherogenic phenotype of endothelial cells 
and, consequently, contributes to the atherosclerotic process.34  
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Elevation in pressure across the cardiac cycle also produces an increase in the rhythmic 
stretching (cyclic strain) of the vessel. Data obtained from in vitro cell culture preparations 
suggest that cyclic strain produces an antiatherogenic endothelial cell phenotype.35 
However, more recent data obtained from an isolated vessel preparation suggests a 
proatherogenic phenotype and increased ROS production.36 Although speculative, the 
discrepancies in results between experiments with whole vessel preparations versus those 
with endothelial and smooth muscle cell culture may point to important crosstalk between 
endothelial and VSMCs in vivo. Research using co-cultured endothelial and VSMCs are 
required to determine the ultimate importance of cyclic strain on the phenotype of the 
endothelium. 
CVD Risk factors affecting the endothelium 
Loss of the delicate balance of the various functions of the endothelium leads to a 
dysfunctional state in which the vasoconstrictive, prothrombotic, and proliferative 
characteristics of the endothelium predominate; ultimately facilitating the process of 
atherosclerosis. Below, we describe how important cardiovascular risk factors influence 
this balance.  
Dyslipidaemia   
Dyslipidaemia relates to excessive levels of low-density lipoproteins (LDL) and/or low levels 
of high-density lipoproteins (HDL). High levels of LDL, and especially oxidised LDL, can 
inhibit eNOS activity through inactivation of eNOS and “eNOS-uncoupling”. This latter 
process is initiated by superoxide, which reacts with NO to form peroxynitrite. Peroxynitrite 
then oxidizes the eNOS-cofactor tetrahydrobiopterin, which causes the generation of 
superoxide.37 This process reduces NO production and potentiates the pre-existing oxidative 
stress. Conversely, high levels of HDL protect the endothelium through the prevention of 
LDL-induced eNOS-uncoupling and upregulation of eNOS mRNA and protein levels; anti-
inflammatory effects through inhibition of NF-κB; as well as antithrombotic activity.38  
Diabetes   
Hyperglycaemia, a common feature in diabetes type 1 and 2, induces reduced NO 
bioavailability as a result of oxidative stress and eNOS uncoupling. Hyperglycaemia 
increases synthesis of vasoconstrictor prostanoids (e.g. PGH2, TXA),39 causing an immediate 
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decline in endothelial function. Another pathway by which diabetes impacts the endothelium 
is production of insulin, which normally acts as a vasodilator and stimulates endothelial NO 
production to facilitate glucose uptake in muscle. However, in diabetes this signalling 
pathway is inhibited, possibly via excess production of free fatty acids and inflammatory 
cytokines from adipose tissue (especially in type 2 diabetes).39   
Hypertension   
In addition to the effects of elevation in transmural pressure (see “Hemodynamic forces 
affecting the endothelium”), Ang-II plays a major role in hypertension through profound 
vasoconstriction, increased renal sodium absorption and elevated pressor responses. The 
resulting high blood pressure stimulates oxidative stress by enhancing NADPH oxidase 
activity, increasing media stress, and stimulation of mechanoreceptors. Ang-II also 
influences remodelling of the vessel wall by stimulating Ca2+ release leading to 
vasoconstriction that may become chronic as deposition of extracellular matrix occurs. In 
addition, Ang II enhances all stages of the inflammatory response.40 These effects of Ang II 
establish a vicious cycle where hypertension begets hypertension through its adverse 
effects on the endothelium and vascular structure. 
Obesity   
Obesity is independently associated with endothelial dysfunction.41 Visceral adipose tissue 
acts as an endocrine organ and is capable of producing proinflammatory adipokines (e.g. 
leptin, resistin and adiponectin). Leptin induces oxidative stress in endothelial cells and 
stimulates the secretion of the proinflammatory cytokines TNF-α and IL-6 causing a state 
of chronic low-grade inflammation. Resistin inhibits glucose uptake in skeletal muscle cells 
and stimulates ET-1 production. Conversely, obesity is typically characterised by a reduced 
production and activity of adiponectin.42 Adiponectin has anti-atherogenic properties and 
stimulates insulin sensitivity, reduces the expression of adhesion molecules, inhibits the 
transformation of macrophages into foam cells and reduces VSMC-proliferation. 
Furthermore, obesity is associated with increased plasma levels of free fatty acids which 
may contribute to endothelial dysfunction.41 
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Concluding remarks 
The endothelium is the central regulator of vascular homeostasis. Changes in endothelial 
cell phenotype support vessel repair, remodelling and resolution of infection or 
inflammation. Whilst these alterations are usually transient, prolonged exposure to 
potentially harmful or beneficial stimuli activate various processes that ultimately lead to 
changes in endothelial function. Prolonged exposure to potentially harmful stimuli, 
characterised by reduced NO bioavailability, represents a critical step in the process of 
atherosclerosis and is present long before overt pathophysiological changes occur. 
Therefore, the endothelium remains an important target for: 1. early prediction of future 
CVD, and 2. Interventions for primary and secondary prevention of CVD.  
Outline of this thesis 
The pivotal role of the endothelium in cardiovascular health has spurred the development 
of several techniques to evaluate endothelial function, which are valuable tools to predict 
future CVD risk/disease as well as the evaluation of effects of various pharmacological, 
dietary and lifestyle related interventions. Currently, the most widely used technique to 
study endothelial function in vivo is flow-mediated dilation (FMD) of the brachial artery. This 
technique is popular because it is a non-invasive, ultrasound-based method, correlates well 
with endothelial function of the coronary arteries,43, 44 and independently predicts future CVD 
events.45, 46 Additionally, interventions can achieve changes in FMD within a much shorter 
time frame than vascular endpoints related to structure, such as carotid intima-media 
thickness or arterial stiffness. 47 An important caveat is that minor changes in the methods 
to measure FMD may critically impact variability and decrease reproducibility of the FMD 
response. 48-50 This, along with the fact that currently no formal normative data for FMD 
exists, importantly limits the comparison of FMD results between studies. Therefore, the 
first general aim of this thesis is to assess the importance of adherence to expert-consensus 
guidelines, and of methodological and subject-related factors for, the reproducibility of brachial 
artery FMD. 
To explore this general aim, we present a series of short communications on the need for 
age-, sex- and CVD-specific normative data that are derived from brachial artery FMD 
measurements according to expert consensus guidelines (Chapter 2a). Secondly we 
investigate the importance of adherence to current expert consensus guidelines for FMD 
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measurement in decreasing its measurement error (Chapter 2b). For this study, we 
developed a tool for objectively judging the extent to which published studies adhered to 
expert guidelines for FMD measurement (Chapter 2c).  
Although many of the factors affecting FMD reproducibility can be controlled for through 
adopting expert-consensus guidelines,51, 52 variation in FMD remains present. Previous 
studies found that variation in FMD is related, at least in part, to lifestyle factors (e.g. 
smoking, physical activity), methodology (e.g. cuff placement, duration of ischemia), intake 
of food and beverages, hormonal changes, and method of analysis.52, 53 The significance of 
these potential sources of variation has never been systematically studied. In Chapter 3 we 
describe a study wherein we combined data from previous studies performed according to 
expert-consensus guidelines52 (from 8 laboratories world-wide, n=672 subjects who 
underwent repeated measurements of FMD) to assess subject- and methodology-related 
factors that contributed to brachial artery FMD variability.  
In the second part of my thesis, I aim to advance insights in the effects of dietary interventions 
(with specific interest in flavonoids) on endothelial function and pathways known to interact with 
the endothelium. Diet is an important determinant of CVD risk through direct effects on 
traditional CV risk factors (e.g. dyslipidaemia, hyperglycaemia, hypertension & obesity), with 
the endothelium being affected either as a cause, a consequence or both. Interestingly, diet 
itself has a direct impact on the endothelium. For example, increases in blood glucose (or 
hyperglycemia) after a meal can cause transient impairment in endothelial function and 
reductions in FMD.54-57 Conversely, it has been demonstrated that elevation in blood flow and 
shear rate, (induced by e.g. heating of a forearm), can lead to acute31 and chronic58 
improvements in FMD and may prevent the immediate decline in FMD caused by activation 
of the sympathetic nervous system.59 In line with these observations, elevation in shear rate 
may prevent the hyperglycemia-induced decline in endothelial function. In Chapter 4 we 
examine whether increases in blood flow protect against the transient decrease in 
endothelial function mediated by postprandial increases of blood glucose in healthy subjects 
as well as patients with type 2 diabetes mellitus. 
One of the most extensively studied dietary components with regard to cardiovascular 
health are flavonoids: secondary plant metabolites purported to have beneficial effects on 
human health.60, 61 Epidemiological evidence has linked consumption of black tea, a 
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prominent source of flavonoids in the human diet, with reduced CVD risk, specifically stroke 
morbidity and mortality.62 However, intervention studies on the effects of tea consumption 
on blood pressure in humans have reported inconsistent results. In Chapter 5 we assess 
the available evidence on the blood pressure lowering effects of black tea consumption by 
means of a systematic literature review and meta-analysis of controlled human intervention 
studies.  
Resistance vessel function plays an important role in blood pressure regulation.63 Since 
consumption of flavonoid-rich foods and beverages such as tea is associated with improved 
endothelial function of conduit arteries,64, 65 it is conceivable that flavonoids may lower blood 
pressure via improvements in resistance artery endothelial function. However, little is 
known about the potential impact of tea ingestion on endothelial function of resistance 
vessels. In Chapter 6 we describe the acute effects of black tea consumption on forearm 
resistance artery endothelial function in healthy middle-aged subjects. 
Red wine and grapes represent another major source of dietary flavonoids, and increased 
intake of red wine and grapes has been linked with a reduced risk of CVD.66 Intervention 
studies have demonstrated that supplementation with wine and grape extracts can lower 
blood pressure and improve measures of endothelial function in humans.67, 68 Most previous 
studies on the blood pressure lowering effects of wine and/or grape extracts have been 
conducted in healthy participants or in non-medicated hypertensives.69 Results of such 
studies are difficult to translate to the majority of hypertensive patients, who typically 
receive lifelong antihypertensive medication and could theoretically achieve the largest 
benefit of blood pressure-lowering interventions. Accordingly, in Chapter 7 we describe a 
study in drug treated patients with essential hypertension on the effects of 8-week 
consumption of a grape-wine extract mix on ambulatory blood pressure, endothelial 
function and muscle sympathetic nerve activity.  
Methods applied in this thesis 
In the studies in this thesis, we measured blood pressure, vascular function, vascular 
structure, as well as autonomic (re)activity using a variety of techniques, which are outlined 
below. More detailed descriptions of the methods can be found in the corresponding 
chapters of this thesis. 
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Blood pressure  
Office blood pressure was measured according to standardized procedures70 with an 
oscillometric automatic device (Omron 705CP) applied to the non-dominant arm. After 5-
minute resting in the sitting position, 3 consecutive recordings at 2-minute intervals were 
taken and the average of the last two recordings were used for analysis. Twenty-four hour 
ambulatory blood pressure recording was performed using Spacelabs monitors (Type 90 
217; Spacelabs Medical Inc.) placed on the non-dominant arm. Blood pressure was recorded 
at 15-min intervals throughout the day and at 20-min intervals during the night (11 PM – 8 
AM). The average of the 24-hour, night-time and daytime blood pressure values were used 
for analysis.  
Vascular ultrasound measurements 
To examine vascular function we measured shear rate patterns as well as endothelium-
dependent and independent dilation of the brachial artery using high-resolution ultrasound 
machines  with 10 MHz linear array transducers (Terason T3000, Burlington, MA, USA and 
MyLab25, ESAOTE, Florence, Italy). All measurements were conducted by well-trained 
sonographers according to current expert consensus guidelines.52 
Brachial artery endothelium-dependent and independent dilation. Flow mediated dilation of the 
brachial artery was measured as a noninvasive index of endothelial function.43 The brachial 
artery was imaged 2-3 cm proximal to the antecubital fossa. A rapid inflation and deflation 
pneumatic cuff (Hokanson, Bellevue (Washington), USA) was applied to the forearm (distal 
to the measurement site). A 1-minute baseline ultrasound recording of the brachial artery 
was acquired after which the cuff was inflated to supra-systolic pressure (≥220 mmHg) for 
5 minutes. After cuff release, ultrasound recording of brachial artery diameter and blood 
flow continued for at least 3 minutes. Endothelium-independent reactivity was evaluated by 
measuring the brachial artery dilation in response to an exogenous NO donor. After a 1-
minute baseline ultrasound recording of the brachial artery, 25 μg glyceryl trinitrate (GTN) 
was administered sublingually and brachial diameter recording continued for a further 5 
minutes. Analysis of changes in brachial artery diameter was performed using 
computerized edge detection systems, which are independent of investigator bias.71-73 FMD 
and the response to GTN were calculated as the maximal percentage increase in arterial 
diameter.  
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Shear rate pattern. Blood flow in the brachial artery was calculated from synchronized 
diameter and velocity data (as the product of arterial lumen cross-sectional area and 
Doppler velocity).48 Shear rate (an estimate of shear stress) was calculated as 4 times mean 
blood velocity/vessel diameter.74 Baseline shear rate were calculated as the mean of data 
acquired across the 1 minute preceding the cuff inflation period. The post-cuff deflation 
shear rate data, derived from simultaneously acquired velocity and diameter measures at 
30 Hz, was used to calculate the area under the shear rate curve (SRAUC) for data up to the 
point of maximal post-deflation diameter (FMD) for each individual. In addition, we 
calculated the peak blood flow across a 10-second period after cuff release.  
Resistance artery endothelial function 
Forearm resistance artery endothelial function was evaluated by means of the isolated and 
perfused forearm technique, which is the gold standard for assessment of endothelial 
function.75 Briefly, forearm blood flow (FBF) was measured bilaterally by strain-gauge 
venous occlusion plethysmography with the brachial artery of the non-dominant arm 
cannulated for vasoactive drug infusion at systemically ineffective doses.76 FBF was 
calculated using standard formulae and expressed as mL/100 mL forearm volume/min. To 
assess forearm resistance artery endothelium-dependent and -independent dilation as well 
as the contribution of NO to vascular tone, we infused increasing doses of acetylcholine 
(ACh; an endothelium-dependent dilator), NG-monomethyl-L-arginine (L-NMMA; blocker of 
NOS) and sodium nitroprusside (SNP; an endothelium-independent dilator), respectively. 
Additionally, to examine whether the effect of tea on endothelial function is mediated 
through reduction in oxidative stress, we repeated the ACh-infusion protocol under co-
infusion of ascorbic acid (i.e. a powerful anti-oxidant). To further explore the role of the NO-
pathway in this process, study procedures were repeated with co-infusion of L-NMMA and 
ascorbic acid.77 
Arterial stiffness and wave reflection 
Evaluation of arterial stiffness was done by means of pulse wave analysis and aortic pulse 
wave velocity (PWV) measurement. To obtain these data, arterial tonometry was performed 
according to international recommendations.78, 79 Briefly, a hand held probe was placed on 
the radial artery and 10–15 subsequent images were recorded. The radial pressure 
waveform was transformed into the aortic pressure waveform by pulse wave analysis 
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(SphygmoCor, AtCor Medical) using a validated transfer function. Two successive 
measurements were recorded and averaged. Augmented pressure was calculated as the 
difference between the second systolic peak and the first systolic peak, and augmentation 
index (AIx) was calculated as the ratio between augmented pressure and pulse pressure. 
Since AIx is correlated with heart rate, values were normalized at a heart rate of 75 beats 
per minute. Aortic PWV was assessed with the same device, sequentially recording pressure 
waveforms at the femoral and carotid site. PWV was calculated as the ratio of the surface 
distance between the two recording sites (subtracting the carotid–sternal notch distance 
from the femoral–sternal notch distance) and wave transit time.  
Sympathetic nervous system activity 
Multiunit recording of efferent postganglionic muscle sympathetic nerve activity (MSNA) of 
the peroneal nerve was obtained using microneurography. Briefly, a tungsten 
microelectrode with an uninsulated 1–5-μm-diameter tip (Medical Instruments, University 
of Iowa) was transcutaneously inserted in the peroneal nerve just posterior to the fibular 
head.80 A reference electrode was inserted subcutaneously 1 to 3 cm from the recording 
site. The signal was integrated with a 0.1-s time constant, amplified with a gain of 50,000–
80,000, band-pass filtered (700–2000 Hz), and acquired at 1000 Hz through a digital 
acquisition system (ACQ-16; Gould Electronics). MSNA was identified according to 
previously outlined criteria80, 81 Obtained neurograms were recorded together with BP and 
heart rate by means of dedicated computer software (Ponemah; LDS). Recordings were 
considered acceptable if the signal to noise ratio exceeded the value of 3. MSNA responses 
were measured at rest and during 2-min of mental stress (serial 7 subtraction82) 
immediately followed by 2-min of cold pressor test. Data were quantified as bursts/min 
(burst frequency) and bursts/100 heart beats (burst incidence).  
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Chapter 2a 
Time for reference values and high-quality measurement to assess 
endothelial function? 
Dick H.J. Thijssen Arno Greyling, Daniel J. Green 
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To the editor: 
Cardona et al. have performed a meta-analysis of published studies on the ability of 
endothelial function to predict future development of CVD.1 The analysis included 35 
studies, involving 17,206 patients that were followed up for > 80,000 person-years. 
Although measures of endothelial function significantly predicted future CV events, 
the relative risk ratios varied considerably between methods to assess endothelial 
function. Accordingly, the authors concluded that ‘...current evidence base does not 
support its use as a potentially useful measurement for risk stratification in people at 
lower risk of CVD’. 
In the study from Cardona, several techniques were included. Consequently, 
vasodilator function was assessed in different arteries, dilation was induced by 
various stimuli, while evidence to support an endothelium-dependent dilation is 
lacking for most techniques (except FMD2). Lack of correlation between different 
measures of vasodilator function has been discussed several times before.3 
Nonetheless, Cardona’s study reinforces that measures of endothelial function 
strongly predict future CVD events. One further aspect to consider is that, in addition 
to the predictive value, measures of endothelial (dys)function may also improve 
classification/risk prediction. Yeboah et al. found that brachial artery FMD improved 
the classification of subjects as low, intermediate and high CVD risk.4 Therefore, 
based on the presented evidence, it seems ill-advised to reject measures of 
endothelial function as useful measurement for risk stratification in people at lower risk 
of CVD. 
More importantly, we were triggered by the observation that the year of baseline 
measurements was strongly related to the predictive capacity. This likely reflects 
improved technological ability and adoption of guidelines.5 For example, well after 
the introduction of FMD and publication of the first prognostic studies on FMD, 
studies have started to highlight the importance for optimal methods of data 
collection, data analysis and correcting for factors influencing measurements. Close 
adherence to contemporary, evidence-based guidelines,5 therefore, seems 
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prerequisite for valid assessment of endothelial function. Therefore, the 
observations from Cardona et al. would be of interest when all studies adopted 
state-of-the-art techniques and evidence-based guidelines to assess endothelial 
function. 
Another remarkable observation is that statements were made based on comparing 
‘top’ versus ‘bottom’ thirds of measures of endothelial function. This highlights 
arguably the largest caveat in the field; lack of age-, sex- and CVD-specific normative 
data using expert-consensus/evidence-based guidelines. Despite its relatively 
straight-forward approach, measures of FMD are technically difficult and various 
factors must be considered. For instance, experience with high-quality echo-
Doppler is critical. The observation that older studies (with likely poorer adherence 
to guidelines and lack of experience) demonstrate no predictive capacity of the FMD 
supports this notion.  
We believe the study from Cardona and co-workers highlights the importance to 
construct normative data based on evidence-based guidelines. Subsequently, the 
verdict on the prognostic value of FMD should be based on studies acknowledging 
and adopting contemporary technological aspects associated with measurement of 
the FMD. We hope these recommendations will lead to a well-balanced and 
evidence-based decision on the potential role for measurements of endothelial 
function for the prediction of future CVD. 
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Abstract 
Background: Brachial artery FMD is widely used as a non-invasive measure of endothelial 
function. Adherence to expert guidelines is believed to be of vital importance to obtain 
reproducible measurements. We conducted a systematic review of studies reporting on the 
reproducibility of the FMD in order to determine the relation between adherence to current 
expert guidelines for FMD measurement and its reproducibility. 
Methods: Medline-database was searched through July 2015 and 458 records were 
screened for FMD reproducibility studies reporting the mean difference and variance of 
repeated FMD measurements. An adherence score was assigned to each of the included 
studies based on reported adherence to published guidelines on the assessment of brachial 
artery FMD. A Typical Error Estimate (TEE) of the FMD was calculated for each included 
study. The relation between the FMD TEE and the adherence score was investigated by 
means of Pearson correlation coefficients and multiple linear regression analysis.  
Results: Twenty-seven studies involving 48 study groups and 1,537 subjects were included 
in the analyses. The adherence score ranged from 2.4 to 9.2 (out of a maximum of 10) and 
was strongly and inversely correlated with FMD TEE (adjusted R2 = 0.36, P<0.01). Use of 
automated edge-detection software, continuous diameter measurement, true peak 
diameter for %FMD calculation, a stereostatic probe holder, and higher age emerged as 
factors associated with a lower FMD TEE. 
Conclusions: These data demonstrate that adherence to current expert consensus 
guidelines and applying contemporary techniques for measuring brachial artery FMD 
decreases its measurement error. 
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Introduction 
The endothelium is a key regulator of vascular homeostasis and endothelial dysfunction is 
an early manifestation of atherosclerosis.1 Currently, the most widely used technique to 
study endothelial function in vivo is the flow-mediated dilation (FMD) of the brachial artery. 
This is a non-invasive, ultrasound-based method which correlates with endothelial function 
of the coronary arteries2, 3 and independently predicts cardiovascular disease (CVD).4, 5 The 
technique is attractive as a surrogate end-point, especially since changes in FMD can be 
detected across a relatively short timeframe.6 Despite its popularity, minor changes in the 
methodological approach may critically impact variability and decrease reproducibility of 
the FMD response.7-9 
Previous expert consensus guidelines have made important contributions to standardize the 
technical approach and to set minimum standard requirements for FMD measurements.10, 
11 However, not all studies on FMD apply these recommendations, or only in part. The impact 
of adherence to these guidelines on the reproducibility of FMD measurements is currently 
unclear, but may importantly contribute to the measurement error of the FMD technique 
Furthermore, little is known about the relative importance of the individual aspects of the 
expert-consensus guidelines to contribute to the reproducibility of the FMD. Better 
quantitative data on this matter can help reduce variation within and between studies, which 
will increase the statistical power of studies on FMD to detect changes and, subsequently, 
decrease chances for type II errors. 
In light of these considerations, we hypothesized that adherence to expert consensus 
guidelines is related to better reproducibility of FMD measurements.10, 11 Therefore, we 
performed a systematic search for published studies that reported data on reproducibility 
of FMD measurements, and investigated the relation between (full or partial) adherence to 
current expert consensus guidelines and reproducibility of the FMD. Secondly, we explored 
which subject- and methodology-related factors were related to FMD reproducibility. 
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Methods 
Search strategy 
The MEDLINE bibliographic database was searched (January 2000 through July 2015) for 
studies that assessed the reproducibility of the FMD using the following search terms: "flow 
mediated dilation", "flow mediated dilatation", "flow mediated vasodilation", "flow mediated 
vasodilatation", "endothelial function", "endothelial dysfunction", “FMD”, “FMV”, "brachial 
artery", “reproducibility”, “reliability”, “repeatability”, "coefficient of variation", “CV”, and 
“variance”. The search was limited to studies in human adults published in the English 
language. Additionally, we supplemented the search by hand-searching references of 
included studies and relevant reviews and meta-analyses on this topic. 
Selection of studies 
Included studies were identified by means of a two-step selection process. During the first 
step, two reviewers (ACCMvM, AG) independently screened titles, abstracts and keywords 
of publications to identify potentially eligible studies. Studies were included if the mean 
difference and variance of repeated FMD measurements of the brachial artery were 
reported. During step 2 of the selection, both reviewers examined the full text of these 
publications to gauge eligibility based on two additional inclusion criteria: FMD was 
determined through noninvasive ultrasound imaging, and a reactive hyperaemia protocol 
(with an ischemia duration of 4 to 5 minutes) was used to elicit the shear stress stimulus 
required for FMD. Thus, studies that adopted (ischemic) hand-grip exercise, passive 
movement and/or skin warming protocols to elicit (brachial) artery dilation were not 
included in our analysis. In cases of discrepancy between the reviewers, eligibility was 
discussed along with a third reviewer (DHJT) until consensus was reached. 
Data extraction 
Study and subject characteristics: A standardized data collection sheet was used to extract 
general publication details (author, year of publication, country) and specific study- and 
subject characteristics: number of subjects, mean age (in years); CVD risk status of the 
study population (defined as presence of diagnosed CVD, hypertension or diabetes); baseline 
brachial artery diameter (in mm); % brachial artery FMD and its associated variance for each 
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repeated measurement; and the mean absolute difference between repeated FMD 
measurements and its associated variance.  
Adherence to guidelines: We extracted information from the methods sections of the 
individual papers to assess the adherence to current expert-consensus guidelines. Based 
on recent guidelines, 11 we scored each individual study on the reporting of 19 different 
factors which were divided over 4 categories. The categories were related to: 1. Subject 
preparation (10 items), 2. Image acquisition (4 items), 3. Data analysis (3 items), and 4. 
Laboratory (2 items). Before performing the systematic literature search, values were 
assigned to each factor proportional to its perceived importance for valid assessment of the 
FMD. This was done through expert consensus discussion within the Working Group (AG, LG 
and DHJT).12 The “Adherence Score” that could be assigned to a study ranged from 0 to 10 
points, depending on how many of the 19 different factors that were reported. In addition, 
we counted the number of previous studies on FMD published by the principal author of each 
study included in the systematic review. This number served as a measure of the perceived 
experience in FMD measurements for each centre at the time of publication of the 
reproducibility data included here. 
Statistical analysis 
Reported measures of FMD reproducibility varied between studies. Many studies presented 
the coefficient of variation (CV) of repeated measurements, although this measure was 
calculated in a number of different ways, precluding direct comparisons. Measures of 
reproducibility included the technical error of the measurement (TEM), Pearson- and 
intraclass correlation coefficients (ICC), and limits of agreement. In order to make valid 
comparisons between studies, we defined as primary outcome measure the typical error of 
estimate (TEE) of FMD ,which is calculated as standard deviation of the paired 
differences/√2.13 
Data are presented as mean ± SD or median (range) as appropriate for continuous variables 
and as frequencies for categorical variables. FMD TEE data were highly skewed (Shapiro-
Wilk test, P<0.0001) and were log transformed prior to the analyses. Relations between log-
FMD TEE and continuous variables were determined by Pearson correlation coefficients 
analysis. For categorical variables, the statistical significance of differences in FMD TEE 
between different levels were assessed by the Mann-Whitney U test. Significant correlates 
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were entered in a multivariate linear regression analyses with backward elimination to 
identify independent predictors of FMD TEE. All analyses were conducted using JMP version 
11.0 (SAS Institute Inc., Cary, NC, USA). 
Results 
Our systematic search identified 446 potentially relevant publications and an additional 12 
were obtained through review of references of included studies, relevant reviews and meta-
analyses. Twenty-seven studies 14-40 with 48 relevant study groups met our inclusion criteria 
and were included in our analysis (Figure 1).  
 
 
Figure 1. Flow diagram of the study selection procedure. 
Characteristics of the included study groups are presented in Table 1. The 48 study groups 
comprised a total of 1,537 subjects (mean sample size 32; range, 8-135) with a mean age of 
41.5 years (range, 22-79 years). Eleven study groups included subjects with increased CVD 
risk, i.e. presence of diagnosed CVD, hypertension or diabetes. The other remaining 37 study 
groups consisted of healthy subjects. The time between repeated FMD measurements 
ranged from 25 minutes to 9 months. Mean baseline brachial diameter was 3.9 mm (range, 
3.5 to 4.7 mm) and mean baseline FMD (i.e. this first of the two repeated measurements) 
was 7.1% (range, 1.8 to 19.9%). The FMD TEE ranged from 0.33 to 4.83% across study 
groups, with a mean value of 1.4%. The level of experience for each centre at the time of 
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publication of the reproducibility study in question varied widely (number of previously 
published studies on FMD ranging from 0 to 71, median of 3). 
Methodology-related factors versus variation in FMD 
There was considerable variation in the methodological factors between studies. Adherence 
scores ranged from 2.4 to 9.2, with a mean of 5.3 (out of a maximum of 10). The adherence 
score was inversely correlated with log FMD TEE (adjusted R2=0.36, P<0.01, Figure 2).  
 
 
Figure 2. Linear correlation between the Typical Error of the Flow Mediated Dilation Estimate (FMD 
TEE) and adherence to expert guidelines (Adherence Score) in 27 studies (involving 48 study groups) 
of FMD reproducibility. 
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To explore the impact of the different aspects of the adherence score on the FMD TEE, we 
compared the FMD TEE between adherence (Yes vs No) to various methodological variables. 
Statistically significant differences in FMD TEE were found for use of the true peak diameter 
to calculate %FMD, continuous brachial artery diameter measurement over the cardiac 
cycle, use of automated edge detection software and smoking cessation prior to 
measurements (Table 2). 
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Subject-related factors versus variation in FMD 
For the remaining methodology related factors and subject characteristics, there were 
weak, but statistically significant correlations of log FMD TEE with age (adjusted R2= -0.18, 
P<0.01) and with baseline FMD (adjusted R2 0.11, P=0.013). In addition, FMD TEE was 
significantly smaller in the subgroup of studies that applied a stereostatic probe holder, 
and in studies performed by groups with more experience according to number of earlier 
publications on FMD. The %FMD TEE of studies above and below the median duration 
between repeated measurements (7 days) was not significantly different (Table 3), and 
there was no correlation between %FMD TEE and the time between repeated 
measurements (adjusted R2= -0.02, P<0.75). 
 
Table 3. Relationship of subject- and methodology-related characteristics with FMD TEE. 
Continuous variables Adjusted Pearson R2 P-values 
Age (years) -0.18 <0.01 
Baseline FMD (%)‡ 0.11 0.01 
Baseline diameter (mm) -0.02 0.15 
Number of subjects (n) -0.001 0.33 
Categorical variables Median (IQR) %FMD TTE 
 n No n Yes P-values 
CVD risk 37 1.15 (0.79-2.01) 11 0.94 (0.85-1.07) 0.31 
Distal occlusion cuff 
placement 
5 2.01 (0.91-2.6) 43 1.04 (0.79-1.47) 0.17 
Stereostatic probe 
holder 
18 1.82 (1.02-2.85) 30 0.92 (0.73-1.22) <0.01 
Experienced centre* 23 1.32 (0.88-2.5) 25 0.91 (0.80-1.19) 0.01 
Time between repeated 
measurements above 
median† 
18 0.94 (0.81-1.72) 30 1.06 (0.71-1.61) 0.77 
P values in bold are significant at P≤0.05. 
‡ Baseline FMD refers to the first of the two repeated measurements. 
*Centre experience was defined as the number of previous studies on FMD published by the principle author of 
each included study. The effect of centre experience was examined by comparing the %FMD TEE of studies 
below (No) and above (yes) the median number of previously published FMD studies. 
†The effect of the time duration between studies was examined by comparing the %FMD TEE of studies below 
(no) and above (yes) the median duration of 7 days. 
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We constructed a stepwise multivariate regression model with log FMD TEE as the 
dependent variable and all factors that significantly influenced FMD TEE based on the 
individual analyses (adherence score, age, baseline FMD, probe holder and previous 
experience). The stepwise multivariate regression model predicted 51% of the variability in 
log FMD TEE. Adherence score (β = -0.16), age (β = -0.01) and probe holder (β = -0.19) 
remained as statistically significant (P<0.05) predictors in the model (Table 4).  
 
Table 4. Relation of the adherence score, subject- and methodological factors with the 
reproducibility of the FMD measurement. 
Stepwise Regression Analysis (model Adj R2=0.51) 
Variable β 95% CI P-value 
Adherence Score (unit) -0.16 -0.24; -0.07 <0.01 
Age (year) -0.01 -0.02; -0.001 0.03 
Stereostatic probe holder (yes) -0.19 -0.06; -0.33 <0.01 
The regression coefficient β represents the increase in the log FMD TEE per unit increase in each factor. 
Baseline FMD and Centre experience did not remain in the model. 
P values in bold are significant at P≤0.05. 
Discussion 
In the recent years the measurement of FMD in the brachial artery has been associated with 
predictive capacity for future CVD events. Despite this, and the relatively straightforward 
and non-invasive approach to its measurement, the clinical use of the FMD is hampered by 
its sensitivity to variations in methodology.  
Our systematic analysis of previous studies that explored FMD reproducibility provides us 
with a number of novel observations. First, we found considerable variation in the 
methodology applied to measure FMD and consequently, differences between studies in the 
adherence to current expert consensus guidelines. Secondly, these data show a robust 
inverse association between adherence to the guidelines and FMD reproducibility, with 
higher adherence to guidelines being related to smaller variation in FMD. Thirdly, we 
identified methodological factors that were associated with smaller variation in FMD. 
Specifically, the use of automated edge detection software, continuous measurement of 
brachial artery diameter across the cardiac cycle, calculating %FMD by means of the true 
peak diameter and use of a stereostatic probe holder were related to a better 
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reproducibility. Taken together, our study provides strong scientific data that highlight the 
importance of rigorous application of standardized contemporary methodology to reduce 
measurement error of FMD and, consequently, improve its use in (pre)clinical studies.  
To our knowledge, no previous study has explored the (relative) importance of adherence to 
expert consensus guidelines for measures of vascular health, including frequently used 
techniques like intima-media thickness, pulse wave velocity, and finger 
photoplethysmography. Taking all studies on the reproducibility of the FMD together, 
involving 1,537 subjects, we found a TEE of 1.4% based on an average FMD of 7.1%. This 
indicates an overall good-to-acceptable reproducibility of the FMD. However, significant 
variation was observed between studies, with adherence to the expert consensus guidelines 
representing an important determinant of this variation. Our data suggests that roughly 36% 
of the variation in FMD reproducibility can be explained through adherence to the guidelines 
alone. The presence of a linear relation between adherence to the guidelines and variation 
of the FMD suggests that measurement error would be further reduced with stricter 
adherence to the guidelines. Our data also indicate that even with full adherence to current 
expert consensus guidelines, some level of measurement error remains present. 
Nonetheless, a significant amount of variation in the FMD can be prevented by strong 
adherence to guidelines. 
Our analysis provides further insight into methodological factors that determine within-
person error of the FMD measurement. For example, we found that taking the true peak 
artery diameter (rather than a fixed time point), continuous diameter measurement and 
automated edge-detection contribute to minimizing measurement error. The importance of 
these methodological factors have already been acknowledged in previous work. For 
example, Black et al. found that the peak diameter following cuff release differs between 
young and older subjects.7 Consequently, calculating the FMD% at an arbitrary time point 
(e.g. 60 seconds) may lead to misleading conclusions compared to an approach in which 
diameter of the brachial artery is recorded continuously, allowing for the detection of the 
true peak dilation. Furthermore, previous work demonstrated that the adoption of edge-
detection software to perform observer-independent analysis leads to smaller variation 
compared to the application of manual calipers, the latter being highly prone to 
measurement bias.36, 41, 42 Whilst these studies highlight the importance of considering these 
factors for valid use of FMD, the present study also highlights the importance of considering 
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these factors to lower variation. Therefore, our study provides an additional rationale to 
perform continuous assessment of the diameter and the adoption of edge-detection 
software when performing valid and reproducible assessments of the FMD. 
Another important observation in our study was that previous experience of a laboratory 
with the FMD resulted in a smaller variation. A potential explanation for this finding is that 
experienced laboratories are more likely to demonstrate better adherence to the expert 
consensus guidelines. Indeed, when all factors were included in the final regression 
analysis (including adherence to the guidelines), previous experience of a laboratory with 
FMD did not emerge as an independent predictor of FMD reproducibility. Another factor that 
contributed to a smaller variation of the FMD was the use of a probe holder. The use of such 
devices is largely dependent on the personal preference of the laboratory and the effect on 
measurement reproducibility is a complex topic, since highly skilled operators with years of 
experience are able to conduct FMD measurements with exceptional reproducibility, 
regardless of the use of a probe holder.19 One may speculate that sonographers’ learning 
curves will likely differ depending on whether a probe holder is used or not and also 
depending on the design and construction of the probe holder itself. Therefore, despite the 
significant inverse association in our analysis, it remains difficult to ascertain whether use 
of a probe holder leads to a smaller variation in FMD per se. Further studies are needed to 
confirm the importance of using a probe holder to reduce variability of the FMD. 
Of the subject-related factors (age, diameter and baseline FMD), only age contributed 
independently to the variation in FMD. Notably, higher age of subjects was associated with 
a smaller variation in FMD. Older age is typically associated with a lower FMD,43, 44 which 
may contribute to a smaller (biological) variation and/or less ability to change in response 
to hemodynamic stimuli, consequently leading to a smaller measurement error. However, 
at least a previous work suggests the presence of larger variability for measurements of 
vascular health in clinical groups. For example, Craiem et al. found that subjects with CVD, 
despite comparable baseline FMD% values, demonstrate a larger coefficient of variation 
compared to healthy controls.22 Our data suggest that the reproducibility of the FMD may 
differ between (clinical) groups. 
Interestingly, the time between repeated measurements did not significantly affect FMD 
reproducibility in our analyses. This might seem counter-intuitive, as poorer reproducibility 
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is expected as the time between repeated measurements increases. Indeed, a recent study 
specifically designed to determine FMD reproducibility over short (48 hours), medium (3 
months) and long (9 months) time frames did find poorer reproducibility at 9 months 
between repeated measurements.15 Reproducibility was comparable for the shorter time 
periods however, which is in agreement with a recent Italian multicenter study which found 
no differences in FMD reproducibility up to 30 days between measurements.16 It should be 
noted that there was a large heterogeneity in time between measurements in the included 
study groups, with the majority ranging between one and 15 days (n = 32) and some up to 30 
(n=11), 90 (n = 4) and 270 days (n = 1). Excluding these last 16 studies from the analyses did 
not appreciably change our findings our findings however (data not shown). 
Limitations. An obvious limitation of our systematic review is that the degree of adherence 
to expert consensus guidelines was assessed from information as provided in the papers. If 
a methodological description omitted one or more of the 19 different scoring factors, no 
points were assigned for those factors. As a consequence some studies with sparse 
methodological descriptions received lower scores. Poor methodological reporting might 
therefore have confounded our outcomes. It should also be acknowledged that our 
estimation of the experience of a laboratory with FMD measurements does not necessarily 
reflect the experience of an individual sonographer. However, a laboratory more 
experienced in performing FMD measurements will generally require a level of skill and 
training for their sonographers that will meet at least the standard of their previous work. 
This highlights the importance of the level of experience in performing studies with FMD as 
an outcome variable. Another limitation is that our analysis on the relative importance of 
individual subject- and/or methodology-related factors could only be based on a between-
study comparison of factors contributing to the reproducibility of the FMD. Various other 
factors may have influenced this analysis. Therefore, future studies are necessary to further 
explore the importance of (some of) the methodology-related factors, including the effects 
of factors which we could not examine with the current dataset such as the observer/analyst, 
the time of cuff occlusion and changes in baseline brachial artery diameter. 
In conclusion, this systematic review shows that adherence to current expert consensus 
guidelines significantly reduces measurement error when assessing brachial artery FMD in 
humans. Moreover, when adopting the guidelines, we found that the use of contemporary 
techniques (i.e. continuous diameter recording, edge-detection and wall-tracking software 
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and under some circumstances the use of a probe holder) is crucial to improve 
reproducibility of the FMD measurement. Considering these factors will importantly 
decrease measurement error of the FMD and, consequently, decrease chances for type II 
errors in studies that rely on FMD as their primary outcome parameter. In other words, 
ignoring current expert-consensus guidelines causes significant variability of the FMD and, 
consequently, may lead to spurious conclusions. This study delivers important insight that 
should be taken into account when developing future updates to expert-consensus 
guidelines. 
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Abstract 
Brachial artery flow mediated dilation (FMD) is widely used as a non-invasive measure of 
endothelial function. Adherence to expert consensus guidelines on FMD measurement has 
been found to be of vital importance to obtain reproducible data. This article lists the 
literature data which was considered in the development of a tool to aid in the objective 
judgement of the extent to which published studies adhered to expert guidelines for FMD 
measurement. Application of this tool in a systematic review of FMD studies 
(http://dx.doi.org/10.1016/j.atherosclerosis.2016.03.011)1 indicated that adherence to 
expert consensus guidelines is strongly correlated to the reproducibility of FMD data. 
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Specifications Table 
Subject area Medicine 
More specific subject 
area 
Vascular Physiology 
Type of data Table 
How data was acquired Systematic literature survey and expert consensus 
Data format Processed  
Experimental factors  Methodological parameters related to valid measurement FMD 
Experimental features  Assessment tool based on 33 studies pertaining to the most 
appropriate methods to assess FMD in humans identified from 
literature and expert guidelines for FMD measurement 
Data source location  Nijmegen, The Netherlands 
Data accessibility Data is within this article 
 
Value of the data 
 The literature data provided here establishes an evidence base and a physiological 
background rationale for the individual components included in the Adherence 
Score, aiding in the improvement of the practical guidance and technical approaches 
to FMD measurement and analysis. 
 This “Adherence Score” which ranges between 0 (i.e. no adherence) and 10 (i.e. full 
adherence) can conceivably be employed to evaluate the perceived quality of studies 
reporting FMD data, with a higher outcome of this measure being strongly related to 
better reproducibility of the FMD data. 
 This tool may prove useful additional information when pooling, contrasting and 
comparing different studies, e.g. for the purpose of meta-analyses or systematic 
reviews.  
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Data 
A tool to enable objective assessment of the level adherence to the FMD guidelines was 
developed. Table 1 presents the 19 different factors that make up the “Adherence Score” tool 
along with citations to the literature data which justify the inclusion of each factor in 
question.  
Experimental design, materials and methods 
Based on previous expert-consensus guidelines,35 we devised a scoring system reliant on 
the reporting of 19 different methodological factors related to FMD measurement. These 
factors were identified after critical review and appraisal of published physiological studies 
pertaining to the most appropriate methods to assess FMD in humans. Values were 
assigned to each component proportional to its perceived importance for valid assessment 
of the FMD. This was done through expert consensus discussion within the Working Group 
(AG, LG and DHJT). The “Adherence Score” that any given study can be assigned ranges from 
0 to 10 points depending on how many of the 19 different factors that are reported or 
referred to in the text of the paper in question. 
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Abstract 
Objectives: Brachial artery flow-mediated dilation (FMD) is a popular technique to examine 
endothelial function in humans. Identifying volunteer and methodological factors related to 
variation in FMD is important to improve measurement accuracy and applicability. 
Methods: Volunteer-related and methodology-related parameters were collected in 672 
volunteers from eight affiliated centres worldwide who underwent repeated measures of 
FMD. All centres adopted contemporary expert-consensus guidelines for FMD assessment. 
After calculating the coefficient of variation (%) of the FMD for each individual, we 
constructed quartiles (n  =  168 per quartile). Based on two regression models (volunteer-
related factors and methodology-related factors), statistically significant components of 
these two models were added to a final regression model (calculated as β-coefficient and 
R2). This allowed us to identify factors that independently contributed to the variation in 
FMD%.  
Results: Median coefficient of variation was 17.5%, with healthy volunteers demonstrating 
a coefficient of variation 9.3%. Regression models revealed age (β  =  0.248, P  <  0.001), 
hypertension (β  =  0.104, P  <  0.001), dyslipidemia (β  =  0.331, P  <  0.001), time between 
measurements (β  =  0.318, P  <  0.001), lab experience (β  =  -0.133, P < 0.001) and baseline 
FMD% (β  =  0.082, P  <  0.05) as contributors to the coefficient of variation. After including all 
significant factors in the final model, we found that time between measurements, 
hypertension, baseline FMD% and lab experience with FMD independently predicted 
brachial artery variability (total R2  =  0.202). 
Conclusions: Although FMD% showed good reproducibility, larger variation was observed 
in conditions with longer time between measurements, hypertension, less experience and 
lower baseline FMD%. Accounting for these factors may improve FMD% variability. 
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Introduction 
Cardiovascular disease remains the world’s leading cause of morbidity and mortality. 
Previous studies have provided convincing evidence that endothelial dysfunction is an early 
manifestation of cardiovascular disease,1, 2 contributing to development and/or acceleration 
of the atherosclerotic process. Based on the detrimental role of endothelial dysfunction in 
this common disease process, studies have attempted to develop and validate (non-invasive) 
methods and biomarkers to assess endothelial function in humans. The conceptual idea is 
that identification of endothelial dysfunction, in symptomatic as well as asymptomatic 
volunteers, is related to increased risk for future development of cardiovascular events.3, 4 
A frequently-used, non-invasive technique to examine endothelial function in humans in vivo 
is flow-mediated dilation (FMD).5 This measurement adopts high resolution ultrasonography 
to measure the conduit artery diameter dilatation in response to marked elevation in blood 
flow (and therefore shear stress) after a 5-minute period of distal limb ischemia.6 Studies 
have provided evidence that the FMD-response is endothelium-dependent 7 and largely 
mediated by nitric oxide,8 an important and potent vasodilator and anti-atherogenic 
molecule. The measurement of endothelial function using FMD has become popular in 
clinically-orientated studies, likely because of its non-invasive nature, ability to predict 
cardiovascular events 4, 9-11 and correlation to coronary artery endothelial function.2, 12 
Despite its valid conceptual basis, a number of factors influence the variability of FMD.13, 14 
Previous studies found that FMD is influenced by lifestyle factors (e.g. smoking, physical 
activity), methodology (e.g. cuff placement, duration of ischemia), intake of food and 
beverages, hormonal changes, and method of analysis.8, 11 Although many of these factors 
are currently being controlled for through adopting expert-consensus guidelines,11, 15 
variation in FMD remains. These sources of variation may be volunteer-and/or 
methodology-dependent, but this has not yet been systematically studied. Identification of 
such factors will contribute to the control of measurement error, which will help to 
appropriately power studies and aid in the construction of rigorous and standardized 
guidelines.11, 16 
The purpose of this study was to identify volunteer- and methodology-related factors that 
contribute to FMD variation in humans. To this end, we combined data from previous studies 
(from 8 research centres) that performed repeated measurements within-volunteers of 
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brachial artery FMD in a total of 672 individuals. All included studies were performed 
according to expert-consensus guidelines.11 Subsequently, we assessed volunteer- and 
methodology-related factors that contributed to brachial artery FMD variability.   
Methods 
Study population 
The International Working Group on Flow-Mediated Dilation (IWG-FMD) originates from 
eight different research groups in four different countries. All groups provided written 
consent to contribute their data. We compiled volunteer-level data from all participating 
research centres (see supplementary list), including a total of 19 different studies. All 
affiliated researchers provided details on methodology of included studies in a specifically 
designed questionnaire. These details were cross-checked with earlier published and/or 
unpublished data. All centres received an outline of the datasheet, to enhance sufficient and 
complete data collection. A total of 84 parameters were explored. Data from a total of 672 
individuals with measurement of the brachial artery FMD, assessed on at least two separate 
occasions, obtained by B-mode ultrasound systems were available for data analyses. When 
studies included more than one repeated measurement, only the first and second 
measurement were included prior to statistical analyses. All subsequent repeated 
measurements were rejected, to prevent distortion included parameters.  
Brachial artery flow mediated dilation measurements: methodological 
considerations 
We included data from participants whose FMD data were collected on 2 separate occasions 
without an intervention between both measurements. These measurements were limited to 
the brachial artery (measurements of e.g. the radial-, femoral or popliteal arteries were 
excluded), in either the right or left arm (consistent for both measurements). To examine 
brachial artery FMD, participants extend the scanned arm following a short (10-15 minutes) 
resting period in the supine position. A rapid inflation and deflation pneumatic cuff was 
positioned on the forearm of the imaged arm distal to the olecranon process to provide a 
stimulus of forearm ischemia.11, 15 With an ultrasound system, B-mode images of the 
brachial artery in the distal third of the upper arm (above the antecubital fossa in the 
longitudinal plane) were made. When an optimal image was obtained, the ultrasound probe 
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was held stable (manually or by using a clamp) and ultrasound parameters were set to 
optimise the longitudinal B-mode image. At least one minute of baseline diameter was 
recorded, after which the pneumatic cuff was inflated to at least 50 mmHg above systolic 
pressure to occlude arterial inflow for a standardised length of time (i.e. standardised time 
of 5 minutes of occlusion). Subsequent cuff deflation induced a brief high-flow (hyperaemic) 
state that increased wall-shear stress at the brachial artery, causing it to dilate. To assess 
flow velocity, a mid-artery pulsed Doppler signal was obtained during the protocol.11, 15 
Whilst all study centres used slightly different protocols to collect the repeated FMD 
measurements, all followed the above described expert-consensus guidelines. 
Different types of ultrasound systems were used across the different centres, including; 
TerasonT3000 (Terason, Aloka, United Kingdom; 10-MHz multifrequency linear array 
transducer, n=136), Sonos 5500 (Hewlett-Packard, 7.5-MHz linear array transducer, n=20), 
ESAOTEMyLab25 (ESAOTE, Florence, Italy; 10-MHz linear array transducer, n=54), ESAOTE 
Picus Just 4D (ESAOTE, Maastricht, the Netherlands, 7.5-MHz linear array transducer, 
n=60), ESAOTE MyLabTM70 (ESAOTE, Maastricht, the Netherlands; 7.5-MHz linear array 
transducer, n=51), VIVID E9 (VIVID E9, General Electric, Waukesha, WI, USA, 15-MHz linear 
array transducer, n=109), AU5 Armonic system (ESAOTE, Florence, Italy; 7.0-MHz linear 
array transducer, n=136). One included study is a multi-centre study consisting of 7 sub-
studies, which used a range of devices (ESAOTE, Philips, Siemens and General Electric, 7.5-
10 MHz linear array transducer, n=110).  
All studies used (semi)automatic analysis software. However, different software was used 
across the centres:(1) Custom made MyFMD software, V2012.2, Prof. A.P.G. Hoeks, 
Department of Biomedical Engineering, Maastricht University, Maastricht, the Netherlands 
(n=130); (2) Custom made software,17 Pisa, Italy (n=135); (3) Custom made DICOM software 
for edge-detection (n=135);18, 19 and (4) FMD Studio, Cardiovascular Suite, ClinicalPhysiology, 
National ResearchCouncil, Pisa, Italy (n=272).20, 21 All centres collected continuous 
measurements of the diameter and recorded these (on either VCR or digitally) for post-study 
analyses. No study used fixed time points for diameter estimation. 
Sources of variation 
Our primary outcome parameter was the variation between both FMD measurements, for 
which we calculated the coefficient of variation (CV) for each individual's repeated 
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measurements, calculated as [(sdFMD/meanFMD)*100]. Furthermore, we recorded FMD 
(%), baseline diameter (cm), maximal diameter (cm), and time between measurements 
(categorized in <24h, 1-7 days, 8-14 days, 2-4 weeks, or >4 weeks).  
Measurement of volunteer-related factors. We included the following volunteer-related 
factors, that were all presented using a continuous scale; age (inclusion ≥18 years, range 
18-82 years); weight (range 45-171 kg); height (range 1.55-1.94 m); body mass index 
(calculated as weight (kg)/ height2(m), range 17.6-55.8kg/m2); systolic- and diastolic blood 
pressure (in mmHg) and calculated mean arterial pressure [MAP, calculated as (2*diastolic 
pressure + systolic pressure) / 3, range 64-139 mmHg]; and blood-specific parameters (i.e. 
total cholesterol; high density lipoprotein, HDL; low density lipoprotein, LDL; triglycerides; 
glucose; all in mmol/L). All original parameters were rescaled to the same metric or most 
frequently used units (i.e. cholesterol and glucose values converted from mg/dL to 
mmol/L).22 
We also presented volunteer-related factors using categorical scales: sex (male/female); 
presence of hypertension (conform current guidelines defined as: systolic pressure ≥140 
mmHg and/or diastolic pressure ≥90 mmHg, or using blood pressure-lowering drugs, 
yes/no); the presence of diabetes (type 1 or type 2); smoking status (yes/no/history of 
smoking); presence of dyslipidemia (yes/no, as specified by each contributing centre), and 
history and/or presence of cardiovascular disease (CVD).  
Measurement of methodology-related parameters. All assessments followed the expert-
consensus FMD guidelines, ensuring that the protocol involved cuff placement around the 
forearm, occlusion for 5-minutes and cuff inflation ≥50 mmHg above systolic pressure. 
Furthermore, we assessed the following factors; use of a probe holder (yes/no); lab 
experience (total number of peer-reviewed publications that included measurement of FMD 
from contributing principal investigator through a Pubmed-based search using the search 
term “[author] AND flow mediated dilation”); mention of the laboratory’s own reported 
coefficient of variation (mentioned as CV% reported); use of continuous and/or ECG-gated 
diameter recording; measurement of artery diameter across the cardiac cycle; and the time 
between measurements (<24h, 1-7 days, 8-14 days, 2-4 weeks, and >4 weeks). The 
Supplementary material provides details of the questionnaire used to assess these factors. 
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Missing values 
Since missing data were present for all of the 82 individual parameters, we used multiple 
imputation chained equations to impute parameters. We performed this procedure with a 
maximum up to 30%, as previously described.23, 24 Parameters for which 31% or more was 
data were missing, were excluded from analyses and are not further mentioned. A more 
detailed outline of the imputation model can be found in the Supplementary material.  
Statistical analysis 
All data are presented as N(%) or mean ± standard deviation unless stated otherwise. The 
main outcome measure for the reproducibility of the FMD is the coefficient of variation (CV) 
calculated for the mean difference between both FMD measurements. All descriptive data 
were examined in the pooled dataset and in quartiles of variation in FMD (i.e. CV). Based on 
the CV, we qualified the reproducibility as excellent (0-10%), good (10-20%), moderate (20-
30%) or poor (>30%).25 In multiple linear regression analyses we used the (log transformed) 
FMD CV as the dependent variable to identify factors that independently contributed to the 
variability of the FMD measurement, using backward regression analysis. A total of 4 
models were constructed; Model 1a - Volunteer-related factors (continuous scale), Model 
1b–Volunteer-related factors (categorical scale, i.e. presence of hypertension), Model 2–
Methodology-related factors, and Model 3–Significant factors from previous models 1a-1b-
2. Details of all regression models are given in the Supplemental information. All statistical 
analyses were performed using the Statistical Package for Social Sciences, version 20.0 
(SPSS, INC. Chicago, IL, USA). 
Results 
A median CV of 17.5% was observed for the entire population of 672 volunteers, whilst a 
median CV of 9.3% was observed for volunteers without CV risk factors (n=109). We observed 
substantial variation between volunteers regarding the individual CV for the FMD% (Figure 
1). When dividing volunteers into 4 quartiles, we calculated the CV for each quartile (Mean 
CV 29.9±46.5, range 0.14-745.33; Median CV Quartile-1 3.25%; Quartile-2 11.74%; Quartile-
3 24.76%; Quartile-4 61.03%). We found an excellent, good or moderate CV in 33% (n=221), 
22% (n=147), and 14% (n=94) of the sample, respectively. A poor CV was observed in 31% of 
the cases (n=210). 
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Figure 1. Individual reproducibility in brachial artery FMD. Data of all volunteers (n=672) relating 
to the individual reproducibility of the brachial artery FMD across 2 repeated measurements. 
Volunteer-related factors 
Age, BMI, total cholesterol, and glucose levels showed a gradual increase across quartiles, 
with Q3 and Q4 (i.e. large variation in FMD) showing significantly higher values than Q1 
(Table 1). Systolic, diastolic and mean blood pressure were highest in Q2-3, whilst this 
difference was lost in Q4 (Table 1). When volunteer-related factors were presented using a 
categorical scale, hypertension and dyslipidemia had significant impact on the 
reproducibility of the FMD (presence of hypertension Q1 15.5%, Q2 30.4%, Q3 32.1% and Q4 
21.4%, diabetes Q1 0%, Q2 0%, Q3 1.2% and Q4 0.6%, both P<0.001), but not sex, smoking 
status, diabetes mellitus and CVD. 
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Table 1. Volunteer-related factors. 
Continuous scale 
Pooled 
{29.9±46.5} 
Quartile 1 
{3.25%} 
Quartile 2 
{11.74%} 
Quartile 3 
{24.76%} 
Quartile 4 
{61.03%} 
P-value 
Age (years) 
46±17   
(655) 
40±16  
(163) 
42±15  
(164) 
46±16* 
(164) 
54±16* 
(164) 
<0.001 
Sex (% male) 
66         
(671) 
64         
(168) 
67         
(168) 
68         
(167) 
67         
(168) 
0.895 
Weight (kg) 
77.4±13.1 
(636) 
75.9±12.1 
(163) 
76.7±11.8 
(161) 
78.6±14.4 
(160) 
78.3±14.1 
(152) 
0.210 
Height (cm) 
1.75±0.1 
(637) 
1.76±0.1 
(163) 
1.76±0.1 
(161) 
1.75±0.1 
(160) 
1.75±0.1 
(152) 
0.657 
BMI (kg/m) 
25.3±3.7 
(657) 
24.6±3.4 
(164) 
24.9±3.3 
(165) 
25.8±4.2* 
(164) 
25.9±3.5* 
(164) 
0.003 
Systolic BP (mmHg) 
129±15 
(645) 
127±13 
(161) 
131±14* 
(163) 
130±16* 
(159) 
128±15 
(162) 
0.023 
Diastolic BP (mmHg) 
79±11   
(645) 
78±11  
(161) 
81±12* 
(163) 
79±12  
(159) 
76±11  
(162) 
<0.001 
Mean BP (mmHg) 
96±12   
(655) 
94±11  
(135) 
98±12* 
(165) 
96±13  
(163) 
94±11  
(164) 
0.002 
Cholesterol (mmol/L) 
5.3±1.0 
(544) 
5.1±1.0 
(135) 
5.2±1.0 
(134) 
5.4±1.0* 
(134) 
5.6±0.9* 
(141) 
<0.001 
HDL (mmol/L) 
1.4±0.4 
(508) 
1.4±0.3 
(127) 
1.4 ±0.3 
(126) 
1.4±0.3 
(124) 
1.4±0.4 
(131) 
0.414 
LDL (mmol/L) 
3.5±0.8 
(466) 
3.3±0.8 
(115) 
3.3±0.8 
(109) 
3.5±0.9* 
(112) 
3.7±0.8* 
(130) 
<0.001 
Triglycerides (mmol/L) 
1.4±1    
(529) 
1.3±0.8 
(129) 
1.4±1.3 
(130) 
1.4±0.9 
(130) 
1.3±0.8 
(140) 
0.924 
Glucose (mmol/L) 
5.1±0.7 
(466) 
5.0±0.7 
(132) 
5.0±0.9 
(132) 
5.0±0.7 
(114) 
5.4±0.7* 
(88) 
<0.001 
Volunteer-related factors for whole group (n=672) and quartiles (of n=168 each) with median CV reported per 
quartile. Data are reported as mean ± SD with total number of volunteers available for analysis presented in 
brackets in italic. P-value refers to an ANOVA. *Post-hoc significantly different from Quartile 1 at P<0.05 
 
Methodology-related factors 
FMD% and baseline diameter were significantly different across quartiles of the CV (Table 
2). Volunteer in Q4 had a lower FMD and a larger baseline diameter (Table 2). We found that 
all factors related to the practical performance of the FMD, except the use of a probe holder, 
were significantly different between quartiles (Table 2). Larger variation in CV FMD% (i.e. 
Q3-4) was associated with absence of ECG-gated recording, no measurement of the 
diameter across the cardiac cycle, longer time between tests, less experience of the 
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research centre in FMD measurements, and absence of reporting the CV of the laboratory 
in manuscripts (Table 2). 
 
Table 2. Methodological-related factors. 
Continuous scale 
Pooled 
{29.9±46.5} 
Quartile 1 
{3.25%} 
Quartile 2 
{11.74%} 
Quartile 3 
{24.76%} 
Quartile 4 
{61.03%} 
P-value 
Baseline diameter (mm) 4.3±0.8 (672) 4.1±0.8 (168) 
4.3±0.7* 
(168) 
4.4±0.8* 
(168) 
4.4±0.8* 
(168) 
<0.001 
Maximal diameter (mm) 4.5±0.8 (672) 4.3±0.8 (168) 
4.5±0.7* 
(168) 
4.6±0.9* 
(168) 
4.5±0.8* 
(168) 
<0.001 
FMD (%) 5.4±3.0 (672) 6.1±2.8 (168) 5.8±2.4 (168) 5.7±2.8 (168) 
4.1±3.6* 
(168) 
<0.001 
Laboratory experience 
(papers per PI) 
29.2±24.8 
(672) 
35.6±21.9 
(168) 
35.1±22.9 
(168) 
30.9±25.3* 
(168) 
15.4±23.6* 
(168) 
<0.001 
CV reported (%) 
16.8±9.5 
(612) 
14.7±6.9 
(155) 
14.6±6.7 
(160) 
16.5±9.5 
(158) 
22.2±12.4 
(139) 
<0.001 
Categorial scale       
Analysis by laboratory 
96  
(672) 
99  
(168) 
99  
(168) 
95*  
(168) 
92*  
(168) 
<0.001 
ECG-gated recording 
28  
(672) 
25  
(168) 
38*  
(168) 
35*  
(168) 
13*  
(168) 
<0.001 
Cardiac cycle (%) 
84  
(672) 
87  
(168) 
88  
(168) 
87  
(168) 
73*  
(168) 
<0.001 
Probe holder (%) 
80  
(672) 
77  
(168) 
79  
(168) 
77  
(168) 
86  
(168) 
0.110 
Time: <24 hours (%) 53 69 69 52 21 <0.001 
1-7 days (%) 6 6 9 6 4  
8-14 days (%) 7 5 5 10 8  
2-4 weeks (%) 9 9 6 8 11  
>4weeks (%) 25 11 11 24 56  
 (672) (168) (168) (168) (168)  
Methodological-related factors presented for whole group (n=672) and quartiles (n=168 each) with 
median CV reported per quartile. Data are reported as mean ± SD with the total number of volunteers 
available for analysis presented in brackets in italic. P-value refers to an ANOVA. *Post-hoc significantly 
different from Quartile 1 at P < 0.05. 
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Regression analyses 
Model 1a – Volunteer-related factors (continuous). After including all volunteer-related factors 
that significantly differed across quartiles, this model showed an R2 = 0.087 and adjusted R2 
= 0.086. We found that only age predicted variation in FMD%CV (β = 0.248, ratio of 28.1%, 
CI[0.020-0.035], p-value <0.001).  
Model 1b–Volunteer-related factors (categorical). Including all volunteer-related factors that 
differed across quartiles, we found an R2 = 0.112 and adjusted R2 = 0.108. We identified 
hypertension (β = 0.104, ratio of 11%, CI [0.095-0.533], p-value 0.005), dyslipidemia (β = 0.331, 
ratio of 39.2%, CI [0.813-1.275], p-value <0.001) and sex (β = -0.069, ratio of -6.7%, CI [-0.390-
0.010], p-value 0.063) as significant predictors for the reproducibility of the FMD%. 
Model 2–Methodology-related factors. This model showed an R2 = 0.198 and adjusted R2 = 0.184 
when including methodology-related factors that differed across quartiles. The model 
identified time between measurements (β = 0.318, ratio of 37.5%,CI [0.179-0.298], p-value 
<0.001), FMD% at baseline (β = -0.124, ratio of -11.7%, CI [-0.098--0.021], p-value 0.002), 
baseline diameter (β = 0.082, ratio of 8.6%, CI [0.007-0.270], p-value 0.039) and lab 
experience (β = -0.133, ratio of -12.4%, CI [-0.011--0.003], p-value 0.001) as significant 
contributors to the variation in FMD% CV.  
Model 3 - Overall model. Factors identified by models 1a, 1b and 2 were included in the overall 
model which resulted in an R2 = 0.208 and adjusted R2 = 0.202. Backward linear regression 
analysis identified time between measurements (β = 0.291, ratio of 33.8%, CI [0.156-0.273], 
p-value <0.001), hypertension (β = 0.096, ratio of 10.1%, CI [0.068-0.501], p-value 0.010), 
baseline FMD% (β = -0.142, ratio of -13.3%, CI [-0.105--0.030], p-value <0.001) and lab 
experience (β=-0.131, ratio of -12.3%, CI [-0.012--0.003], p-value 0.001) as significant 
contributors to the variation in FMD% across 2 repeated measurements (Figure 2). Baseline 
diameter demonstrated a borderline significant association with FMD% reproducibility (β = 
0.070, ratio of 7.2%, CI [-0.015-0.242], p-value 0.084). 
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Figure 2. Regression analysis. Plot for regression coefficient β for the coefficient of variation (CV) of 
the flow mediated dilation (FMD). * implies a statistical significant contribution in final model. 
Discussion 
This study included 672 repeated measurement of the brachial artery FMD, involving data 
from different research centres and various populations. This allowed us to 
comprehensively explore factors contributing to the within-volunteer variability of brachial 
artery FMD%, when measured according contemporary guidelines.11 We present the 
following observations. First, the majority of the measurements showed an excellent-to-
good reproducibility. For asymptomatic volunteers, the median CV was 9.3%. This 
demonstrates that FMD is a reproducible tool to assess endothelial function in vivo. 
Secondly, we also found substantial variation between individuals in the CV of FMD% within 
volunteers. In particular, the presence of hypertension contributed to a larger variation in 
FMD%, independent of other factors. Third, we found that a poorer reproducibility of the 
FMD was associated with the presence of a lower baseline FMD%, a higher baseline brachial 
artery diameter, a longer time period between repeated measurements, and less 
experience of the laboratory with the FMD measurement. Taking these factors into 
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consideration for sample size calculations in future studies will help to decrease chances of 
type II errors. 
 
Volunteer-related factors 
Several previous studies have explored and described reproducibility of brachial artery FMD 
and presented mixed results, ranging from an excellent to poor reproducibility.13, 26, 27 The 
overall median CV% in our analysis of 17.5% in the whole study population, and 9.3% in 
volunteers without CV risk/disease, are in line with findings of most previous studies that 
reported a good reproducibility.14, 16, 28-30 An important strength of our analysis is the large 
number of repeated measurements, which allowed us to identify between-volunteer and –
laboratory related factors contributing to the variation in brachial artery FMD% within an 
individual. Interestingly, we found that older age, dyslipidaemia and presence of 
hypertension were related to larger variation in FMD%. This suggests, in agreement with 
previous work,28 that reproducibility of the FMD may be lower in populations with clinical 
symptoms than in healthy, young volunteers.  
An explanation for the larger variation in clinical populations could be the presence of a 
lower baseline FMD% that is typically observed in older volunteers 31 and in those with 
hypertension,32 CVD 33 or dyslipidaemia.14 Indeed, we found that baseline FMD% is a strong 
and independent predictor for larger variability. Therefore, baseline FMD% was added to the 
statistical model to explore its impact on variability in FMD% independent of older age, 
hypertension and dyslipidaemia. Interestingly, in this model the impact of age and 
dyslipidaemia disappeared, suggesting that the lower baseline FMD% in older volunteers is 
at least partly responsible for the larger variation with increasing age. In contrast, the 
impact of hypertension remained significant, indicating that other factors play a role in the 
larger variation in repeated measurements of brachial artery FMD%. Possibly, this poorer 
reproducibility may relate to higher stiffness of the vessels in clinical populations, compared 
to healthy volunteers.34 Craiem et. al. also found that volunteers with CVD, despite 
comparable baseline FMD% values, demonstrate a larger coefficient of variation compared 
to healthy controls.28 
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Methodology-related factors 
Identification of methodology-related factors that contribute to the variation in FMD is highly 
relevant because such factors can potentially be controlled for. Several previous studies 
have highlighted the importance of methodological factors, which formed the basis for the 
FMD expert consensus guidelines.11 The present study identified time between 
measurements and lab experience as independent determinants of the variation in FMD%, 
with more time between FMD measurement leading to a higher CV. Most studies that 
explored FMD reproducibility included fixed time points between measurements, which 
makes direct comparisons of the duration between testing difficult. Interestingly, Charakida 
et. al. explored FMD reproducibility after a few hours, 2 day, 3 months and 9 month 35. In 
agreement with our findings, this study also demonstrate a poorer CV with increased time 
between re-testing. In contrast, Sorensen et. al. found no difference in reproducibility when 
FMD was repeated after 1-2 days, 1-2 weeks or 2-4 months.27 However, this study did not 
apply FMD measurements according to current guidelines, which may have affected the 
results. Whilst longer time between repeated measures may be associated with increased 
variability due to purely methodological variation, it is also likely that true biological 
variability is greater under circumstances where the repeated measure is more distant in 
time.  
Laboratories that provided data for this analysis adopted expert consensus guidelines to 
perform and analyse FMD. This makes it difficult to explore the importance, for 
reproducibility, of the individual aspects within these guidelines. Nonetheless, our analysis 
showed that laboratory experience with FMD measurements independently contributes to 
the variation in FMD measurement. More specifically, the greater the experience of a 
laboratory with the FMD technique, the smaller the variation between repeated FMD 
measurements. This somewhat self-evident finding is nonetheless important, as it should 
guide laboratories who adopt the technique in attaining the level of practice and experience 
required before robust measures can be assumed. Nonetheless, limited experience of FMD 
did not completely invalidate assessment: the subgroup of healthy volunteers without CV 
risk/disease that showed a CV of 9.3±19% (n=109) included data from both experienced and 
less experienced laboratories, demonstrating the feasibility of a low CV in FMD 
measurements. This is in accordance with previous multi-centre studies.16 These data 
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demonstrate the importance of adherence to the expert-consensus guidelines in addition to 
a priori practice and experience with the FMD-technique. 
Practical relevance. This study demonstrates that, in addition to adopting current guidelines, 
some factors should be considered that might affect the variation of the FMD. For example, 
larger FMD reproducibility is observed when the time between measurements increases 
and/or in the presence of hypertension, and low resting FMD%. These factors should be 
taken into consideration when performing a sample size calculation and in the design of the 
study. Furthermore, the data of this study also emphasise that, in addition to fair 
reproducibility of the FMD in less experienced laboratories, training and gaining more 
experience is likely to minimise measurement error of the FMD-technique. 
Limitations. One limitation of our study is that it was not prospectively designed to address 
FMD reproducibility. This may have introduced some error, especially relating to controlling 
physical activity and/or dietary instructions for the time between testing. However, all data 
was collected as in a ‘real world’ study rather than being set-up as a reproducibility study. 
Therefore, our study possesses ecological validity and can be extrapolated to various 
research settings. Another limitation is that all data in our analysis derive from laboratories 
adopting current guidelines for FMD measurement. Therefore, we were unable to address 
the relative importance of individual aspects included in these guidelines. In addition, whilst 
all centres indicated they adhered to the expert-consensus guidelines, we have no specific 
data on the internal control of adherence and/or small variation within these guidelines 
between centres (e.g. differences in analysis software, ultrasound machines). Such 
differences may in part contribute to the inherent variability of the FMD 
In conclusion, we have shown in a large dataset of repeated measurements that the majority 
of FMD measurements show an excellent-to-moderate reproducibility. Despite adopting 
expert consensus guidelines, several volunteer and methodology-related factors have 
independent impact on the variation in FMD% between two measurements. These include 
the presence of hypertension, a lower resting FMD%, a larger baseline artery diameter, a 
longer time between subsequent measurements, and less laboratory experience with the 
measurement. Future studies should take these volunteer- and methodology-related 
factors into consideration to improve sample size calculation. Such procedures will 
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importantly decrease variability of the FMD and, consequently, decrease chances for type II 
errors in studies that rely on FMD as their primary outcome parameter.  
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Supplementary material 
1. Included studies 
All included studies involved in the analysis are listed below, grouped per country on 
alphabetical order, with contributing author(s).  
Australia   University of Western Australia - prof. Daniel Green 
 1 study   dr. Ceri Atkinson, dr. Louise Naylor and dr. Howard Carter 
Italy     Università di Pisa - prof. Lorenzo Ghiadoni 
 3 studies  dr. Rosa Maria Bruno 
The Netherlands Maastricht University - prof. Ronald Mensink & dr. Koen Reesink 
 1 study   dr. Frank van Bussel and dr. Yvo Kusters (CARIM) 
 1 study   dr. Peter Joris (NUTRIM) 
   Radboudumc Nijmegen - prof. Dick Thijssen 
 2 studies  dr. Tim Schreuder 
 1 study   drs. Joost Seeger 
 1 study   dr. Constatijn Wouters 
 1 study   prof. Dick Thijssen 
   Unilever - dr. Peter Zock 
 2 studies  dr. Arno Greyling 
   Wageningen University - prof. Marianne Gelijnse 
 1 study   dr. Lieke Gijsbers 
 1 study   dr. James Dower 
The United Kingdom - Liverpool John Moore's University - prof. Dick Thijssen and   
   prof. Daniel Green 
 2 studies  dr. Gurpreet Birk 
 2 studies  dr. Tom Bailey  
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2. Methodological questionnaire 
This Supplementary data contains the methodological questionnaire we asked all 
contributing centres (and authors) to fill in, to acquire the necessary methodological 
information.  
Study name :       
Number of volunteers included in the study:       
1. Investigators  
Please provide below the names and e-mail addresses of all investigators responsible for your study 
who should be mentioned as co-authors in this project 
Name 
      
E-mail address 
      
2. Study information  
Please give a short description of the study population below (e.g. apparently healthy, specific age 
range, obese individuals, hypertensive individuals, etc.) 
      
Please list all inclusion and exclusion criteria for the study below 
      
Please list all references to publications containing results of this study below 
      
3. Diameter/Flow Mediated Dilation measurements of the brachial artery 
Please give a short description of the volunteer preparation prior to the FMD measurement protocol 
below (i.e. resting, refrained from smoking/alcohol/exercise or not, vasoactive medications withheld 
or not, position of the participant, etc.) 
      
Please give a short description of the post occlusive reactive hyperemia protocol below (i.e. brachial 
artery occluded distal or proximal to the ultrasound probe, occlusion cuff pressure, duration of 
occlusion, etc.)  
      
Which device was used for obtaining B-mode images of the brachial artery (i.e. name, version, type & 
frequency of probe, etc.) 
      
(Semi)Automated analysis using edge detection and wall tracking software? 
If yes, please provide details of the system used (i.e. name, version, software 
version, etc.) 
Yes:     No:   
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Continuous measurement of diameter? 
If yes, what was the size of the time bins (sec)? 
Yes:     No:   
      
Diameter measured at fixed time points? 
If yes, at which time points? 
Yes:     No:   
      
Were diameter measurements ECG-gated? Yes:     No:   
Were diameter measurements averaged over the cardiac cycle? Yes:     No:   
Were FMD measurements centrally analyzed? Yes:     No:   
Simultaneous acquisition of pulse-wave Doppler velocity signal for quantification 
of shear stimulus? 
If yes, what was the insonation angle and how was the shear stimulus defined? 
Yes:     No:   
      
Was a stereostatic probe-holder used Yes:     No:   
      
What was the time duration between repeated measurements? 
      
What was the CV of the lab for %FMD at the time of the study? 
      
What was the level of the sonographer’s experience at the time of the study? (i.e. number of 
years/number of measurements conducted) 
      
Was endothelium-independent dilation measured? 
If yes, please provide details of the protocol used (i.e. dose of GTN, duration of 
measurement, etc.) 
Yes:     No:   
      
 
3. Imputation model 
This Supplementary data provides a more detailed description of the imputation model used 
to impute missing values. Parameters for which 31% or more was data were missing, were 
excluded from analyses and are not further mentioned. This model was developed in 
collaboration with dr. Lian van Engelen, who had previous experience with related data 
assessments. All analyses were done in SPSS 20.0, as described earlier.  
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MULTIPLE IMPUTATION weight height BMI SBP DBP MAP t_chol ldl_chol hdl_chol diabetes glucose 
lntrig  
    lnage lnFMD_CV hypertension_control mean_FMD stdev_FMD time dyslipidaemia smoking_1 
smoking_2  
    smoking_3 smoking  
  /IMPUTE METHOD=AUTO NIMPUTATIONS=10 MAXPCTMISSING=NONE  MAXCASEDRAWS=50 
MAXPARAMDRAWS=2 
  /CONSTRAINTS weight( MIN=40.0 MAX=175.0) 
  /CONSTRAINTS height( MIN=1.45 MAX=2.1) 
  /CONSTRAINTS BMI( MIN=15.0 MAX=57.0) 
  /CONSTRAINTS SBP( MIN=80.0 MAX=200.0) 
  /CONSTRAINTS DBP( MIN=40.0 MAX=120.0) 
  /CONSTRAINTS MAP( MIN=60.0 MAX=145.0) 
  /CONSTRAINTS t_chol( MIN=0 MAX=12) 
  /CONSTRAINTS ldl_chol( MIN=0.0 MAX=10.0) 
  /CONSTRAINTS hdl_chol( MIN=0.0 MAX=5.0) 
  /CONSTRAINTS glucose( MIN=0.0 MAX=12.0) 
  /CONSTRAINTS lntrig( MIN=-2.0 MAX=3.0) 
  /CONSTRAINTS lnage( ROLE=IND) 
  /CONSTRAINTS lnFMD_CV( ROLE=IND) 
  /CONSTRAINTS hypertension_control( ROLE=IND) 
  /CONSTRAINTS mean_FMD( ROLE=IND) 
  /CONSTRAINTS stdev_FMD( ROLE=IND) 
  /CONSTRAINTS time( ROLE=IND) 
  /CONSTRAINTS smoking_1( ROLE=IND) 
  /CONSTRAINTS smoking_2( ROLE=IND) 
  /CONSTRAINTS smoking_3( ROLE=IND) 
  /MISSINGSUMMARIES NONE  
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  /IMPUTATIONSUMMARIES MODELS DESCRIPTIVES  
  /OUTFILE IMPUTATIONS=IWG_imputation_total . 
 
To briefly elaborate on the model above, we imputed missing data for; weight, height, BMI, 
SBP, DBP, MAP, t_chol, ldl_chol, hdl_chol, diabetes, glucose, and lntrig. To provide for 
enough possible data points, we used; lnage, lnFMD_CV, hypertension_control, mean_FMD, 
stdev_FMD, time, dyslipidaemia, smoking_1, smoking_2, and smoking_3 as independent 
predictors (ROLE=IND).  
For all imputed data we set constraints on reasonable values, to assure that the imputations 
would be possible within the normal distributional range.  
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Abstract 
Hyperglycaemia, commonly present after a meal, causes transient impairment in 
endothelial function. We examined whether increases in blood flow (BF) protect against the 
hyperglycaemia-mediated decrease in endothelial function in healthy subjects and patients 
with type 2 diabetes mellitus (T2DM). Ten healthy subjects and 10 age- and sex-matched 
T2DM patients underwent simultaneous bilateral assessment of brachial artery endothelial 
function by means of flow-mediated dilation (FMD), using high-resolution echo-Doppler. 
FMD was examined before and 60, 120 and 150 minutes after a 75-gr oral glucose challenge. 
We unilaterally manipulated BF by heating one arm between minute 30 and 60. Oral glucose 
administration caused a statistically significant, transient increase in blood glucose in both 
groups (P < 0.001). Forearm skin temperature, brachial artery BF and shear rate 
significantly increased in the heated arm (P < 0.001), and to a greater extent compared to 
the non-heated arm in both groups (interaction-effect, P < 0.001). The glucose load caused 
a transient decrease in FMD% (P < 0.05), whilst heating significantly prevented the decline 
(interaction-effect: P < 0.01). Also when correcting for changes in diameter and shear rate, 
we found that the hyperglycaemia-induced decrease in FMD can be prevented by local 
heating (P < 0.05). These effects on FMD were observed in both groups. Our data indicate 
that non-metabolically driven elevation in BF and shear rate can similarly prevent the 
hyperglycaemia-induced decline in conduit artery endothelial function in healthy volunteers 
and in patients with type 2 diabetes. Additional research is warranted to confirm that other 
interventions increasing BF and shear rate equally protect the endothelium when 
challenged by hyperglycaemia. 
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Introduction 
Type 2 diabetes mellitus (T2DM) affects approximately 200 million people worldwide.1 Whilst 
the inability to maintain appropriate glucose levels plays a central role in the etiology of 
T2DM, mortality and morbidity in T2DM is largely related to the presence of cardiovascular 
diseases and vascular complications.2, 3 In developing cardiovascular complications, the 
presence of endothelial dysfunction plays a major role.4, 5 Various stimuli are identified that 
potentially alter endothelial (dys)function.6, 7 For example, increased blood glucose levels or 
hyperglycemia, which is frequently present in T2DM despite optimal pharmacological 
treatment,8 induces a transient impairment in endothelial function.9-14 The detrimental 
impact of hyperglycemia on endothelial function has been found in several studies in healthy 
adults 9, 10, 12, 14 as well as in patients with T2DM.13, 15 Given the frequent exposure to 
hyperglycemia, these observations highlight the importance for strategies to prevent or 
attenuate the impact of hyperglycemia on endothelial function. 
Studies in animals 16, 17 and humans 18 suggest that elevation in shear rate, i.e. the frictional 
force of blood upon the arterial wall, leads to improvements in vascular function and 
structure. A recent series of studies in humans demonstrated that elevation in shear rate, 
induced by heating of a forearm, can acutely 19 and chronically 20 improve vascular function. 
Moreover, we recently found that increases in shear rate (via heating of the forearm) 
prevents the immediate decline in brachial artery endothelial function during activation of 
the sympathetic nervous system.21 In line with these recent observations, elevation in shear 
rate may prevent the hyperglycemia-induced decline in endothelial function in healthy 
volunteers and in T2DM. 
The primary objective of this study, therefore, was to examine whether increases in shear 
rate (through heating of the skin) protect against the transient hyperglycemia-mediated 
decrease in endothelial function in healthy subjects and patients with T2DM. For this 
purpose, we bilaterally examined brachial artery flow mediated dilation (FMD) as a measure 
for endothelial function before and after a 75-gr glucose load, which is demonstrated to 
cause marked elevations in blood glucose and a transient decrease in endothelial function.9, 
10, 12-15 In addition, we unilaterally manipulated shear rate in the brachial artery by heating 
the arm for 30-minutes, to examine the hypothesis that (non-metabolically driven) increases 
in shear rate prevent the decline in endothelial function.  
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Methods 
Participants 
Ten male subjects with T2DM (age 63 ± 6 years) and 10 age-matched healthy male controls 
(57 ± 9 years) were included in our study. Individuals were excluded if they smoked, had past 
or present cardiovascular disease, hypercholesterolemia or hypertension (>160 mmHg 
systolic and/or >90 mmHg diastolic pressure). The subjects in the T2DM group had to be 
diagnosed with type 2 diabetes mellitus at least two years ago. Subjects in this group were 
excluded if they had vascular complications due to type 2 diabetes mellitus (e.g. diabetic foot 
ulcer). All participants provided written informed consent before participation. The study 
procedures were approved by the medical ethics committee of the region Arnhem-
Nijmegen, the Netherlands and adhered to the Declaration of Helsinki (2000). This study is 
registered at the Netherlands Trial Registry as NTR4631. 
Experimental design 
In this study, both groups reported to our laboratory once for assessment of glucose 
homeostasis and brachial artery endothelial function. First, we performed simultaneous, 
bilateral assessment of brachial artery FMD, immediately followed by the ingestion of 75-gr 
of glucose dissolved in 200 mL water. Thirty minutes after ingestion, we unilaterally heated 
one forearm for 30 minutes. Heating of the arm was randomized between subjects. 
Subsequently, bilateral simultaneous assessment of brachial artery FMD was repeated at 
60, 120 and 150 minutes after ingestion of the glucose load. 
Experimental measures 
Ultrasound assessments were performed in a quiet temperature-controlled room (22°C). 
Measurements in a single arm were always performed by the same sonographer for each 
individual subject. All measurements were performed following a ≥6 hour fast, ≥18 hour 
abstinence from coffee (and other products containing caffeine, including energy drinks), 
alcohol, vitamin supplements, products with high levels of vitamin C, polyphenol-rich foods, 
and at least 24 hours after strenuous physical activity. All glucose lowering and vasoactive 
medication was also withheld on the morning of the measurement.22 We performed all tests 
between 8 AM and 4 PM to control for variation in FMD between subjects.23-26 
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Brachial artery FMD. Measurements were performed by 2 well-experienced sonographers 
following a resting period of at least 20 minutes in the supine position. We simultaneously 
measured FMD in the right and left brachial arteries according to recent guidelines for 
assessment of FMD as previously described by Thijssen et al.22 For this purpose, both arms 
were extended and positioned at an angle of ~80° from the torso. A rapid inflation and 
deflation pneumatic cuff (D.E. Hokanson, Bellevue, WA) was positioned on the forearm, 
immediately distal to the olecranon process to provide a stimulus to forearm ischemia. A 
10-MHz multi-frequency linear array handheld probe, attached to a high-resolution 
ultrasound machine (T3000; Terason, Burlington, MA) was then used to image the brachial 
artery in the distal one third of the upper arm. When an optimal image was obtained, the 
probe was held stable and the ultrasound parameters were set to optimize the longitudinal, 
B-mode image of the lumen-arterial wall interface. Settings were identical between all 
assessments of the FMD. Continuous Doppler velocity assessments were also obtained 
using the ultrasound and were collected using the lowest possible insonation angle (always 
<60°). Baseline images were recorded for 1 minute after which the forearm cuff was inflated 
(>200 mmHg) for 5-minutes. Diameter and flow recordings resumed 30 sec prior to cuff 
deflation and continued for 3 minutes thereafter, in accordance with recent technical 
specifications.27 
Forearm skin temperature. During the complete protocol, forearm skin temperature of both 
forearms was measured using iButtons® (Maxim Integrated, San Jose, CA). These data 
were transferred to a computer and analyzed afterwards. Furthermore, forearm skin 
temperature was also measured manually using a standard auricle thermometer before 
every FMD and every five minutes during the heating process so that the researcher had a 
direct indication of the heating progress.  
Venous blood. In all individuals, a routine haematochemical check was performed by 
standard methods before testing. A venous blood sample was taken at baseline for 
assessment of fasting blood lipids, glucose and insulin levels. The subjects’ degree of insulin 
resistance was assessed by calculating the HOMA-IR index from fasting glucose and insulin 
levels. Furthermore, venous blood was repeatedly taken to assess blood glucose levels at 
60, 120 and 150 minutes after glucose ingestion.  
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Brachial artery diameter and blood flow analysis 
Analysis of brachial artery diameter was performed using custom-designed edge-detection 
and wall-tracking software, which is independent of investigator bias. Previous papers 
contain detailed descriptions of our analysis approach.27 From synchronized diameter and 
velocity data, blood flow (the product of arterial lumen cross- sectional area and Doppler 
velocity) were calculated at 30 Hz. Shear rate (an estimate of shear stress without viscosity) 
was calculated as 4 times mean blood velocity/vessel diameter. Reproducibility of diameter 
measurements using this semi-automated software is significantly better than manual 
methods and reduces observer error significantly.27 
Baseline diameter and shear rate were calculated as the mean of data acquired across the 
1 minute preceding the cuff inflation period. Following cuff deflation, peak diameter 
following cuff deflation was automatically detected according to an algorithm which 
identified the maximum bracket of data subsequent to performance of a moving window 
smoothing function. This smoothing routine calculates the median value from 100 
consecutive samples, before the window shifts to the next bracket of data which shares 20% 
overlap with the preceding bracket. The maximum value of all the calculated median values 
is then automatically detected and chosen to represent the peak of the diameter curve. 
FMD was calculated as the percentage rise of this peak diameter from the preceding 
baseline diameter. Calculation of FMD was therefore observer-independent and based on 
standardized algorithms applied to data which had undergone automated edge-detection 
and wall-tracking. The post-deflation shear rate data, derived from simultaneously acquired 
velocity and diameter measures at 30 Hz, was used to calculate the area under the shear 
rate curve (SRAUC) for data up to the point of maximal post-deflation diameter (FMD) for each 
individual. In addition, we calculated the peak blood flow across a 10-second period after 
cuff release. Reproducibility of the brachial artery FMD using this semi-automated software 
possesses a CV of 6.7-10.5%.  
Statistical analysis 
Statistical analyses were performed using SPSS 21.0 software (SPSS, Chicago, IL). 
Descriptive statistics are presented as means and standard deviation (SD). All data are 
reported as LSmeans (95%CI), unless reported otherwise and was considered statistically 
significant at P < 0.05. Baseline differences between both arms were examined using a 
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paired Student’s t-test. A two-way repeated measures ANOVA was used to assess difference 
in blood glucose levels after glucose ingestion. To examine the impact of hyperglycemia and 
local heating on outcome parameters between both groups, we performed a Linear Mixed 
Model. This model assessed whether the baseline-adjusted changes in FMD over time 
(repeated, within-subject variable ‘time’: 0 vs 60 vs 120 vs 150 minutes) were altered by local 
heating of a forearm (repeated, within-subject variable ‘arm’: heated vs non-heated), and 
whether such changes differ between groups (between-subject factor ‘group’: controls vs 
T2DM). When a main effect or interaction-effect was observed, post-hoc tests were 
performed to identify the differences. Additionally, FMD data were also analyzed and are 
presented as covariate-controlled for baseline artery diameter as this approach is more 
accurate for scaling changes in artery diameter than simple percentage change in some 
cases.28 
Results 
Baseline characteristics are described in Table 1. T2DM patients had significantly higher 
glucose and HOMA-IR compared to controls whereas the control group had significantly 
higher total- and LDL cholesterol concentrations. There were no apparent differences in 
brachial artery diameter, blood flow, shear rate and FMD between groups at baseline (all 
comparisons P > 0.05). 
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Table 1. Subject characteristics from patients with type 2 diabetes (n=10) and healthy, age-
matched controls (n=10). P-value refers to an unpaired Student’s t-test. Data are presented 
as mean ± SD. 
 Controls T2DM  
Characteristics Mean ± SD  Mean ± SD  P-value 
Age (years)  57 ± 9  63 ± 6  0.14 
Height (cm) 178 ± 6  176 ± 7  0.43 
Weight (Kg) 85 ± 10  90 ± 13  0.35 
Body Mass Index (Kg/m2) 26.7 ± 3.6  29.0 ± 3.6  0.16 
Systolic BP 132.4 ± 14 138.2 ± 17.3 0.42 
Diastolic BP 79.0 ± 6.2 79.9 ± 6.7 0.77 
Total Cholesterol (mmol/L) 6.2 ± 1.1  4.7 ± 1.1  <0.01 
High-density lipoproteins (mmol/L) 1.5 ± 0.2  1.3 ± 0.3  0.07 
Low-density lipoproteins (mmol/L) 4.0 ± 1.0  2.7 ± 1.0  <0.01 
Triglycerides (mmol/L) 1.9 ± 0.9  2.0 ± 0.8  0.85 
Insulin (mmol/L)† 6.0 ± 6.1  10.3 ± 5.7  0.13 
Glucose (mmol/L) 4.9 ± 0.5  7.1 ± 1.0 <0.001 
HOMA-IR† 1.4 ± 1.6  3.3 ± 1.9  0.04 
† One erroneous measurement from the control group was excluded 
 
Impact of hyperglycemia and heating on blood flow, diameter and glucose 
In both groups, ingestion of 75-gr glucose resulted in a significant increase in blood 
glucose levels at 60 minutes, which returned towards baseline levels within 150 minutes 
(“Time” effect, P < 0.001, Figure 1). The increase in blood glucose was significantly larger 
in T2DM patients compared to controls (“Time*Group”-interaction effect, P = 0.002, Figure 
1). Forearm skin temperature significantly increased in the heated arm during the 
experiment (“Time” effect, P < 0.001, Table 2) and to a greater extent compared to the non-
heated arm (“Time*Arm”-interaction effect, P < 0.001). Both T2DM patients and controls 
demonstrated a comparable change in skin temperature across time in both arms 
(“Time*Arm*Group”-interaction effect, P = 0.09). 
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Figure 1. Blood glucose levels before (0) and after 75-gr oral glucose (60, 120 and 150 minutes) in 
patients with type 2 diabetes (n=10, diamonds) and healthy, age-matched controls (n=10, circles). P-
values refer to a two-way ANOVA with ‘group’ (diabetic vs control) and ‘time’ (0, 60, 120 and 150 
minutes) as fixed effects and subject as random effect. Data are presented as LSmeans ± SE 
corrected for baseline.*Post-hoc significantly different from baseline at P<0.05. †Post-hoc 
significantly different from control group at P < 0.05. 
Similar to skin temperature, brachial artery blood flow and shear rate significantly 
increased in the heated arm during the experiment (both: “Time” effect, P < 0.001) (Figure 
2A-B) and to a greater extent compared to the non-heated arm (both: “Time*Arm”-
interaction effect, P < 0.001). T2DM patients and controls demonstrated a comparable 
change in blood flow and shear rate across time in both arms (“Time*Arm*Group”-
interaction effect, P = 0.15 and 0.25, respectively). In both groups, post hoc analyses 
indicated a significant increase in blood flow and shear rate at 60 minutes in the heated arm 
which returned to baseline within 150 minutes. The increase in blood flow and shear rate at 
60 minutes was significantly greater in the controls compared to the T2DM patients (both P 
< 0.05). Baseline brachial artery diameter did not change during the experiment and differed 
neither between arms nor healthy controls and T2DM patients (Table 2). 
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Table 2. Brachial artery diameter and skin temperature before (0) and 60, 120 and 150 minutes 
after 75-gr oral glucose load  in the non-heated control arm and the heated arm in patients with 
type 2 diabetes (n=10) and healthy, age-matched controls (n=10). Data are presented as 
LSmeans (95% CI) corrected for baseline (time = 0). 
  Time Linear Mixed Model 
Baseline D (mm) 0 60 120 150 Time Arm Time*Arm 
Time*Arm*
Group 
Controls Heated 
4.3  
(4.2; 4.5) 
4.6  
(4.4; 4.7) 
4.6  
(4.4; 4.7) 
4.5  
(4.3; 4.6) 
0.09 0.88 0.85 0.61 
 
Non-
heated 
4.3  
(4.2; 4.5) 
4.5  
(4.3; 4.6) 
4.4  
(4.2; 4.6) 
4.4  
(4.3; 4.6) 
T2DM Heated 
4.3  
(4.2; 4.5) 
4.3  
(4.2; 4.5) 
4.4  
(4.2; 4.6) 
4.4  
(4.2; 4.5) 
 
Non-
heated 
4.4  
(4.2; 4.5) 
4.4  
(4.2; 4.6) 
4.5  
(4.3; 4.6) 
4.4  
(4.3; 4.6) 
Temperature (ºC)        
Controls Heated 
31.8  
(31.0; 32.5) 
41.1  
(40.3; 41.9)*† 
33.8  
(33.0; 34.6)* 
32.9  
(32.1; 33.7)* 
<0.001 <0.001 <0.001 0.09 
 
Non-
heated 
31.6  
(30.9; 32.4) 
32.9  
(32.1; 33.6)* 
33.1  
(32.3; 33.8)* 
32.5  
(31.8; 33.3) 
T2DM Heated 
31.9  
(31.2; 32.6) 
39.4  
(38.7; 40.2) *† 
33.1  
(32.4; 33.8)* 
32.7  
(32.0; 33.5) 
 
Non-
heated 
31.8  
(31.1; 32.5) 
33.4  
(32.7; 34.2)* 
32.6  
(31.8; 33.3) 
32.3  
(31.5; 33.0) 
D; diameter. *Post-hoc significantly different from baseline at P < 0.05 (paired t-test). †Post-hoc significantly 
different from non-heated arm at P < 0.05 (unpaired t-test) 
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Figure 2. Brachial artery blood flow (A) and shear rate (B) before (0) and after 75-gr oral glucose (60, 
120 and 150 minutes) in the control arm (solid symbols) and the heated arm (open symbols) in patients 
with type 2 diabetes (n=10, diamonds) and healthy, age-matched controls (n=10, circles). P-values 
refer to a linear mixed model to assess whether the change in blood flow and shear rate during the 
experiment (‘Time’) differed between the heated and non-heated arm (‘Arm’) and/or between 
controls and type 2 diabetes patients (‘Group’). Data are presented as LSmeans ± SE corrected for 
baseline. *Post-hoc significantly different from baseline at P < 0.05. 
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Impact of hyperglycemia and heating on brachial artery FMD 
A significant Time*Arm-interaction was found (P = 0.01). Post hoc analyses indicated that 
hyperglycemia induced a significant decrease in FMD in the non-heated arm of 1.4% at 60 
minutes (P < 0.05). In contrast, the heated arm demonstrated an increase in FMD of 1.5% 
and 1.3% at 60 and 150 minutes, respectively, despite the presence of hyperglycemia (P < 
0.05). The difference in FMD between the heated and non-heated arms was statistically 
significant at 60, 120 and 150 minutes (P < 0.05, Figure 3). When comparing the responses 
between controls and T2DM patients, we found no time*arm*group-interaction effect 
(Figure 3). These outcomes were reinforced when we repeated our analyses using the 
absolute (mm) or allometrically scaled FMD (Table 3). No changes across time or 
differences between arms or groups were evident for baseline diameter (Table 2) or shear 
rate area-under-the-curve (Table 3). 
 
Figure 3. Brachial artery flow mediated dilation (FMD) before (0) and after 75-gr oral glucose (60, 120 
and 150 minutes) in the control arm (solid symbol) and the heated arm (open symbol) in patients with 
type 2 diabetes (n=10, diamonds) and healthy, age-matched controls (n=10, circles). P-values refer to 
a linear mixed model to assess whether the change in FMD during the experiment (‘Time’) differed 
between the heated and non-heated arm (‘Arm’) and/or between controls and type 2 diabetes patients 
(‘Group’). Data are presented as LSmeans ± SE corrected for baseline. *Post-hoc significantly 
different from baseline at P < 0.05. 
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Discussion 
The aim of this study was to examine whether non-metabolically driven increases in blood 
flow and shear rate (through heating of the skin) protects the hyperglycemia-mediated 
decrease in endothelial function in healthy subjects and patients with type 2 diabetes 
mellitus. For this purpose, we performed bilateral assessment of brachial artery endothelial 
function which enabled us to simultaneously study the effects of both a systemic challenge 
(i.e. hyperglycemia) and a local intervention (i.e. increased blood flow through unilateral 
heating). This provides a number of observations. First, we confirmed previous observations 
9-14 that hyperglycemia, induced by a 75-gr glucose load, leads to a transient decline in 
brachial artery endothelial function. Secondly, local heating of a forearm leads to a marked 
increase in blood flow and shear rate, which effectively prevented the hyperglycemia-
induced decline in brachial artery endothelial function. Third, the ability of increases in blood 
flow and shear rate to prevent brachial artery endothelial dysfunction after hyperglycemia 
is similarly present in healthy middle-aged controls and type 2 diabetes mellitus patients. 
Taken together, these data suggest that elevation in blood flow or shear rate can prevent 
the hyperglycemia-induced decline in conduit artery endothelial function which typically 
occurs after a meal. 
Hyperglycemia may affect endothelial function via different pathways. NO bioavailability is 
decreased through inhibition of eNOS and increased production of reactive oxygen species 
(ROS). Moreover, hyperglycemia may increase production of vasoconstrictor prostanoids 
such as prostaglandin H2 and thromboxane A2.29, 30 Transient damage to the endothelial 
glycocalyx may also occur. This luminal surface layer serves as a mechanosensor of shear 
stress to mediate shear-induced release of NO.11, 31 Consequently, a decline in (partly NO-
mediated) endothelial function is observed after a meal or glucose load in healthy 
volunteers, 12, 14, 32 with some suggestion of an exaggerated impairment in T2DM patients.13, 
33 
Mechanistic work from Hambrecht and coworkers revealed that increases in shear stress, 
for example through exercise,18 can improve NO-mediated vasodilator function, increases 
eNOS expression and endothelial content of phospho-eNOSSer1177, Akt, and phospho-Akt. 
Other mechanistic work demonstrated that elevation in shear also down-regulates 
expression of vasoconstrictors, adhesion molecules and coagulation factors.34 Based on this 
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mechanistic work, we hypothesized that elevation in shear may attenuate or prevent the 
hyperglycemia-induced decrease in FMD. After successfully increasing blood flow and 
shear rate in the heated arm, we confirmed our hypothesis in that FMD in the heated arm 
showed no decrease. In fact, a significant increase was observed, which may be explained 
by the marked increases in blood flow during the heating intervention. Previous studies also 
found that (local) heating can acutely and chronically increase brachial artery FMD%.19, 20 In 
addition to the effects of shear rate, sympathetic- and sensory nerve activity play a major 
role in vasodilatory responses to local heat in the skin.35, 36 We cannot exclude that these 
responses in the skin could also have affected our observations in the brachial artery. Taken 
together, our observations suggest that local heat-induced increases in shear stress protect 
the endothelial function under hyperglycemic conditions.  
Our study also allowed for the comparison between healthy volunteers and patients with 
T2DM. The significantly larger increase in blood glucose levels after 75-gr glucose fits with 
the presence of insulin resistance in the diabetic patients. Despite a substantially larger 
increase in blood glucose in the T2DM patients, the attenuation in FMD in the non-heated 
arm was similar to that in the healthy controls. We also found no correlation between 
changes in blood glucose and FMD (data not shown), which is in agreement with two earlier 
studies in healthy subjects.12, 14 Kawano et al. did however report a significant negative 
correlation between plasma glucose and FMD, which may be due to the larger sample size 
and the inclusion of untreated T2DM patients.13  
Additionally, heating resulted in comparable increases in FMD between the two groups. 
Therefore, our results suggest that the ability of increases in shear to prevent 
hyperglycemia-induced endothelial dysfunction is similarly present in T2DM patients and 
healthy, age-matched controls. It is however interesting to note that the change in blood 
flow in response to heating was less pronounced in our group of diabetic patients compared 
to the healthy controls. This could indicate that decreased reactivity of resistance vessels 
and skin microcirculation is already present in type 2 diabetics before overt changes in 
conduit artery endothelial function occur. This observation however should be interpreted 
with caution since a statistically significant group effect was not evident in our main analysis. 
A subsequent sub-group analysis on data from the heated arm did indicate a significant 
time*group interaction at T = 60 minutes for both blood flow and shear rate though (P = 0.05 
and 0.03 respectively, data not shown). This finding is also supported by data from other 
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groups who have demonstrated that diabetics have impaired skin blood flow responses to 
both local 37, 38 and whole body heating.39 Moreover, impaired muscle blood flow responses 
to exercise stimuli in diabetics compared to healthy controls have also been demonstrated 
in a number of studies.40-42 
An unexpected finding in our study is that control subjects and T2DM patients reveal no 
difference in baseline brachial artery FMD. Although it is generally accepted that T2DM 
patients demonstrate lower FMD compared to healthy peers,4, 5 this is not a universal 
finding.43, 44 One potential explanation for our finding is that T2DM patients received optimal 
pharmacological therapy, including statins (60%) and metformin (80%). These drugs are 
associated with improvements in brachial artery FMD 45, 46 and may, therefore, contribute to 
the lack of difference in FMD between groups, despite all medication being withheld on the 
morning of the measurement. Nonetheless, it is important to emphasize that both groups 
demonstrated distinct responses to the heat stimulus. 
Limitations: A potential limitation of our study is that we did not examine endothelium-
independent vasodilation. Due to the prolonged effects of glyceryl trinitrate (unpublished 
data), including repeated measurements of endothelium-independent dilation would 
importantly compromised our study design and outcomes. However previous studies have 
found no indication that acute heating or hyperglycemia directly affect vascular smooth 
muscle cell reactivity.9, 13, 20, 47 Our study set-up did not allow us to explore specific 
mechanisms, such as the evaluation of NO metabolites, to better understand the underlying 
mechanisms of our findings. Another potential limitation relates to our method of heating. 
We employed a simple setup involving directed hot air. This inadvertently caused a small 
increase in ambient- and skin temperature of the control arm (Table 2). As a result small 
(non-significant) increases in blood flow and shear rate were evident in the non-heated arm 
(Figure 2). Therefore, although a reduction FMD was still evident in the non-heated arm, it 
may have been attenuated to a small extent. 
Clinical relevance: A potential clinical relevance of our findings relates to the suggestion that 
(repeated) exposure to transient periods of endothelial dysfunction contributes to the 
development of atherosclerosis. Although speculative, prevention or attenuation of 
endothelial dysfunction during hyperglycemia seems a potential target. Our observations 
suggest that non-metabolically driven elevations in shear may be of use to prevent the 
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presence to endothelial dysfunction. Similarly, (high-intensity) exercise is demonstrated to 
prevent the post-prandial decrease in endothelial function.48 As exercise is a strong 
stimulus for elevation in blood flow,49 our observations warrant future studies to explore 
whether the immediate benefits of physical activity or exercise to prevent post-prandial 
endothelial dysfunction relate to shear stress-mediated mechanisms, and may contribute 
to preservation of endothelial function in diabetic patients. 
In conclusion, post-prandial hyperglycemia resulted in a transient impairment in brachial 
artery FMD in healthy subjects and type 2 diabetics, whilst a heating induced increase in 
brachial artery blood flow and shear rate countered the impairment in FMD. Therefore, our 
data suggest that interventions which are aimed at elevating blood flow or shear rate can 
prevent the hyperglycemia-induced decline in conduit artery endothelial function which 
typically occurs after a meal. 
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Abstract 
Objective: Epidemiological evidence has linked consumption of black tea, produced from 
Camellia sinensis, with a reduced risk of cardiovascular diseases. However, intervention 
studies on the effects of tea consumption on blood pressure (BP) have reported inconsistent 
results. Our objective was to conduct a systematic literature review with meta-analysis of 
controlled human intervention studies examining the effect of tea consumption on BP. 
Methods: We systematically searched Medline, Biosis, Chemical Abstracts and EMBASE 
databases through July 2013. For inclusion, studies had to meet the following pre-defined 
criteria: 1) placebo controlled design in human adults, 2) minimum of 1 week black tea 
consumption as the sole intervention, 3) reported effects on systolic BP (SBP) or diastolic 
BP (DBP) or both. A random effects model was used to calculate the pooled overall effect of 
black tea on BP. 
Results: Eleven studies (12 intervention arms, 378 subjects, dose of 4–5 cups of tea) met 
our inclusion criteria. The pooled mean effect of regular tea ingestion was −1.8 mmHg (95% 
CI: −2.8, −0.7; P  =  0.0013) for SBP and −1.3 mmHg (95% CI: −1.8, −0.8; P < 0.0001) for DBP. 
In covariate analyses, we found that the method of tea preparation (tea extract powders 
versus leaf tea), baseline SBP and DBP, and the quality score of the study affected the effect 
size of the tea intervention (all P < 0.05). No evidence of publication bias could be detected. 
Conclusions: Our meta-analysis indicates that regular consumption of black tea can reduce 
BP. Although the effect is small, such effects could be important for cardiovascular health 
at population level. 
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Introduction 
Blood pressure is acknowledged to bear an independent continuous relationship with the 
occurrence of cardiovascular events.1 Furthermore hypertension is recognised as the 
leading global risk factor for mortality.2 Considering this, even relatively small reductions in 
population blood pressure can be considered of major interest to public health.2-4 
A high dietary flavonoid intake has been linked to a reduced risk of CVD,5 possibly through 
effects on BP and endothelial function. 6, 7 Black tea, produced by fermentation of the leaves 
of Camellia sinensis, is the major source of dietary flavonoids in many countries.8, 9 10 
Epidemiological data support a link between black tea consumption and a reduced risk of 
CVD.11 Possibly, a BP lowering effect may contribute to the reduced risk of CVD associated 
with regular tea consumption,12 although results from intervention studies examining 
effects of tea on BP are inconsistent.13-19 Indeed, previous meta-analyses have found no 
significant effect of black tea consumption on BP.16, 19 Several high quality randomized 
controlled trials have however been published since.13-15, 17, 18 Our objective was therefore to 
perform an up-to-date systematic review with meta-analysis of controlled human 
intervention studies investigating the effects of black tea consumption on BP. 
Methods 
This systematic review and meta-analysis was conducted in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines. 
The associated checklist (Checklist S1) can be found in the supporting information section. 
Search strategy 
The Medline, Biosis, Chemical Abstracts and EMBASE databases were searched (from the 
date of inception until July 2013) to identify potentially relevant studies conducted in human 
adults and published in the English language. Titles, abstracts and keywords were searched 
for the following terms: Tea, black tea, flavonoid(s), tea extract(s), tea component(s), tea solid(s), 
camellia sinensis, blood pressure, hypertension, hypertensive, hypotension, hypotensive, 
endothelium, endothelial function, endothelial dysfunction. Bibliographies from obtained 
publications were searched for additional potentially relevant studies. 
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Selection of trials 
To qualify for inclusion, studies had to meet the following pre-defined inclusion criteria: 1) 
randomized controlled trial in human adults; 2) use of freshly brewed black tea or black tea 
powder produced by drying freshly brewed tea (not purified or isolated substances from tea) 
for ≥ 1 week; 3) reported effects on SBP or DBP or both, along with measures of variability; 
4) no intentional co-intervention from which the effect of tea could not be isolated. 
We followed a two-step process for selection of studies to be included in the meta-analysis. 
During the first step, titles, abstracts and keywords of publications were screened to identify 
potentially eligible studies. During the second step, the full texts of these publications were 
examined to gauge eligibility based on the abovementioned inclusion criteria. Eligibility was 
assessed separately by two authors (AG and RD). In case of discrepancy, eligibility was 
discussed among authors until consensus was reached. 
Data extraction 
After eligible publications were identified, the following information was extracted: 1) 
publication details (author, year of publication, country); 2) study design characteristics 
(crossover or parallel, blinding, duration); 3) subject characteristics (age, BP medication 
use, gender and health status); 4) treatment characteristics (type and dosage of tea, type of 
control); 5) BP measurement characteristics (office or ambulatory BP); 6) SBP and DBP data 
(including measures of variance), and 7) characteristics needed to gauge study quality. If any 
of the required data were not reported, the authors of the publication in question were 
approached in order to obtain it (successful in three occasions 13, 17, 20). 
Quality assessment 
Assessment of methodological quality was done by means of a tool based on the Delphi 
Consensus that we had previously developed.21, 22 Because of the subjective nature of quality 
assessments like this, we decided a priori to not use the obtained quality scores for 
excluding or weighing studies in the meta-analysis. We did however examine the association 
between methodological quality and effect size. 
The extent of heterogeneity in results between studies was assessed by using the Cochran's 
Q statistic (with P<0.1 considered to represent statistically significant heterogeneity) and the 
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I2-statistic (with 25% considered to be low-level heterogeneity, 25%–50% moderate-level 
heterogeneity, and >50% high-level heterogeneity).23, 24 
Publication bias was evaluated by means of visual inspection of funnel plots (constructed by 
plotting inverse standard errors (SE) against the respective SBP and DBP effects for each 
trial) and Egger's regression test.25 
Statistical analysis 
For parallel studies, the change in BP was calculated as the change from baseline in the 
intervention group subtracted from the change from baseline in the control group. For 
cross-over studies, the change in BP was calculated as the difference between BP at the 
end of intervention period and BP at the end of the control period. The study of Grassi et. al. 
measured both office and 24-hour ambulatory BP in one control and four treatment periods 
(each with an increasing dose of tea).14 To ensure that the weight of this small study was not 
disproportionately large, we averaged the effects of the four treatments into a single value. 
The office and ambulatory BP outcomes of this study were entered separately into the 
analysis, but we halved the weights in these arms so that the office and ambulatory BP 
outcome each contributed 50% of the overall weight of the study. 
The pooled effect and corresponding 95% CIs were calculated by means of fixed and random 
effects models.26, 27 Since a random effects model with studies weighted by the inverse of 
their variance (1/SE2) results in a more conservative estimate of statistical significance, this 
served as the primary model. If SE's of the change in BP were not reported, they were 
derived from P-values or calculated according to the equations by Follmann et al.28 
assuming a within-subject correlation coefficient of 0.68.19 
To test whether a particular study was exerting excessive influence on the results, we 
conducted influence analysis by systematically excluding each study one-by-one and then 
reanalyzing the remaining data. We also explored the potential effects of pre-defined 
covariates on the overall outcome by calculating pooled BP effects for different subgroups 
of dichotomous covariates (only if subgroups consisted of >4 study arms), and by performing 
weighted meta-regression for continuous covariates.29, 30 The pre-defined covariates were 
mean baseline BP (using BP of the control group at the end of the trial period to avoid 
regression to the mean), dose of tea flavonoids, type of tea (leaf tea or standardized powder), 
type of placebo (caffeine controlled, yes or no), duration and quality. Calculations were done 
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using the PROC MIXED model of the SAS analytical system (SAS v9.2, SAS Institute, Cary, 
NC, USA). 
Results 
The systematic searches yielded a total 866 potentially relevant publications (Figure 1). After 
exclusion of irrelevant publications and studies that did not meet the pre-defined inclusion 
criteria, 9 studies remained. Two additional eligible studies were published after the conduct 
of the systematic search yielding a total of 11 studies (12 study arms) that were included in 
our meta-analysis.13, 18 Trial characteristics are summarized in Table 1. 
 
 
Figure 1. Flow diagram of the study selection procedure. 
 
 
Drinking black tea lowers blood pressure | 119 
 
 
 
T
a
b
le
 1
. 
C
h
a
ra
ct
e
ri
st
ic
s 
o
f 
1
1
 c
o
n
tr
o
ll
e
d
 in
te
rv
e
n
ti
o
n
 s
tu
d
ie
s 
o
n
 t
e
a
 a
n
d
 b
lo
o
d
 p
re
ss
u
re
 in
cl
u
d
e
d
 i
n
 t
h
e
 m
e
ta
-a
n
a
ly
si
s.
 
Q
u
a
li
ty
 
6
 
6
 
7
 
7
 
7
 
7
 
5
 
6
 
6
 
5
 
4
 
6
 
1
A
B
P
M
, 
2
4
-h
o
u
r 
a
m
b
u
la
to
ry
 b
lo
o
d
 p
re
ss
u
re
 m
o
n
it
o
ri
n
g
; 
C
A
D
, 
co
ro
n
a
ry
 a
rt
e
ry
 d
is
e
a
se
; 
M
H
C
, 
m
il
d
ly
 h
yp
e
rc
h
o
le
st
e
ro
le
m
ic
; 
S
B
P
, 
sy
st
o
li
c 
b
lo
o
d
 p
re
ss
u
re
; 
C
V
D
, 
ca
rd
io
va
sc
u
la
r 
d
is
e
a
se
; 
2
R
, 
ra
n
d
o
m
iz
e
d
; 
S
, 
si
n
g
le
 b
li
n
d
; 
C
, 
cr
o
ss
o
ve
r 
tr
ia
l;
 D
, 
d
o
u
b
le
 b
li
n
d
; 
P
, 
p
a
ra
ll
e
l 
tr
ia
l;
 3
W
h
e
re
 d
o
se
 in
 m
L
 t
e
a
 o
r 
m
g
 f
la
vo
n
o
id
s 
w
a
s 
n
o
t 
re
p
o
rt
e
d
, 
it
 w
a
s 
ca
lc
u
la
te
d
 a
cc
o
rd
in
g
 t
o
 A
st
il
l 
e
t 
a
l.
4
9
; 
4
C
C
, 
p
la
ce
b
o
 m
a
tc
h
e
d
 f
o
r 
ca
ff
e
in
e
 c
o
n
te
n
t 
o
f 
th
e
 t
e
a
 i
n
te
rv
e
n
ti
o
n
. 
B
a
s
e
li
n
e
 
D
B
P
 
(m
m
H
g
) 
7
5
.1
 
7
7
 
9
2
 
8
0
.8
 
7
4
.4
 
7
3
.1
 
7
2
 
7
3
 
7
7
.5
 
- 
7
5
.1
 
7
8
.3
 
B
a
s
e
li
n
e
 
S
B
P
 
(m
m
H
g
) 
1
2
0
.1
 
1
3
7
 
1
4
5
.6
 
1
2
8
.8
 
1
2
1
.2
 
1
2
2
.4
 
1
2
1
 
1
2
3
 
1
3
5
.5
 
1
3
8
.4
 
1
3
3
.2
 
1
3
2
 
C
o
n
tr
o
l4
 
W
a
te
r 
(C
C
) 
W
a
te
r 
P
la
ce
b
o
 
te
a
(C
C
) 
P
la
ce
b
o
 
te
a
(C
C
) 
P
la
ce
b
o
 
te
a
(C
C
) 
P
la
ce
b
o
 
te
a
(C
C
) 
W
a
te
r 
W
a
te
r 
W
a
te
r 
(C
C
) 
W
a
te
r 
W
a
te
r 
W
a
te
r 
D
o
s
e
 (
m
g
 
fl
a
vo
n
o
id
s
)3
 
1
4
9
4
 
8
7
3
 
2
4
0
.2
 
3
7
5
 
3
7
5
 
3
6
0
.4
 
1
0
3
7
.5
 
1
0
3
7
.5
 
8
3
0
 
3
1
8
 
1
0
3
7
.5
 
4
9
8
 
D
o
s
e
 
(m
L
)3
 
1
8
0
0
 
9
0
0
 
4
0
0
 
4
0
0
 
4
0
0
 
6
0
0
 
1
2
5
0
 
1
2
5
0
 
1
0
0
0
 
6
0
0
 
1
2
5
0
 
6
0
0
 
In
te
rv
e
n
ti
o
n
 
p
ro
d
u
ct
 
L
e
a
f 
te
a
 
E
xt
ra
ct
 
p
o
w
d
e
r 
E
xt
ra
ct
 
p
o
w
d
e
r 
E
xt
ra
ct
 
p
o
w
d
e
r 
E
xt
ra
ct
 
p
o
w
d
e
r 
E
xt
ra
ct
 
p
o
w
d
e
r 
L
e
a
f 
te
a
 
L
e
a
f 
te
a
 
L
e
a
f 
te
a
 
E
xt
ra
ct
 
p
o
w
d
e
r 
L
e
a
f 
te
a
 
L
e
a
f 
te
a
 
B
P
 
m
e
d
ic
a
ti
o
n
 
N
o
 
Y
e
s 
N
o
 
N
o
 
N
o
 
N
o
 
N
o
 
N
o
 
N
o
 
Y
e
s 
Y
e
s 
N
o
 
M
a
le
s
 
(%
) 
4
7
.7
 
7
8
 
2
6
.3
 
1
0
0
 
1
0
0
 
3
4
.7
 
7
2
.7
 
7
6
.2
 
7
6
.9
 
3
5
.7
 
4
2
.3
 
4
0
 
M
e
a
n
 
B
M
I 
(k
g
/m
2
) 
2
4
.2
 
2
9
.7
 
2
6
.8
 
2
3
.9
 
2
3
.9
 
2
5
.1
 
2
7
 
2
7
.5
 
2
7
 
2
9
.1
 
2
7
.4
 
2
5
.1
 
M
e
a
n
 
a
g
e
 (
y)
 
4
0
.7
 
5
5
 
5
1
.3
 
3
2
.9
 
3
2
.9
 
5
6
.6
 
5
9
 
5
9
.1
 
5
9
.8
 
6
5
.8
 
7
3
 
5
4
 
S
iz
e
 
(n
) 
6
5
 
5
0
 
1
9
 
1
9
 
1
9
 
9
5
 
2
2
 
2
1
 
1
3
 
2
8
 
2
6
 
2
0
 
S
tu
d
y 
d
u
ra
ti
o
n
 
(w
e
e
k
s
) 
4
 
4
 
1
 
1
 
1
 
2
6
 
4
 
4
 
1
 
2
6
 
2
 
1
 
S
tu
d
y 
d
e
s
ig
n
2
 
R
, 
S
, 
C
 
R
, 
S
, 
C
 
R
, 
D
, 
C
 
R
, 
D
, 
C
 
R
, 
D
, 
C
 
R
, 
D
, 
P
 
R
, 
S
, 
C
 
R
, 
S
, 
P
 
R
, 
S
, 
C
 
R
, 
S
, 
P
 
R
, 
S
, 
P
 
R
, 
S
, 
C
 
P
o
p
u
la
ti
o
n
1
 
H
e
a
lt
h
y 
C
A
D
 
H
yp
e
rt
e
n
si
ve
 
H
e
a
lt
h
y 
H
e
a
lt
h
y 
H
e
a
lt
h
y 
H
e
a
lt
h
y 
M
H
C
 
H
ig
h
-n
o
rm
a
l 
S
B
P
 
H
ig
h
 C
V
D
 r
is
k
 
H
yp
e
rt
e
n
si
ve
 
H
e
a
lt
h
y 
A
u
th
o
r 
B
in
g
h
a
m
 e
t 
a
l.
 1
9
9
7
 
D
u
ff
y 
e
t 
a
l.
 
2
0
0
1
 
G
ra
ss
i 
e
t 
a
l.
 
2
0
1
2
 
G
ra
ss
i 
e
t 
a
l.
 
2
0
0
9
 (
o
ff
ic
e
) 
G
ra
ss
i 
e
t 
a
l.
 
2
0
0
9
 (
A
B
P
M
) 
H
o
d
g
so
n
 e
t 
a
l.
 2
0
1
2
 
H
o
d
g
so
n
 e
t 
a
l.
 2
0
0
3
 
H
o
d
g
so
n
 e
t 
a
l.
 2
0
0
2
 
H
o
d
g
so
n
 e
t 
a
l.
 1
9
9
9
 
M
u
k
a
m
a
l 
e
t 
a
l 
2
0
0
7
 
R
a
k
ic
 e
t 
a
l 
1
9
9
6
 
S
ch
re
u
d
e
r 
e
t 
a
l.
 2
0
1
3
 
 
120 | Chapter 5 
 
 
A total of 378 subjects participated in the 11 studies. The number of subjects per study 
ranged from 13 to 95. Mean age ranged from 33 to 73 years and mean BMI from 24 to 30 
kg/m2. One study included only men 14; in the remaining studies, the percentage of male 
subjects ranged from 26% to 78%. Five of the 11 studies included healthy normotensive 
populations. The other studies included coronary artery disease patients,31 hypertensive 
subjects,13, 20 subjects at high cardiovascular risk 17 and subjects with mildly elevated blood 
pressure 32 and cholesterol 33. Mean baseline SBP and DBP ranged from 120 to 150 mmHg 
and from 72 to 92 mmHg, respectively. 
Seven studies used a cross-over design and 4 studies a parallel design. Study duration 
ranged from 1 week to 6 months. The dose of tea consumption in the intervention arms 
ranged from 400 to 1800 mL per day, providing an estimated 240 to 1500 mg of flavonoids 
per day. Six of the 11 studies provided intervention products in the form of leaf tea that 
subjects had to infuse in a defined amount of hot water (200 to 300 mL) for a defined time 
period (1 to 2 min). In the remaining 5 studies, tea was prepared by dissolving standardized 
doses of tea extract powder in hot water. In three studies 13-15, the control treatment was 
matched for appearance, taste and caffeine content of the tea interventions, whereas in two 
studies 32, 34 this was done only for caffeine content. In the remaining six studies 17, 18, 20, 31, 33, 35 
the control treatment was plain hot water. 
Pooled SBP effects showed moderate heterogeneity (P  =  0.11, I2  =  35%) between studies, 
whilst there was no evidence for heterogeneity in DBP effects (P  =  0.26, I2  =  20%). In the 
pooled analyses using random effects models, tea intake reduced SBP with 1.8 mmHg (95% 
CI: −2.8, −0.7; P  =  0.0013) and DBP with 1.3 mmHg (95% CI: −1.8, −0.8; P < 0.0001). The 
overall estimates of BP effects were similar when using fixed effects models (−2.0 and −1.3 
mmHg for SBP and DBP, respectively) (Figure 2 A & B). 
In covariate analyses (Table 2), studies using tea extract powders found larger reductions in 
SBP than studies using leaf tea. Baseline SBP and DBP had a significant impact on the effect 
of tea ingestion on BP, with a ∼1 mmHg larger reduction for every 10 mmHg higher baseline 
SBP and DBP respectively. Interestingly, each 1-point increase in the perceived quality score 
of the studies was associated with a 1 mmHg larger reduction in the DBP effect estimate. 
The covariate analysis found no substantial influence of amount of tea flavonoids, controlling 
for caffeine content, or the duration of the intervention. 
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Figure 2. Net changes in SBP (A) and DBP (B) in randomized studies of black tea consumption. 
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Omitting each study from the analysis to check for disproportionate impact of a single study 
did not materially affect results for SBP or DBP. Pooled estimates ranged from −1.3 to −2.2 
mmHg and −1.2.to −1.5 mmHg for SBP and DBP respectively and remained statistically 
significant in all cases. Visual inspection of Funnel plots did not indicate the presence of 
publication bias and this was supported by the outcome of Egger's linear regression test 
(intercept: 0.56; P  =  0.45 for SBP and intercept: 0.76; P  =  0.37 for DBP) (Figure 3 A and B). 
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Figure 3. Funnel plots of trials included in the meta-analysis for (A) systolic blood pressure and (B) 
diastolic blood pressure 
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Discussion 
This meta-analysis, summarizing evidence from 11 randomized controlled intervention 
studies including 378 subjects, found that daily consumption of black tea for ≥ 1 week is 
associated with a statistically significant reduction in SBP and DBP of 2 and 1 mmHg, 
respectively. Although these reductions in BP are modest from an individual's perspective, 
such reductions are relevant on a population-wide scale and may translate to substantial 
reductions in CVD risk. 3, 4 Moreover, we found that the effect of tea ingestion was more 
pronounced in those with a higher a priori baseline BP. In fact, data from the Prospective 
Studies Collaboration indicate that a 2 mmHg lower SBP is associated with a 10% lower 
stroke mortality and about 7% lower mortality from ischemic heart disease or other 
vascular causes in middle age subjects.3 Therefore, our findings provide a possible 
explanation for the reductions in risk for stroke observed in epidemiological studies on tea 
consumption.36-38 
Our rationale for conducting this meta-analysis was the recent publication of a number of 
high-quality randomized controlled trials, which could appreciably change the outcomes 
from previous meta-analyses and the general consensus from those analyses that tea may 
not impact BP. Three of the newly included studies reported statistically significant 
effects.13-15 These studies had well-standardized interventions, robust double-blind designs 
with repeated BP measurements and low variances causing them to contribute a large 
amount of weight to the analysis. This explains our observation of a relation between the 
perceived quality score of the studies and the reported effect size of tea on BP. More 
specifically, studies with higher quality scores generally reported lower BP variances which 
mean higher statistical power to detect statistically significant reductions in BP after tea 
intake. It is thus important for future studies on tea and BP to achieve the highest possible 
level of quality. 
A biological mechanism that could, at least in part, explain the BP lowering effect of black 
tea relates to the influence of black tea flavonoids on endothelial function. Previous studies 
found that endothelial function shares a complex relationship with hypertension and it has 
been suggested as an early marker for BP changes.39 Human intervention studies 
consistently indicate that black tea consumption improves endothelial function as measured 
by brachial artery flow mediated dilation (FMD),22 most likely through improved 
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bioavailability of nitric oxide (NO).40, 41 Accordingly, the decrease in BP after daily tea 
ingestion may be, at least partly, mediated through an improvement in endothelial function, 
which may contribute to a lowering in peripheral vascular resistance. 
The magnitude of the effect of tea ingestion on BP may be dependent on baseline BP. We 
found that each 10 mmHg higher baseline SBP was associated with a 1 mmHg larger SBP 
effect size and a similar association was seen for DBP. The dependence of treatment effect 
size on baseline BP has been reported previously.42-45 This would imply that individuals with 
a higher resting BP and therefore higher risk for CVD would benefit most from measures to 
reduce BP, including tea consumption. This observation might have been due to the 
regression to the mean effect since it is known to be a serious confounder in blood pressure 
studies. Our statistical approach should have avoided this however and the control and 
intervention arms of the studies included in our analyses were well matched for baseline 
BP levels. 
Our study found no evidence for a substantial influence of the duration of the intervention or 
the amount of daily flavonoid intake on the BP effect. Kay et al. meta-analyzed data from 77 
studies of various flavonoid sources (tea, but also chocolate, red wine, berries or grapes and 
flavonoid extracts) to relate BP and FMD effects with flavonoid contents. In agreement with 
our study, no dose-response relation could be detected between flavonoid intake and BP.7 
In the American Cancer Society's CPS-II Nutrition Cohort, McCullough et al. found nonlinear 
associations between flavonoid intake and fatal CVD, with lower risk already apparent in the 
second intake quintile.46 Combined with our current meta-analysis, this suggests that 
beneficial effects of flavonoid-rich foods like black tea on BP and CVD risk could be already 
attained at moderate intake levels. 
Several limitations of this meta-analysis should be noted. Firstly, the majority of the 
included studies had relatively small sample sizes, potentially leading to publication bias 
and overestimation of treatment effects, because smaller trials might be methodologically 
less robust and are prone to report larger effect sizes.47, 48 However, we could not detect 
evidence of systematic publication bias in our analysis although such bias can never be fully 
ruled out. Secondly, only three of the included studies were double-blinded. It is well 
possible that detection bias has occurred in the other studies where the subjects and, in 
some cases, the investigators were not blinded as to the treatments. Interestingly, in our 
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analysis a larger effect size of tea ingestion on BP was related with a high quality rating. 
This indicates that the BP lowering effect of tea estimated here cannot be simply explained 
by the inclusion of the un-blinded, lower quality studies. Finally, the outcomes of the 
covariate analyses on factors influencing the BP effect of tea should be interpreted with 
caution because our meta-analysis included a relatively small number of studies, and was 
therefore not suited to reliably estimate the impact of potential covariates. 
In conclusion, this review provides an up-to-date overview of controlled human intervention 
studies on the effects of black tea consumption on BP. Our analysis indicates that daily 
consumption of 4 to 5 cups of black tea can reduce BP by 1–2 mmHg. Although this effect is 
modest, it may be of importance for cardiovascular health at the population level because 
of the widespread consumption of black tea and the high prevalence of hypertension and 
consequent risk of CVD. 
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Abstract 
Background: Black tea is a main source of flavonoids in the Western diet and has been 
associated with reduced risk for cardiovascular disease (CVD), possibly through lowering 
blood pressure. These effects may be mediated through improving endothelial function of 
resistance arteries.  
Objective: Examine the acute impact of black tea on forearm resistance artery endothelial 
function in healthy, normotensive middle-aged subjects. 
Design: Twenty middle-aged men and women (age-range 45-75 years) were recruited to 
take part in a double-blind, randomized, placebo-controlled crossover intervention study. 
Forearm resistance artery blood flow (FBF, measured using venous occlusion 
plethysmography) in response to incremental doses of acetylcholine, sodium nitroprusside 
and L-NG-monomethyl arginine were determined 2 hours after consumption of either black 
tea containing ~400 mg flavonoids (equivalent to 2-3 cups of tea) or a taste- and color-
matched placebo. 
Results: The mean FBF-response to acetylcholine after tea consumption was 23% higher 
compared to the response after placebo (95% CI: -20%, +88%), but this difference did not 
reach statistical significance (P=0.32). No significant differences in the FBF-responses to 
sodium nitroprusside and L-NG-monomethyl arginine were found between the tea and 
placebo interventions (P = 0.96 and 0.74, respectively). Correcting FBF for changes in blood 
pressure did not alter the outcomes. 
Conclusions: We found no evidence that acute intake of black tea significantly altered 
endothelium-dependent vasodilation of forearm resistance arteries in healthy middle-aged 
subjects. Interventions with a longer duration of tea ingestion are required to further explore 
the (long-term) impact of tea flavonoids on blood pressure regulatory mechanisms. This 
trial was registered at clinicaltrials.gov as NCT02328339. 
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Introduction 
High blood pressure is a major risk factor for cardiovascular diseases (CVD) which are 
estimated to currently represent ~13% of the global mortality rate (equivalent to 7.5 million 
deaths annually).1 Changes in lifestyle, such as diet, can lower blood pressure and, as a 
consequence, reduce CVD risk in both symptomatic and asymptomatic subjects.2, 3 For 
example, a high dietary intake of flavonoids has been associated with reductions in CVD risk 
and improvements in various CV risk factors in prospective follow-up- 4, 5 and human-
intervention studies.6 Black tea, brewed from the leaves of Camellia sinensis, represents a 
major source of dietary flavonoids in most Western countries.7, 8 Prospective data have 
shown associations between tea consumption and reduced CVD incidence and mortality.9 
These associations may, at least partly, be mediated through the blood pressure lowering 
effects of tea.10, 11 
Resistance vessel endothelial function plays an important role in blood pressure 
regulation.12 Consequently, the blood pressure lowering effects of tea may be facilitated 
through improvements in endothelial function, mediating a drop in peripheral vascular 
resistance. It has been described previously that tea consumption results in improved 
endothelial function in conduit arteries.13 Whilst these observations suggest an impact of tea 
on vascular health at conduit artery level, regulation of blood pressure is typically ascribed 
to resistance arteries. To date, only few studies have directly evaluated the effects of tea 
flavonoids on resistance arteries. For example, a recent study found that consumption of a 
flavonoid-rich fraction of black tea to improve (post-prandial) perfusion of resistance 
arteries in insulin-resistant men.14 Another study found improved resistance artery 
endothelial function after consumption of isolated green tea flavonoids in male smokers.15 
Whether such improvements in resistance artery endothelial function are present in the 
general population after ordinary black tea consumption is currently unknown. 
The purpose of this study is to examine the impact of an acute dose of black tea on resistance 
artery endothelial function, evaluated by means of the isolated and perfused forearm 
technique,16 in a group of healthy middle-aged men and women. The study hypothesis was 
that, in agreement with earlier findings in conduit arteries, acute tea ingestion improves 
endothelial function in resistance arteries as indicated by an increase in the acetylcholine-
mediated forearm blood flow (FBF) response compared to placebo. 
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Methods 
Study participants 
Twenty middle-aged (median age 63 years, range 50-72 years) men (n=10) and post-
menopausal women (n=10) without a history of cardiovascular diseases or diabetes mellitus 
were included. None of the participants used medication known to influence endothelial 
function. Subjects were selected from a database with volunteers who showed interest in 
contributing to studies as a participant. Current smokers, subjects who stopped smoking 
less than 6 months before study participation, subjects with a self-reported alcohol intake 
of ≥21 units per week and subjects who performed over 2 hours of strenuous exercise per 
week were excluded. Use of medication that does not influence endothelial function was 
allowed if medication use was stable for ≥3 months. This study was performed according to 
the guidelines stated in the declaration of Helsinki 2013 and the Dutch Medical Research 
Involving Human Subjects Act (WMO). This study was approved by the Ethics Committee of 
the Radboud University Medical Center Nijmegen (CMO Arnhem-Nijmegen). All participants 
provided written informed consent prior to participation in the study. 
Study design 
This study followed a double-blind randomized cross-over design. Subjects reported twice 
to our laboratory. On both days, subjects ingested either black tea or a taste-, color- and 
temperature-matched placebo beverage in a randomized order. Subsequently, subjects 
were instrumented for assessment of forearm resistance artery endothelial function. 
Changes in FBF were measured using venous occlusion plethysmography (VOP) during 
intrabrachial administration of vasoactive drugs, which is the gold standard for assessment 
of endothelial function.16 Increasing doses of acetylcholine (ACh; endothelium-dependent 
vasodilator), sodium nitroprusside (SNP; endothelium-independent vasodilator), and L-NG-
Monomethyl-arginine (L-NMMA; endothelium-dependent vasoconstrictor) were used. This 
allowed us to explore the impact of black tea on forearm resistance artery endothelium-
dependent and -independent dilation as well as the contribution of nitric oxide (NO) to 
baseline vascular tone. 
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Tea and placebo 
The intervention product was prepared using commercially available black tea (Lipton 
Yellow Label, Unilever B.V., The Netherlands) according to a standardized brewing protocol 
which produced tea infusions with a total flavonoid content of 1.28 ± 0.06 mg/mL (as 
determined with the Folin Ciocalteu assay using gallic acid as a standard 17, 18) and a caffeine 
content of 0.47 ± 0.02 mg/mL (as determined with reverse phase HPLC 19). Due to the 
duration of the FBF protocol, subjects were provided with a loading dose of 240 mL test 
product (307 mg flavonoids) given 2 hours before, and a maintenance dose of 120 mL (102 
mg flavonoids) given 10 minutes before the start of the measurement. This amounted to a 
total flavonoid dose of approximately 409 mg (and ~150 mg caffeine, equivalent to ~3 cups 
of black tea 20). The timing and size of the respective tea (flavonoid) doses were based on 
previously published plasma kinetic profiles of tea flavonoids.21, 22 The placebo was provided 
as a powder which contained no flavonoids and consisted of 93.4% maltodextrin, 6% tea 
flavor and 0.6% silicon dioxide. For the loading and maintenance doses, 2 and 1 grams of 
placebo powder was respectively dissolved in 240- and 120 mL hot water. The test products 
were freshly prepared for each subject by an analyst not involved in the FBF measurements.  
Protocol 
Subjects underwent a medical screening, consisting of a medical history, physical 
examination (including measurement of body weight and -height) and collection of blood for 
assessment of fasting lipid spectrum and glucose levels. Upon approval for inclusion, 2 
subsequent testing days were scheduled, with an interval of 2 to 6 weeks. During the week 
preceding the measurements, subjects were instructed not to consume tea (or tea-
containing products). In the 24 hours prior to the measurements, subjects were instructed 
to additionally avoid other foods high in flavonoids (e.g. cocoa, chocolate, red wine), 
strenuous exercise and abstain from or vitamin C and from products containing caffeine or 
alcohol. All measurements were performed after an overnight fast in a quiet, darkened, air-
controlled room (22˚C).  
Venous occlusion plethysmography: After the tea/placebo loading dose (and before the 
maintenance dose), the brachial artery of the non-dominant arm was cannulated for 
vasoactive drug infusion and intra-arterial blood pressure monitoring. Forearm blood flow 
was measured in both the experimental and contralateral forearm by ECG-triggered VOP. 
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Mercury-in-silastic strain gauges were placed around the widest portion of the upper third 
of both forearms to quantify changes in FBF from changes in forearm volume. At least 20 
minutes after cannulation of the brachial artery, and 10 minutes after consumption of the 
maintenance dose, infusion of the vasoactive drugs started. Following a fixed order, ACh 
was administered at 5, 10, 20 and 40 μg/mL, followed by SNP at 2, 4, and 8 μg/mL and L-
NMMA at 2, 4 and 8 μmol/mL, respectively. Each dose was infused for 5 minutes at an 
infusion rate of 1 mL per 1000 mL of forearm volume per minute. Forearm volume was 
individually determined by measurement of water displacement in a glass column. Between 
each series of drug infusions, FBF was allowed to return to basal value during a 30 minute 
washout period (Figure 1). 
 
 
Figure 1. Schematic presentation of measurement protocol. Concentrations presented are in µg/L 
for ACh and SNP and µmol/L for L-NMMA. ACh, acetylcholine; FBF, forearm blood flow; L-NMMA, 
NG-Monomethyl-L-arginine; SNP, sodium nitroprusside. 
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This protocol was repeated at the next visit, during which subjects received the other 
intervention (according to a computer-generated randomized allocation sequence between 
subjects). The reproducibility of VOP to assess forearm blood flow shows a coefficient of 
variation of 8.6% (i.e. 7 days between testing).23 Forearm blood flow was calculated using 
standard formulae and expressed as mL/100 mL forearm volume/min as previously 
reported.23 This data analysis was performed by two investigators (TLCW & DMB) blinded to 
the subject’s allocation to treatment. To account for any potential systemic hemodynamic 
variation, FBF data were also analyzed in terms of changes in forearm vascular resistance 
(FVR, calculated by dividing mean arterial pressure (MAP) by FBF) and changes in the blood 
flow ratio between the infusion and control arm (FBF ratio). For all measures the area under 
the dose-response curve (AUC), expressed in arbitrary units (AU), for each drug was 
calculated and analyzed as the primary outcome measure. 
Statistical methods 
It was estimated that to detect a 15% increase in the mean FBF AUC response to ACh with 
80% power and at the 5% significance level, a sample size of 20 participants was required 
to complete the study (assuming a standard deviation of 20% for a within-subject difference 
of two forearm blood flow measurements).23 
The statistical analysis was performed using SAS software version 9.4 (SAS Institute, Cary, 
NC). Data are expressed as mean ± SD, unless otherwise stated. Due to the skewed nature 
of the FBF data, logarithmic transformation was performed prior to analysis. Changes in 
FBF AUC responses to the different vasoactive drugs were analyzed using a series of Mixed 
ANOVA models. In each case the log of the mean recorded FBF per drug dosing level was 
treated as the response; Treatment, Period and Dose were treated as fixed effects; the log 
of the mean baseline FBF for the treatment arm in question and the average baseline value 
across both treatment arms were treated as covariates; subject and subject*visit were 
treated as random effects. Similar models were used to examine the effect of the 
interventions on FVR, FBF ratio, MAP and heart rate. Conclusions were drawn by comparing 
treatments across all doses at a 5% level of significance. 
Both an Intention-To-Treat (ITT) and a Per Protocol (PP) analysis were performed. The ITT 
population was defined as all subjects randomized in the study and having completed at 
least one intervention. The PP was the population in which data from subjects who were 
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non-compliant, who took concomitant medication or who had an adverse event that could 
have influenced vascular function have been removed. Where baseline data were deemed 
invalid, the subject concerned was necessarily omitted from the analysis in question. Where 
only a subset of dosed responses were deemed invalid the remaining data were employed, 
the analysis approach adjusting for the estimated effects of missing data. 
Results 
Baseline characteristics of the study participants are provided in Table 1. All 20 subjects 
completed the study. During blind review, all data from one subject who had an adverse 
event (emesis after test product consumption) and another who reported gastric illness 
symptoms on the day prior to a measurement visit were excluded from the Per Protocol (PP) 
analyses. Additionally, FBF data from 4 different subjects had to be removed from the PP 
and Intention To Treat (ITT) analyses due to technical problems (n=2 during L-NMMA, n=1 
during ACh, n=1 during SNP). An overview of the trial design and subject disposition is 
provided in Figure 2. Since the PP and ITT outcomes did not differ, the PP data are 
presented. 
 
Table 1. Characteristics of subjects included in the trial. Data are presented as mean ± SD. 
Characteristics   
N 20  
Gender, females/males 10/10  
Age (years) 62.2 ± 6.2 
Weight (kg) 74.2 ± 14.6 
Body Mass Index (kg/m2) 24.6 ± 4.2 
Systolic blood pressure (mmHg) 130.4 ± 11.1 
Diastolic blood pressure (mmHg) 79.4 ± 7.9 
Plasma glucose (mmol/l) 4.8 ± 0.3 
Total cholesterol (mmol/l) 6.0 ± 1.2 
HDL cholesterol (mmol/l) 1.7 ± 0.5 
LDL cholesterol (mmol/l) 4.0 ± 1.0 
Triglycerides (mmol/l) 1.3 ± 0.3 
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Figure 2. Enrollment, randomization and trial design. *One subject experienced an adverse event 
(emesis after test product consumption) and was subsequently excluded from the Per Protocol 
analyses. ACh, acetylcholine; FBF, forearm blood flow; L-NMMA, NG-Monomethyl-L-arginine; SNP, 
sodium nitroprusside. 
Hemodynamic effects: Baseline heart rate and MAP did not differ between the placebo and 
tea intervention periods. Heart rate remained stable throughout all three drug infusions 
(Table 2). During ACh infusion, MAP increased after the tea administration (P=0.03, Table 2), 
but this difference did not persist during the SNP and L-NMMA infusions.  
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Resistance artery endothelial function: Due to a skewed distribution, data analysis was 
performed on log-transformed data for FBF (and back-transformed data to present in 
figures). The estimated mean difference in the log FBF-AUC response to ACh for tea vs 
placebo was 0.21 AU (95% CI: -0.22, 0.63). This corresponds to a +23% (95% CI: -20%, +88%) 
difference in the mean FBF-response to ACh after tea consumption compared to the 
response after placebo, but this did not reach statistical significance (Figure 3, P = 0.32). No 
significant differences in the FBF-AUC responses between tea and placebo were found 
during infusion of SNP and L-NMMA (Figure 3). Throughout the study, contralateral FBF 
remained constant (data not shown). 
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Figure 3. Mean (±95% CI) forearm blood flow area under the curve during infusion of acetylcholine 
(ACh, administered at 5, 10, 20 and 40 μg/mL) sodium nitroprusside (SNP, administered at 2, 4, and 
8 μg/mL) and NG-Monomethyl-L-arginine (L-NMMA, administered at 2, 4 and 8 μmol/mL) after 
consumption of ~400 mg tea flavonoids (open bars) or placebo (shaded bars). 
Analyzing data as FVR or FBF ratio, minimizing the impact of changes in blood pressure, or 
potential systemic effects of the study drugs, revealed no significant differences between 
tea and placebo during infusion of ACh or L-NMMA (all P > 0.10, Table 2). Whilst FVR did not 
differ between tea and placebo for SNP infusion, FBF-ratio response to SNP was different 
between both trials, with a larger FBF-ratio response after placebo compared to tea (Table 
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2, P = 0.04). The difference in change over time were not statistically significant between the 
two interventions however (SNP dose*treatment interaction: P = 0.65). 
Discussion 
Epidemiological data suggest the presence of an inverse association between consumption 
of tea beverages prepared from the leaves of Camellia sinensis and the risk of stroke as well 
as prominent risk factors thereof such as blood pressure and arterial stiffness.24-26 
Reductions in blood pressure following continued tea consumption provide a plausible 
explanation for these epidemiological observations.10, 11 This acute intervention study aimed 
to determine whether the consumption of a black tea beverage, providing approximately 400 
mg flavonoids, would result in acute effects on forearm resistance artery endothelial 
function – an important blood pressure regulatory mechanism. In contrast to our 
hypothesis, we did not find a statistically significant increase in endothelium-dependent 
vasodilation in forearm resistance vessels compared to placebo in healthy middle-aged 
subjects. 
Our findings are in contrast to a few previous intervention studies, which have found some 
evidence for acute effects of tea consumption on resistance arteries. For example, Fuchs et 
al. found tea intake to prevent significant elevation in postprandial forearm vascular 
resistance.14 Furthermore, Oyama et al. found significant increases in both ACh and reactive 
hyperemia-induced changes in FBF two hours after consumption of a large dose of isolated 
green tea flavonoids in smokers.15, 27 Direct comparisons between these studies and ours, 
however, is difficult since important differences are present between studies. Whilst we 
included healthy middle-aged subjects, previous work included subjects with increased risk 
for cardiovascular disease with a priori endothelial dysfunction (i.e. smokers and insulin 
resistant obese), potentially making it easier to observe an effect from a food product to 
improve endothelial function. Secondly, we explored the impact of ~3 cups of normal black 
tea to match a real-life situation, whilst previous work examined isolated tea flavonoids and 
compared this with low or placebo-controlled caffeine content. Nonetheless, the 23% 
increase in the FBF-AUC response to ACh that was observed in healthy middle-aged 
subjects was within the expected range based on the abovementioned studies. However, due 
to a larger variation than expected, this effect was not statistically significant.  
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Despite the blood pressure lowering effects of its longer term consumption,10, 28 tea has 
previously been demonstrated to have acute pressor effects, possibly due to the caffeine 
content. 29 In accordance with these findings, we did see a statistically significant increase 
in MAP during the ACh infusion protocol (Table 2). The effect was short-lived however and 
was not evident during infusion of SNP or L-NMMA. It is unlikely that the change in MAP 
affected the FBF response to ACh infusion. Indeed, analyzing the data in terms of FVR and 
the blood flow ratio of the infused to the control arm (both of which correct for systemic 
hemodynamic changes which might affect local blood flow) did not alter the conclusions of 
our work.  
It is interesting to note that several previous human intervention studies have found 
improvements in brachial artery endothelial function, as measured by flow mediated dilation 
(FMD).13 Tea flavonoids and their metabolites may affect conduit artery FMD by improving 
NO bioavailability through stimulation of endothelial NO synthase activity and prevention of 
superoxide-mediated NO breakdown.30 We hypothesized that these effects would also be 
present at the resistance artery level. It is however important to note that that the values 
obtained by these two techniques do not always correlate,31, 32 suggesting that an 
intervention might elicit an effect in one vessel type but not another. As such, differential 
effects of blood pressure lowering drugs on conduit- versus resistance arteries, underlines 
the concept that endothelium is a paracrine organ, whose function/dysfunction can vary 
depending on which vascular district is explored or which stimulus is employed.33 
Tea ingestion acutely improves conduit artery endothelial function, with peak improvements 
in FMD seen within ~2 hours after intake.13 Longer duration studies have also demonstrated 
improvements in fasting FMD following continued tea intake for several days/weeks.34-36 
These findings suggest that the initial acute effects on endothelial function, in conduit 
arteries at least, following tea ingestion may become sustained with continued intake over 
longer time periods. Interestingly, sustained improvements in FMD following longer-term 
tea intake have in some cases been accompanied by reductions in blood pressure and 
measures of small vessel tone, 34 37, 38 suggesting that beneficial effects on resistance artery 
endothelial function might have been observed after a more prolonged (several days/weeks) 
exposure. This provides further support that acute and chronic effects of tea (on blood 
pressure, endothelial function) may not be interchangeable and that future studies are 
required to better understand the long-term effect of tea ingestion. 
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A potential factor which may have influenced the outcome of this study is the caffeine 
content (150 mg) of the test product. We did not control for caffeine in the placebo since our 
intent was to examine the impact of black tea on resistance artery endothelial function such 
as present in a real-life situation and not the effect of its individual components. It is however 
important to note that caffeine is a nonselective competitive antagonist of adenosine 
receptors, known to acutely increase peripheral vascular resistance and reduce resting 
blood flow in the forearm microcirculation.39 The effects of caffeine on endothelium-
dependent dilation in resistance and conduit arteries are not consistent however. Indeed, 
intake of a high dose of caffeine (300 mg) was found to augment the increase in FBF 
responses to ACh in one study,40 whereas studies on brachial artery FMD have produced 
conflicting results.35, 41-43 It is therefore difficult to conclusively comment on the potential 
confounding effects of caffeine in this study based on currently available evidence. 
Strengths of this study include the blinded within-subject crossover design and use of a 
robust measure of resistance artery endothelial function. Some limitations need to be taken 
into account. In this study FBF responses were assessed at 2 h after tea intake, a time-point 
based on the anticipated time of peak tea flavonoid plasma concentrations. Since we did not 
measure circulating or urinary levels of tea flavonoids or their metabolites, we could not 
confirm the time-course of the bioavailability. However, previous studies provided sufficient 
evidence for the elevation of flavonoids and their metabolites several hours after 
consumption of tea,21, 22, 44 which makes it unlikely that we failed to assess resistance artery 
responses during the peak in plasma flavonoid concentrations.  
In summary, this study does not support the hypothesis that tea consumption leads to an 
immediate improvement in resistance artery endothelial function in healthy middle-aged 
subjects. Further evidence is required, preferably from interventions with a longer duration, 
in order to determine whether tea consumption affects peripheral vascular resistance and 
if so, which mechanistic pathways are involved. 
  
148 | Chapter 6 
 
 
References 
[1] WHO, Global health risks: mortality and burden of disease attributable to selected major risks, World 
Health Organization, 2009. 
[2] Hu, D, Huang, J, Wang, Y, et al., Fruits and vegetables consumption and risk of stroke: a meta-analysis 
of prospective cohort studies, Stroke, 2014;45:1613-1619. 
[3] He, FJ, Nowson, CA, Lucas, M, et al., Increased consumption of fruit and vegetables is related to a 
reduced risk of coronary heart disease: meta-analysis of cohort studies, J Hum Hypertens, 2007;21:717-728. 
[4] Wang, X, Ouyang, YY, Liu, J, et al., Flavonoid intake and risk of CVD: a systematic review and meta-
analysis of prospective cohort studies, Br J Nutr, 2014;111:1-11. 
[5] Lajous, M, Rossignol, E, Fagherazzi, G, et al., Flavonoid intake and incident hypertension in women, Am 
J Clin Nutr, 2016;103:1091-1098. 
[6] Kay, CD, Hooper, L, Kroon, PA, et al., Relative impact of flavonoid composition, dose and structure on 
vascular function: a systematic review of randomised controlled trials of flavonoid-rich food products, Mol Nutr 
Food Res, 2012;56:1605-1616. 
[7] Vogiatzoglou, A, Mulligan, AA, Lentjes, MAH, et al., Flavonoid Intake in European Adults (18 to 64 Years), 
Plos One, 2015;10:e0128132. 
[8] Chun, OK, Chung, SJ and Song, WO, Estimated dietary flavonoid intake and major food sources of U.S. 
adults, J Nutr, 2007;137:1244-1252. 
[9] Arab, L, Khan, F and Lam, H, Tea consumption and cardiovascular disease risk, Am J Clin Nutr, 
2013;98:1651S-1659S. 
[10] Greyling, A, Ras, RT, Zock, PL, et al., The effect of black tea on blood pressure: a systematic review with 
meta-analysis of randomized controlled trials, PLoS One, 2014;9:e103247. 
[11] Peng, X, Zhou, R, Wang, B, et al., Effect of green tea consumption on blood pressure: a meta-analysis 
of 13 randomized controlled trials, Sci Rep, 2014;4:6251. 
[12] Folkow, B, The haemodynamic consequences of adaptive structural changes of the resistance vessels 
in hypertension, Clin Sci, 1971;41:1-12. 
[13] Ras, RT, Zock, PL and Draijer, R, Tea consumption enhances endothelial-dependent vasodilation; a 
meta-analysis, PLoS One, 2011;6:e16974. 
[14] Fuchs, D, Nyakayiru, J, Draijer, R, et al., Impact of flavonoid-rich black tea and beetroot juice on 
postprandial peripheral vascular resistance and glucose homeostasis in obese, insulin-resistant men: a 
randomized controlled trial, Nutrition & metabolism, 2016;13:34. 
[15] Oyama, J, Maeda, T, Kouzuma, K, et al., Green tea catechins improve human forearm endothelial 
dysfunction and have antiatherosclerotic effects in smokers, Circ J, 2010;74:578-588. 
[16] Wilkinson, IB and Webb, DJ, Venous occlusion plethysmography in cardiovascular research: 
methodology and clinical applications, British journal of clinical pharmacology, 2001;52:631-646. 
[17] Lakenbrink, C, Lapczynski, S, Maiwald, B, et al., Flavonoids and other polyphenols in consumer brews 
of tea and other caffeinated beverages, J Agric Food Chem, 2000;48:2848-2852. 
[18] Velioglu, YS, Mazza, G, Gao, L, et al., Antioxidant activity and total phenolics in selected fruits, 
vegetables, and grain products, Journal of agricultural and food chemistry, 1998;46:4113-4117. 
[19] Kuhr, S and Engelhardt, UH, Determination of flavanols, theogallin, gallic acid and caffeine in tea using 
HPLC, Zeitschrift für Lebensmittel-Untersuchung und Forschung, 1991;192:526-529. 
[20] Bhagwat, S, Haytowitz, DB and Holden, JMR, Database for the Flavonoid Content of Selected Foods, 
Release 3.1, In, U. S. Department of Agriculture, Agricultural Research Service. Nutrient Data Laboratory Home 
Page: http://www.ars.usda.gov/nutrientdata/flav, 2014. 
[21] Kyle, JA, Morrice, PC, McNeill, G, et al., Effects of infusion time and addition of milk on content and 
absorption of polyphenols from black tea, J Agric Food Chem, 2007;55:4889-4894. 
Black tea effects on forearm blood flow | 149 
 
 
[22] Lee, MJ, Maliakal, P, Chen, L, et al., Pharmacokinetics of tea catechins after ingestion of green tea and 
(-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability, Cancer 
Epidemiol Biomarkers Prev, 2002;11:1025-1032. 
[23] Thijssen, DH, Bleeker, MW, Smits, P, et al., Reproducibility of blood flow and post-occlusive reactive 
hyperaemia as measured by venous occlusion plethysmography, Clinical science, 2005;108:151-157. 
[24] Arab, L, Khan, F and Lam, H, Tea consumption and cardiovascular disease risk, Am. J. Clin. Nutr, 
2013;98:1651S-1659S. 
[25] Lin, QF, Qiu, CS, Wang, SL, et al., A Cross-sectional Study of the Relationship Between Habitual Tea 
Consumption and Arterial Stiffness, Journal of the American College of Nutrition, 2016;35:354-361. 
[26] Yang, YC, Lu, FH, Wu, JS, et al., The protective effect of habitual tea consumption on hypertension, 
Archives of internal medicine, 2004;164:1534-1540. 
[27] Oyama, J, Maeda, T, Sasaki, M, et al., Green tea catechins improve human forearm vascular function 
and have potent anti-inflammatory and anti-apoptotic effects in smokers, Internal medicine (Tokyo, Japan), 
2010;49:2553-2559. 
[28] Hodgson, JM, Puddey, IB, Woodman, RJ, et al., Effects of black tea on blood pressure: a randomized 
controlled trial, Archives of internal medicine, 2012;172:186-188. 
[29] Farag, NH, Whitsett, TL, McKey, BS, et al., Caffeine and blood pressure response: sex, age, and 
hormonal status, Journal of women's health (2002), 2010;19:1171-1176. 
[30] Grassi, D, Aggio, A, Onori, L, et al., Tea, flavonoids, and nitric oxide-mediated vascular reactivity, J Nutr, 
2008;138:1554S-1560S. 
[31] Ingelsson, E, Syvanen, AC and Lind, L, Endothelium-dependent vasodilation in conduit and resistance 
vessels in relation to the endothelial nitric oxide synthase gene, J Hum Hypertens, 2008;22:569-578. 
[32] Lind, L, Hall, J, Larsson, A, et al., Evaluation of endothelium-dependent vasodilation in the human 
peripheral circulation, Clinical physiology (Oxford, England), 2000;20:440-448. 
[33] Virdis, A, Ghiadoni, L, Qasem, AA, et al., Effect of aliskiren treatment on endothelium-dependent 
vasodilation and aortic stiffness in essential hypertensive patients, European heart journal, 2012;33:1530-1538. 
[34] Grassi, D, Mulder, TPJ, Draijer, R, et al., Black tea consumption dose-dependently improves flow-
mediated dilation in healthy males, Journal of Hypertension, 2009;27:774-781. 
[35] Duffy, SJ, Keaney Jr, JF, Holbrook, M, et al., Short-and long-term black tea consumption reverses 
endothelial dysfunction in patients with coronary artery disease, Circulation, 2001;104:151-156. 
[36] Hodgson, JM, Puddey, IB, Burke, V, et al., Regular ingestion of black tea improves brachial artery 
vasodilator function, Clinical science, 2002;102:195-201. 
[37] Grassi, D, Draijer, R, Desideri, G, et al., Abstract P061: Effects of Black Tea With and Without a Fat Load 
on Vascular Function in Mildly Hypertensive Subjects, Circulation, 2012;125:AP061. 
[38] Grassi, D, Draijer, R, Desideri, G, et al., Black tea lowers blood pressure and wave reflections in fasted 
and postprandial conditions in hypertensive patients: a randomised study, Nutrients, 2015;7:1037-1051. 
[39] Riksen, NP, Smits, P and Rongen, GA, The Cardiovascular Effects of Methylxanthines, In, 
Methylxanthines, Berlin, Heidelberg, Springer Berlin Heidelberg, 2011:413-437. 
[40] Umemura, T, Ueda, K, Nishioka, K, et al., Effects of Acute Administration of Caffeine on Vascular 
Function, The American Journal of Cardiology, 2006;98:1538-1541. 
[41] Papamichael, CM, Aznaouridis, KA, Karatzis, EN, et al., Effect of coffee on endothelial function in healthy 
subjects: the role of caffeine, Clin.Sci.(Lond), 2005;109:55-60. 
[42] Buscemi, S, Verga, S, Batsis, JA, et al., Acute effects of coffee on endothelial function in healthy 
subjects, European journal of clinical nutrition, 2010;64:483-489. 
[43] Shechter, M, Shalmon, G, Scheinowitz, M, et al., Impact of Acute Caffeine Ingestion on Endothelial 
Function in Subjects With and Without Coronary Artery Disease, The American Journal of Cardiology, 
2011;107:1255-1261. 
150 | Chapter 6 
 
 
[44] van Duynhoven, J, van der Hooft, JJJ, van Dorsten, FA, et al., Rapid and Sustained Systemic Circulation 
of Conjugated Gut Microbial Catabolites after Single-Dose Black Tea Extract Consumption, Journal of Proteome 
Research, 2014;13:2668-2678. 
 
Black tea effects on forearm blood flow | 151 
 
 
  
 
 
  
Chapter 7 
Effects of wine and grape polyphenols on blood pressure, 
endothelial function and sympathetic nervous system activity in 
treated hypertensive subjects 
Arno Greyling, Rosa M. Bruno, Richard Draijer, Theo Mulder, Dick H.J. Thijssen, Stefano Taddei, 
Agostino Virdis, Lorenzo Ghiadoni 
J Funct Foods. 2016 Dec;27:448-460. 
154 | Chapter 7 
 
 
Abstract 
In a randomized double-blind crossover trial, the effect of 8 weeks supplementation with 
grape and wine polyphenols on functional and structural vascular parameters and 
autonomic activity was evaluated in 40 essential hypertensive patients treated with diuretic 
monotherapy. Ambulatory blood pressure, brachial artery flow mediated dilation (FMD) and 
pulse-wave velocity (PWV) were measured at baseline and after each 8-week intervention. 
Forearm resistance artery endothelial function and muscle sympathetic nerve activity 
(MSNA) response to mental stress and cold-pressor test were measured in two separate 
sub-groups. No statistically significant differences were found across time or between 
groups in either blood pressure, FMD, PWV, resistance artery endothelial function. The 
MSNA response to the two stressors was non-significantly attenuated after grape-wine 
polyphenol supplementation. These results do not support the hypothesis that daily 
consumption of a high dose of grape and wine polyphenols lowers blood pressure or affect 
vascular function in patients already on antihypertensive medication. 
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Introduction 
Mediterranean dietary patterns may confer beneficial effects on the progression of 
cardiovascular disease (CVD).1 These diets are particularly rich in polyphenols, which 
represent secondary plant metabolites purported to mediate these beneficial effects on 
human health.2, 3 Wine is an important component of the Mediterranean diet and is rich in 
polyphenols. Epidemiological studies demonstrate that moderate wine drinkers show lower 
mortality rates than non-drinkers 4 and potential protective effects of grape derived 
polyphenols against certain types of cancer, diabetes, obesity and cardiovascular disease 
have also been reported.5 Polyphenols are potent antioxidants and have been shown to have 
anti-inflammatory and anti-atherogenic properties, such as inhibition of peroxyl radical-
induced DNA strand breakage, protection of low density lipoprotein from oxidative damage, 
inhibition of platelet aggregation and of the expression of adhesion molecules and of 
monocytes/macrophages adhesion to the endothelium.6-8 Moreover, recent work has also 
suggested these compounds act as inhibitors of alpha-glucosidase and lipase activity. 9 
Consequently, these properties may contribute to the health benefits of increased 
polyphenol intake in humans. 
Hypertension is one of the primary risk factors for CVD-related morbidity and mortality. 
Human intervention studies demonstrate that consumption of products rich in grape and 
wine polyphenols lower blood pressure, although the data are not entirely consistent.10-16 
The blood pressure lowering effects of grape-derived polyphenols may be mediated by 
improvement in resistance artery function and/or decreases in peripheral artery vascular 
tone. For example, studies with wine and grape extracts have demonstrated improved 
endothelial function in conduit and resistance arteries,17-19 possibly via nitric oxide 
dependent pathways.19 In addition, studies with tea and cocoa, i.e. prominent sources of 
dietary polyphenols, found improvement in indirect measures of sympathetic nervous 
system (SNS) activity patterns, possibly contributing to lowering of peripheral vascular 
tone.20, 21 
To date, most previous studies investigating the blood pressure lowering effects of wine 
and/or grape extracts were conducted in healthy participants or in non-medicated 
hypertensives.22 Such studies poorly translate to the majority of hypertensive patients who 
typically receive lifelong antihypertensive medication. Accordingly, the objective of the 
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current study was to determine whether 8-week consumption of a polyphenol-rich grape-
wine extract mix affect ambulatory blood pressure, endothelial function and muscle 
sympathetic nerve activity (MSNA) in drug treated patients with essential hypertension. We 
hypothesized that intake of a high daily dose of polyphenols lowers blood pressure, 
regardless of antihypertensive medication use, an effect mediated through improvement in 
resistance artery endothelial function and reduction in MSNA. 
Methods 
Participants 
Fifty-one hypertensive patients on diuretic monotherapy were recruited from the outpatient 
clinic of the University of Pisa (starting December 2009). Inclusion criteria were office 
systolic BP values ≥140 mm Hg and/or office diastolic BP values ≥90 mm Hg, which were 
confirmed on repeated occasions within one month according to current guidelines, if 
untreated or controlled (BP<140-90 mmHg) by diuretic therapy.23 Exclusion criteria were as 
follows: previous cardiovascular or cerebrovascular events, clinically significant 
arrhythmia, diabetes mellitus, smoking, clinically apparent liver disease or kidney damage, 
current treatment with statins and/or hormone replacement therapy, reported alcohol 
consumption > 28 units/week. The study protocol was approved by the local ethical 
committee of University Hospital of Pisa and was in accordance with guidelines in the 
Declaration of Helsinki. Patients gave their written informed consent to participation in the 
study after an explanation of its nature and purpose. 
Experimental design 
This study adopted a randomized, placebo-controlled, double-blind crossover design with 
two 8-week intervention periods. At an initial screening visit, eligible patients were given 
dietary advices for a standard Mediterranean diet and informed to drink no more than two 
units of alcohol per day. Moreover, the patients were instructed to moderate their intake of 
polyphenol-rich products throughout the study (less than two daily cups of coffee and/or 
tea; avoid dark chocolate and red wine). For the 48-h preceding the experimental days, 
subjects were instructed to avoid consumption of all polyphenol-rich foods in order to fully 
exclude the impact of background dietary polyphenols. 
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Following a 4-week run-in period, patients were randomly allocated to either grape-wine 
extract or placebo treatments. After an 8-week intervention, patients were crossed over to 
the other treatment. The diuretic dose was kept stable throughout the run-in and 
intervention periods. Measurements were performed on three different occasions, at 
baseline and immediately after each 8-week treatment period. Invasive measurements 
(forearm resistance vessel endothelial function and muscle sympathetic nerve activity) were 
conducted before and after the first 8-week intervention period only. Therefore, data on 
these measures are available in two different subsets of the study population (Figure 1). 
Intervention 
The grape-wine extract mix comprised of 870 mg of red wine extract (Provinols™; Seppic, 
France) and 540 mg grape juice extract (MegaNatural™ Rubired; Polyphenolics, USA). The 
total polyphenol content of the extract mix amounted to 800 mg (defined as gallic acid 
equivalents): 550 mg from the wine extract and 250 mg from the grape juice extract.  
The polyphenol composition of the red wine- and grape juice extracts was determined in 
duplicate by means of high-performance liquid chromatography with diode array detection 
(HPLC-DAD) and HPLC with electrospray ionization mass spectrometry (HPLC-ESI-MS) 
using an Agilent HPLC series 1100 equipped with ChemStation software as previously 
reported. 24 For determination of anthocyanins a mobile phase consisting of water, formic 
acid and acetonitrile and a Betasil C18 column (Thermo Scientific, 150 x 2.1 mm i.d., 5 µm 
particle size), with a Guard Column Cartridge was used. The individual anthocyanins were 
quantified via DAD using a calibration curve of cyanidin 3-O-glucoside (Roth, Karlsruhe, 
Germany), including a molecular weight correction factor.25 The identification and peak 
assignment were accomplished by simultaneous HPLC-ESI-MS analysis in the positive ion 
mode (selected ion monitoring) as well as in scan mode. Increase of the fragmentor voltage 
resulted in cleavage of the pigments and release of the anthocyanidin aglycones, which were 
identified by comparison of their m/z ratios with those described in the literature.26 
For determination of catechins, flavonols and stilbenes a mobile phase consisting of water, 
acetic acid and acetonitrile and a Synergi Hydro-RP column, (Phenomenex, 250 x 2mm i.d.; 
5µm particle size) with a Guard Column Cartridge, was used. The individual phenolic acids, 
catechins, flavonols and stilbenes were quantified using a calibration curve of the 
corresponding standard compounds (gallic acid, protocatechuic acid, p-hydroxybenzoic 
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acid, vanillic acid, caffeic acid, syringic acid, p-coumaric acid, ferulic acid, chlorogenic acid, 
gallocatechin, catechin, epicatechin, epicatechin-3-gallate, resveratrol (Sigma, St. Louis, 
USA); ellagic acid (Roth, Karlsruhe, Germany); myricetin, kaempferol-3-O-rutinoside 
(Extrasynthése, Lyon, France); quercetin-3-D-galactoside, quercetin-3--D-glucoside, 
quercetin-3-rhamnoside, quercetin (Fluka, Buchs, Switzerland)). The identification and 
quantification was accomplished by HPLC-ESI-MS analysis in the negative ion mode 
(selected ion monitoring). 
Analysis of the extracts revealed that each daily dose of the wine and grape extract mix 
contained approximately 140 mg anthocyanidins and 40 mg flavanols along with small 
amounts of flavonols, phenolic acids and stilbenes with the remaining polyphenolic portion 
of the extracts consisting of unidentified polymeric proanthocyanidins. Detailed 
compositional information of the extracts are reported in Table 1. Each daily dose was 
provided in six gelatine capsules (Capsugel Conisnap no. 0) which were taken at breakfast. 
Identical capsules containing microcrystalline cellulose (Avicel PH101, FMC Biopolymer) 
served as the placebo. Subjects were instructed to return all unused capsules at the end of 
each intervention period and compliance was determined by capsule counting. Average 
compliance was 88%. 
Experimental Measures 
Ambulatory blood pressure  
At baseline and at the end of each 8-week intervention period, a 24-hour ambulatory blood 
pressure recording was performed using a Spacelabs monitor (Type 90 217; Spacelabs 
Medical Inc.) placed on the non-dominant arm. Blood pressure was recorded at 15-min 
intervals throughout the day and at 20-min intervals during the night (11 PM – 8 AM). 
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Table 1. Polyphenol content of the red wine and grape juice extracts. 
 Wine (mg/g) 
Grape juice 
(mg/g) 
Total in 870 mg wine + 540 
mg grape juice 
Anthocyanins 21.50 225.85 140.66 
delphinidin 3,5-diglucoside 0.00 3.59 1.94 
cyanidin 3,5-diglucoside 0.00 1.78 0.96 
delphinidin 3-glucoside 0.47 3.23 2.15 
petunidin 3,5-diglucoside 0.00 10.32 5.57 
cyanidin 3-glucoside 0.11 1.29 0.79 
peonidin 3,5-diglucoside 0.00 46.05 24.87 
malvidin 3,5-diglucoside 0.00 82.75 44.69 
peonidin 3-glucoside 1.76 5.40 4.45 
malvidin 3-glucoside 9.26 11.66 14.35 
delphinidin 3-coumaroyl-5-diglucoside 0.00 3.53 1.91 
cyanidin 3-coumaroyl-5-diglucoside 0.00 0.93 0.50 
petunidin 3-coumaroyl-5-diglucoside 0.00 7.33 3.96 
delphinidin 3-coumaroylglucoside 0.35 1.09 0.90 
peonidin 3-coumaroyl-5-diglucoside 0.00 5.37 2.90 
malvidin 3-coumaroyl-5-diglucoside 0.00 34.51 18.63 
petunidin 3-coumaroylglucoside 0.46 0.70 0.78 
peonidin 3-coumaroylglucoside 0.80 0.65 1.04 
malvidin 3-coumaroylglucoside 5.36 5.66 7.72 
petunidin 3-glucoside 1.29 0.00 1.12 
peonidin 3-acetylglucoside 0.15 0.00 0.13 
malvidin 3-acetylglucoside 1.49 0.00 1.30 
Phenolic acids 7.89 5.22 9.68 
caffeic acid 1.27 0.30 1.26 
p-coumaric acid 0.68 0.46 0.84 
ferulic acid 0.07 0.09 0.11 
gallic acid 1.46 2.02 2.36 
protocatechuic acid 0.62 0.30 0.70 
p-hydroxybenzoic acid 0.20 0.08 0.21 
vanillic acid 0.39 0.19 0.45 
syringic acid 1.02 1.00 1.42 
caftaric acid 0.60 0.18 0.62 
coutaric acid 0.79 0.09 0.73 
fertaric acid 0.52 0.30 0.61 
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Table 1. Continued.    
ellagic acid 0.24 0.19 0.31 
chlorogenic acid (5-O-caffeoylquinic acid) 0.03 0.03 0.05 
Flavanols 45.18 0.40 39.52 
catechin 12.85 0.13 11.25 
epicatechin 12.17 0.10 10.64 
procyanidin B1 9.97 0.05 8.70 
procyanidin B2 6.78 0.02 5.90 
procyanidin C1 1.19 0.00 1.04 
gallocatechin 0.62 0.05 0.56 
epigallocatechin 0.20 0.00 0.17 
epicatechin-3-O-gallate 1.41 0.06 1.25 
Flavonols 4.82 9.48 9.31 
hyperoside (quercetin-3-O-galactoside) 0.13 0.10 0.17 
miquelianin (quercetin-3-O-glucuronide) 1.78 2.49 2.89 
isoquercitrin (quercetin-3-O-glucoside) 0.66 1.39 1.32 
qercitrin (quercetin-3-O-rhamnoside) + 
astragalin (kaempferol-3-O-glucoside) 
0.12 0.11 0.16 
quercetin 0.47 1.17 1.04 
kaempferol 0.05 0.16 0.13 
myricetin-3-O-glucoside 0.94 2.45 2.14 
myricetin 0.67 1.61 1.46 
Stilbenes 0.97 0.15 0.92 
polydatin 1* 0.37 0.06 0.35 
polydatin 2* 0.36 0.07 0.35 
trans-resveratrol 0.24 0.02 0.22 
* Presumably cis-trans-isomers    
 
Forearm resistance vessel endothelial function  
In a subset of 25 subjects (n=13 grape-wine, n=12 control), forearm resistance artery 
endothelial function was evaluated before and after the first 8-week intervention period by 
means of the isolated and perfused forearm technique as described previously.27 Briefly, the 
brachial artery of the non-dominant arm was cannulated for vasoactive drug infusion at 
systemically ineffective doses. Forearm blood flow was measured in the experimental and 
contralateral forearm by strain-gauge venous occlusion plethysmography. Forearm blood 
flow was calculated using standard formulae and expressed as mL/100 mL forearm 
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volume/min. To account for effects of potential arterial pressure variations, forearm 
vascular resistance (FVR) was calculated by dividing mean arterial pressure by forearm 
blood flow. 
Endothelium-dependent vasodilation was assessed by a dose-response curve to intra-
arterial acetylcholine (ACh; cumulative increase in infusion rates by 0.15, 0.45, 1.5, 4.5 and 
15 mg/100 mL forearm tissue per min, 5 min each dose). To evaluate the NO availability, the 
response to ACh was repeated in the presence of the NOS inhibitor NG-monomethyl-L-
arginine (L-NMMA, 4 mmol/min). 27 Because L-NMMA modifies blood flow, sodium 
nitroprusside (SNP; 0.2 mg/100 mL tissue/min for 5 min) was co-infused to neutralize the 
L-NMMA-induced vasoconstriction and restore baseline FVR. The role of reactive oxygen 
species (ROS) generation on endothelial function was investigated by repeating the ACh-
infusion protocol under co-infusion of ascorbic acid (8 mg/100 mL forearm tissue/min) as 
well as during co-infusion of L-NMMA and ascorbic acid. L-NMMA and ascorbic acid infusion 
were started 10 min before ACh-infusion and continued throughout this protocol. A 30 min 
washout was allowed between each dose–response curve, whilst this washout was 
consistently prolonged to 60 min when L-NMMA was infused. Finally, endothelium-
independent vasodilation was assessed with a dose-response curve to intra-arterial 
infusion of SNP (1, 2, and 4 mg/100 mL forearm tissue/min, 5 min each dose). To avoid 
making multiple comparisons, the responses to the vasoactive substances were expressed 
as the area under the curve (AUC) of change in FVR from baseline, expressed in arbitrary 
units. Analysis was performed by a single investigator (A.V.) blinded to the patient’s 
allocation to treatment. 
Muscle sympathetic nerve activity 
In a subset of 16 subjects (n=8 grape-wine, n=8 control), multiunit recording of efferent 
postganglionic muscle sympathetic nerve activity (MSNA) of the peroneal nerve was 
obtained using microneurography before and after the first 8-week intervention period. 
Briefly, a tungsten microelectrode with an uninsulated 1–5-μm-diameter tip (Medical 
Instruments, University of Iowa) was transcutaneously inserted in the peroneal nerve just 
posterior to the fibular head, as previously described.28 A reference electrode was inserted 
subcutaneously 1 to 3 cm from the recording site. The signal was integrated with a 0.1-s 
time constant, amplified with a gain of 50,000–80,000, band-pass filtered (700–2000 Hz), and 
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acquired at 1000 Hz through a digital acquisition system (ACQ-16; Gould Electronics). MSNA 
was identified according to previously outlined criteria.28, 29 Obtained neurograms were 
recorded together with BP and heart rate by means of dedicated computer software 
(Ponemah; LDS). Recordings were considered acceptable if the signal:noise ratio exceeded 
the value of 3. MSNA responses were measured at rest and during 2-min of mental stress 
(serial 7 subtraction 30) followed by 2-min of cold pressor test. Data were quantified as 
bursts/min (burst frequency) and bursts/100 heart beats (burst incidence). MSNA was 
analysed by visual inspection by a single investigator (R.M.B.) blinded to the patient’s 
allocation to treatment. 
Brachial artery flow mediated dilation 
Before and after both 8-week interventions, we examined brachial artery flow meditated 
dilation (FMD) using high-resolution ultrasound with a 10 MHz linear array transducer 
(MyLab25, ESAOTE, Florence, Italy), following recent guidelines as previously described.31 
Endothelium-independent dilation was obtained by sublingual administration of 25 μg 
glyceryl trinitrate (GTN). FMD and the response to GTN were calculated as the maximal 
percentage increase in diameter. Analysis of changes in brachial artery diameter was 
performed using a real-time computerized edge detection system, which is independent of 
investigator bias 32, 33 by a single investigator (L.G.) blinded to patient’s allocation to 
treatment. 
Arterial stiffness and wave reflection  
Before and after both 8-week interventions, we assessed arterial tonometry according to 
international recommendations using procedures previously described.34 A hand held probe 
was placed on the radial artery and 10–15 subsequent images were recorded. Radial 
pressure waveform was transformed into aortic pressure waveform by pulse wave analysis 
(PWA) (SphygmoCor, AtCor Medical) using a validated transfer function. Two successive 
measurements were recorded and averaged. Augmented pressure was calculated as the 
difference between the second systolic peak and the first systolic peak, and augmentation 
index (AIx) was calculated as the ratio between augmented pressure and pulse pressure. 
Since AIx is correlated with heart rate, values have been normalized at a heart rate of 75 
beats per minute. Aortic pulse wave velocity (PWV) was assessed with the same device, 
sequentially recording pressure waveforms at the femoral and carotid site. PWV was 
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calculated as the ratio of the surface distance between the two recording sites (subtracting 
the carotid–sternal notch distance from the femoral–sternal notch distance) and wave 
transit time. Analysis was performed by a single investigator (R.M.B.) blinded to patient’s 
allocation to treatment. 
Statistical analysis 
All statistical analyses were conducted using JMP version 11.0 (SAS Institute Inc., Cary, NC, 
USA). Descriptive statistics are presented as means and standard deviation (SD). All data 
are reported as LSmeans (95%CI), unless reported otherwise and was considered 
statistically significant at P<0.05. The change in outcome parameters of the invasive 
measurements (parallel-group study; FVR, MSNA) were analysed using a repeated 
measures ANCOVA with treatment as between-subject effect and period, ACh dose (for the 
FVR group) and stimulus (for the MSNA group) as within-subject effects and resting baseline 
measurement as covariate. The change in outcome parameters of the non-invasive 
measurements (FMD, PWV, PWA, blood pressure), which were performed before and after 
both interventions, were analysed using a mixed model with subject as random factor, 
treatment and period as fixed effects and the baseline measurement as covariate. 
Power calculations indicated that: 40 subjects (20 per intervention arm) would be sufficient 
to detect an absolute difference of 1% in the FMD response between treatments in a 
crossover study design with a 80% power and a 5% significance; 20 subjects (10 per 
intervention arm) would be sufficient to detect a difference between treatments in the 
expected mean change of 20% in the percent L-NMMA inhibition on ACh-induced 
vasodilation in the forearm microcirculation (80% power, 5% significance in parallel group 
study design); 16 subjects (8 per intervention arm) are sufficient to detect a difference 
between treatments in the expected mean change of 10% in MSNA (burst/minute) (80% 
power, 5% significance in a parallel study design). In the laboratory performing the 
evaluation, the coefficients of variation of the latter variables is less than 5%. 28, 35 
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Results 
Of the 51 subjects screened for inclusion, three were classified as screening failures as they 
all demonstrated blood pressure not ≤140/90 mmHg at the end of the run-in period. A 
further eight subjects did not complete the study procedures for personal reasons – five 
decided to not continue after Visit 0 and three more after Visit 1 (Figure. 1). No subjects were 
excluded during blind review. The Per Protocol and Intention to Treat study populations are 
thus equal and consist of 41 subjects that completed all study procedures of the first phase 
of the study and 40 subjects that completed all study procedures of the second phase of the 
study. Baseline characteristics are described in Table 2. 
 
Table 2. Subject characteristics from hypertensive patients included in the trial. Data 
are presented as mean ± SD 
Characteristics   
N 40  
Gender, females/males 4/36  
Age (years) 46.8 ± 9.0 
Weight (kg) 80.4 ± 8.2 
Body Mass Index (kg/m2) 26.1 ± 2.1 
Systolic blood pressure (mmHg) 141.1 ± 8.0 
Diastolic blood pressure (mmHg) 87.9 ± 5.0 
Plasma glucose (mg/dL) 93.0 ± 10.7 
Total cholesterol (mg/dL) 194.0 ± 38.0 
HDL cholesterol (mg/dL) 52.0 ± 12.0 
LDL cholesterol (mg/dL) 119.6 ± 33.5 
Triacylglycerol (mg/dL) 104.0 ± 51.6 
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Figure 1. Enrolment, randomization and experimental design of the study 
 
24-hour ambulatory blood pressure, large artery endothelial function and 
stiffness 
No statistically significant differences were found across time or between groups in either 
systolic- or diastolic blood pressure, FMD, GTN mediated dilation and PWV. Regarding PWA, 
no statistically significant changes were found across time or between groups in either 
central pulse pressure, augmentation pressure, AIx or AIx75 (Table 3). 
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Table 3. Hemodynamic and vascular measurements at baseline and the end of the grape-
wine and placebo intervention periods. Data are presented as raw unadjusted means ± 
SD 
 Baseline Grape-Wine Placebo P-value* 
24-h SBP (mmHg) 134 ± 9 131 ± 9 131 ± 9 0.9 
24-h DBP (mmHg) 81 ± 8 79 ± 8 79 ± 8 0.7 
24-h HR (bpm) 68 ± 9 68 ± 9 67 ± 8 0.5 
Day-time SBP (mmHg) 138 ± 10 136 ± 10 135 ± 9 0.8 
Day-time DBP (mmHg) 85 ± 8 83 ± 8 83 ± 8 0.8 
Day-time HR (bpm) 71 ± 9 72 ± 10 71 ± 9 0.3 
Night-time SBP (mmHg) 127 ± 9 125 ± 10 125 ± 9 0.6 
Night-time DBP (mmHg) 75 ± 8 73 ± 8 74 ± 8 0.4 
Night-time HR (bpm) 63 ± 9 62 ± 8 62 ± 8 0.7 
Baseline BAD (mm) 4.4 ± 0.8 4.5 ± 0.8 4.4 ± 0.8 0.07 
FMD (%) 4.8 ± 2.6 5.0 ± 2.7 5.2 ± 3.1 0.6 
GTN (%) 7.8 ± 3.8 7.2 ± 4.6 7.2 ± 3.1 0.9 
PWV (m/s) 7.9 ± 1.1 7.8 ± 1.1 7.7 ± 1.2 0.6 
Central PP (mmHg) 45.8 ± 10.2 44.2 ± 8.8 44.2 ± 8.7 0.9 
AIx (%) 27.9 ± 20 23.1 ± 12.5 24 ± 11.3 0.5 
AIx75 (%) 21.4 ± 13.6 18.3 ± 11.7 21.0 ± 14.8 0.2 
AP (mmHg) 13 ± 7.6 11.8 ± 8.4 12.2 ± 7.6 0.7 
SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; BAD, Brachial Artery Diameter; FMD, 
Flow Mediated Dilation; GTN, Glycerol Trinitrate induced dilation; PWV, Pulse Wave Velocity; PP, 
pulse pressure; AIx, Augmentation Index; AIx75, Augmentation Index corrected for heart rate of 75 
bpm; AP, Augmentation Pressure; * P-value refers to a mixed model with subject as random factor, 
treatment and period as fixed effects and the baseline measurement as covariate. 
 
Endothelium-dependent dilation in the microcirculation 
In both the grape-wine and placebo groups, the decrease in FVR in response to ACh infusion 
was larger after the 8-week intervention period (Time effect, P < 0.001, Figure 2). No 
Treatment effect or Time*Treatment*ACh Dose interaction was found, indicating that the 
change in FVR response to ACh-infusion was comparable between groups. Analysing the 
area-under-the-curve of the FVR response to ACh also revealed a change after the 
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intervention period (Time effect P < 0.001) that was not different between the two groups 
(Treatment effect, P = 0.19, Time*Treatment interaction, P = 0.43, Figure 3). 
 
Figure 2. Change in forearm vascular resistance induced by increasing doses of acetylcholine at 
before (Visit 0, closed symbols) and after 8 weeks’ intervention (Visit 1, open symbols) with grape-
wine extract (A) or placebo groups (B). P-values refer to a 3-way repeated measures ANCOVA with 
treatment (grape-wine vs placebo) as between-subject effect, period (Visit 0 vs 1) and stimulus as 
within-subject effects and resting baseline measurement as covariate. Data are presented as 
LSmeans (95% CI). 
Endothelium-independent dilation in the microcirculation 
FVR responses to SNP infusion were greater after the 8-week intervention period (Time 
effect, P = 0.02, Figure 3). No Treatment effect or Time*Treatment interaction was apparent 
however (P = 0.16 and P = 0.28 respectively). 
Nitric Oxide availability & ROS production 
Decreases in FVR in response to ACh were inhibited through co-infusion of L-NMMA, whilst 
the magnitude of inhibition was increased after the 8-week intervention period (Time effect, 
P = 0.02, Figure 3). This indicates a larger contribution of NO to resistance artery endothelial 
function after the intervention period. However, the magnitude of change across time did 
not differ between groups (Figure 3). 
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Co-infusion of Vitamin C with ACh caused a larger decrease in FVR at baseline, indicating a 
role for ROS production to increase resting vascular tone. The intervention was associated 
with an attenuated decrease in FVR during co-infusion of Vitamin C and ACh (“Time effect”, 
P = 0.01), whilst this effect was similarly present in both groups (Figure 3). Finally, we found 
that co-infusion of Vitamin C potentiated the increase in FVR induced by L-NMMA. After the 
intervention, the potentiating effect of Vitamin C on L-NMMA was reduced (Time effect, P = 
0.03), indicating that the improvement in L-NMMA responses after the intervention are, in 
part, mediated through decreased ROS production. Nonetheless, no Treatment effects or 
Time*Treatment interactions were found for the co-infusion of Vitamin C and L-NMMA 
(Figure 3). 
 
Figure 3. Change in forearm vascular resistance expressed as area under curve at baseline (grey 
bars) and after 8 weeks (black bars) in the grape-wine and placebo groups. Data are presented as 
LSmeans (95% CI). 
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Muscle sympathetic nerve activity 
Resting MSNA burst frequency and burst incidence did not change in either grape-wine or 
placebo groups after the 8-week intervention period (Figure 4). The increase in MSNA burst 
frequency in response to mental stress and cold pressor test was comparable after the 8-
week interventions. However, MSNA burst incidence during mental stress and the cold 
pressor test was attenuated after the 8-week intervention in the grape-wine group, whilst 
MSNA burst incidence during these tests increased after placebo. These differences were 
not statistically significant though (Figure 4, Time*Treatment interaction, P = 0.06, 
Time*Treatment*Stimulus interaction, P= 0.24). The increase in mean arterial pressure in 
response to mental stress and cold pressor test was comparable after the 8-week 
interventions. However, a statistically significant Time*Treatment interaction was found for 
the increase in heart rate in response to mental stress and cold pressor test. More 
specifically, heart rate during mental stress and the cold pressor test increased after the 8-
week intervention in the grape-wine group, whilst the increase was attenuated during these 
tests increased after placebo (Table 4). 
 
Table 4. Heart rate and blood pressure responses to mental stress and cold pressor test at 
baseline and the end of the grape-wine and placebo intervention periods. Data are 
presented as raw unadjusted means ± SD. 
 Grape-Wine Placebo ANCOVA P-value* 
Heart rate 
(beats/min) 
Visit 0 Visit 1 Visit 0 Visit 1 Time*Treatment 
Time*Treatment
*Stimulus 
Resting 62 ± 7 61 ± 10 69 ± 13 66 ± 12 
0.03 0.66 MS’2 71 ± 11 74 ± 12 81 ± 13 78 ± 10 
CPT’2 67 ± 17 71 ± 13 76 ± 15 74 ± 13 
MAP (mmHg) Visit 0 Visit 1 Visit 0 Visit 1 Time*Treatment 
Time*Treatment
*Stimulus 
Resting 100 ± 9 100 ± 12 104 ± 11 103 ± 12 
0.72 0.99 MS’2 114 ± 13 114 ± 14 115 ± 14 114 ± 13 
CPT’2 118 ± 15 122 ± 27 119 ± 16 121 ± 14 
MAP, Mean Arterial Pressure; MS’2, 2 min mental stress; CPT’2, 2 min cold pressor test. *P-value refers to a 
repeated measures ANCOVA with treatment as between-subject effect, period, and stimulus as within-subject 
effects and resting baseline measurement as covariate. 
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Figure 4. Change in MSNA burst frequency (A) and burst incidence (B) response to mental stress and 
cold pressor test before (Visit 0, closed symbols) and after 8 weeks intervention (Visit 1, open symbols) 
with grape-wine extract or placebo. P-values refer to a 3-way repeated measures ANCOVA with 
treatment (grape-wine vs placebo) as between-subject effect, period (Visit 0 vs 1) and stimulus as 
within-subject effects and resting baseline measurement as covariate. Data are presented as 
LSmeans (95% CI). 
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Discussion 
The aim of this study was to determine whether a high daily intake of grape and wine 
polyphenols affected blood pressure, endothelial function and MSNA in treated hypertensive 
subjects. We observed that 8 weeks supplementation with a mixture of grape and wine 
extracts, providing a daily dose of 800 mg polyphenols, did not result in changes in 24-hour 
ambulatory blood pressure compared to placebo. Furthermore, we found no effects of 
dietary intake of polyphenols on resistance- or conduit artery endothelial function, arterial 
stiffness or measures of resting SNS activity. However, we found an attenuated increase in 
MSNA during sympathetic stimulation in those who received daily grape-wine polyphenol 
supplementation. Taken together, these data suggest that neither ambulatory 24-h blood 
pressure nor measures of vascular function or tone are affected by grape and wine 
polyphenol intake in patients receiving antihypertensive medication. Possible beneficial 
effects of polyphenols may however be present by attenuating increases in autonomic stress 
reactivity, which is a possible determinant of poor cardiovascular outcome.36 
A recent, well-controlled study in untreated mildly hypertensive subjects, found small 
reductions in blood pressure and endothelin-1 after 4 weeks’ twice daily consumption of 
grape and wine polyphenols.37 Moreover, a recent meta-analysis of 10 studies (including 
mostly un-medicated subjects) indicated a small (1.5 mmHg) reduction in systolic blood 
pressure at an average dose of grape derived polyphenols close to that of our study.22 In the 
current “diseased” study population, it is plausible that a longer treatment duration may be 
needed to elicit a blood pressure lowering effect. Our observations are however in 
agreement with several previous studies, all which have found no effects of grape and/or 
wine polyphenols on blood pressure or measures of vascular function and stiffness in both 
healthy subjects and those with elevated CVD risk.10-12, 14, 38, 39  
Effects on blood pressure and vascular structure and function have been ascribed various 
different individual polyphenols and polyphenol classes present in grape-derived foods, with 
flavanols (e.g. catechin, epicatechin, epigallocatechin gallate) having the most robust 
evidence at this time.40 Isolated anthocyanins, stilbenes and flavonols have to varying extents 
also been associated with either beneficial effects on blood pressure, endothelial function 
or both, although the evidence is not entirely consistent.41-44 As such we opted to utilise a 
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mixture of two grape products in order to cover the spectrum of grape-related polyphenols 
normally found in the diet. 
Polyphenols are thought to improve endothelial function by increasing bioavailability of NO. 
Specifically, polyphenols may stimulate activity of endothelial nitric oxide synthase (eNOS) 
and prevent superoxide-mediated NO breakdown.45, 46 We specifically chose to include only 
subjects on diuretic monotherapy to avoid direct vascular effects of most other commonly 
prescribed anti-hypertensive agents.47 Thiazide diuretics, which were prescribed to the 
patients in our study, are known to have no effects on endothelial function.48-50 Therefore it 
seems unlikely that the use of diuretics would have obscured any potential effects of grape 
and wine polyphenols on measures of endothelial function in our study. 
Polyphenols are rapidly metabolized and eliminated from the circulation with peak plasma 
concentrations usually occurring a few hours after intake.51 Accordingly, several studies 
have found that intake of grape derived polyphenols resulted in increases in brachial artery 
FMD 30 to 120 minutes after intake.52 FMD and resistance artery endothelial function in our 
study was measured several hours after intake of the last dose of polyphenols. It is plausible 
that a transient improvement in endothelial function might have been missed due to the 
single daily dose regime and timing of the measurements. To our knowledge only one other 
study investigated the effects of red wine polyphenols on resistance artery responses to 
infusion of endothelium-dependent and independent agonists.19 In contrast to our findings, 
increases in both ACh and SNP mediated vasodilation were seen after daily consumption of 
red wine for 3 weeks in healthy young women. Time of wine ingestion (acute and the evening 
prior to measurements) differed from our study. This study did not include a control group 
however, so it is unclear what portion of the observed effects could be explained by the 
alcohol content of the wine.  
The polyphenol content of the background diet may also explain the lack of effects on blood 
pressure or endothelial function in the current study. Several prospective follow-up studies 
have found non-linear dose-response relationships between flavonoid intake and CVD risk, 
with low risks already occurring at relatively low levels of intake.53-55 Moreover, dose-
response studies of tea and cocoa flavonoids have found that the relative increases in FMD 
become smaller with increasing doses of flavonoids.56, 57 Given that the average polyphenol 
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content of the Italian diet is relatively high,3 it is plausible that additional grape and wine 
polyphenols would not have caused any demonstrable hemodynamic or vascular effects.  
It is well established that the SNS is involved in regulation of blood pressure and vasomotor 
tone.58 Studies of tea and cocoa polyphenols have found effects on indirect measures of SNS 
activity.20, 21 This led to us hypothesize that grape and wine polyphenol consumption would 
affect resting SNS activity as well as the extent of SNS activation in response to various 
stimuli. We found no change in resting SNS activity in response to grape and wine polyphenol 
consumption. However, the extent of SNS activation by mental stress and the cold pressor 
test was attenuated in the subjects receiving grape and wine polyphenols. This finding may 
be of clinical significance as elevated sympathetic and cardiovascular reactivity to stressful 
stimuli has been associated with the development of hypertension and cardiovascular 
disease.59-61  
The renin–angiotensin system may interfere with the sympathetic function and inhibition of 
angiotensin converting enzyme activity (ACE) has been shown to affect MSNA.62 Isolated 
polyphenols and polyphenol-rich foods have shown ACE inhibitory activity both in vitro and 
in vivo.63-65 Structure-activity relationship studies have found that the presence of: 1) a 
catechol group in the B-ring, 2) a double bond between C2 and C3 at the C-ring, and 3) a 
ketone group in C4 at the C-ring are important determinants of the level of ACE inhibitory 
activity.64 A number of the polyphenols found in wine and grape extracts are known to 
directly interact with the sympathetic and central nervous systems which might explain the 
MSNA effects observed in the present study.66-68 Notably resveratrol has been demonstrated 
to inhibit agonist-induced catecholamine synthesis and secretion by inhibiting nicotinic 
acetylcholine receptor-ion channels in the adrenal medulla and sympathetic neurons in in 
vitro studies.68 It is also noteworthy that AIx was differentially modified (although in a non-
significant manner) in the two intervention arms in the presence of similar values of AP and 
HR. This difference might be explained by the sympathoinhibitory effect of polyphenols 
suggested by the attenuation of autonomic reactivity to stress. Longer treatment might 
induce a greater reduction of AIx, contributing to a possible BP-lowering effect. These 
observations should be interpreted with caution though as the sub-group in which MSNA 
was measured was small (n=16) and the differences did not reach statistical significance.  
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Limitations: We did not measure circulating or urinary levels of polyphenol metabolites. 
Therefore, we cannot comment on the bioavailability of the polyphenols from the 
encapsulated extracts provided in our study. However, after a previous 4-week intervention 
with the same type and dose of grape and wine extracts provided in capsules, we found 
significant elevations in the subject’s urinary excretion of a wide range of phenolic acids.24 
This suggest that at least a portion of the polyphenols from the grape and wine extracts or 
their metabolites formed in the body’s tissues or the colonic microflora will typically reach 
the circulation. The subgroups in which we measured FVR and SNS activity were quite small. 
However, both techniques are highly reproducible and sensitive enough to reveal subtle 
changes.28, 35 Strengths of this study include the double-blind crossover design, long 
duration and the use of accurate 24-hour ambulatory blood pressure measurements 
combined with gold-standard measures of resistance artery endothelial function and SNS 
activity in the same subjects. We observed a consistent absence of effects of grape and wine 
polyphenols on resting blood pressure and across a range of integrated vascular and 
endothelial parameters related to its regulation. These observations support the robustness 
of our findings. 
In summary, this study does not support the hypothesis that 8 week once-daily consumption 
of a high dose of grape and wine polyphenols lowers resting blood pressure in subjects 
receiving antihypertensive medication. The potential of grape and wine polyphenols to 
attenuate over-responsiveness of the SNS should be confirmed in larger, well-controlled 
studies set up for this purpose. Future studies should also determine which subclasses of 
polyphenols common to different foods can lower blood pressure and improve endothelial 
function. It should also be determined whether potential vascular and hemodynamic effects 
vary by subject’s health- and treatment status. 
.  
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General discussion 
The endothelium is the central regulator of vascular homeostasis and impairment of its 
functionality is an early manifestation of cardiovascular disease (CVD), contributing to 
development and acceleration of the atherosclerotic process. Endothelial dysfunction, 
characterised by reduced bioavailability of nitric oxide (NO), presents itself long before overt 
pathophysiological changes occur, indicating that the endothelium is an important target for 
early prediction of future CVD, and interventions for primary and secondary prevention of 
CVD. As such, diet is an important determinant of CVD risk and the impact of dietary 
interventions in CVD prevention has been the subject of intense study and debate for many 
years. In addition to direct effects on traditional cardiovascular risk markers (e.g. 
dyslipidaemia, hyperglycaemia, hypertension & obesity), dietary factors may also directly 
impact endothelial function to influence cardiovascular risk.  
Currently, the most widely used non-invasive technique to study endothelial function in vivo 
is flow-mediated dilation (FMD) of the brachial artery. Previous work found that FMD has 
independent predictive value for risk of future CVD events 1, 2 and interventions can affect it 
within a relatively short time frame, 3 making the FMD a valuable tool for the evaluation of 
potential CV health effects of dietary and lifestyle related interventions. Various 
methodology- and subject related aspects critically impact variability and decrease 
reproducibility of the FMD response however, making comparison across trials difficult. The 
significance of these potential sources of variation has never been systematically studied. 
The aims of this thesis were, therefore, to firstly assess the impact of various factors on the 
reproducibility of brachial artery FMD, and secondly to explore the effects of dietary 
interventions (with specific interest in flavonoids) on endothelial function and pathways 
known to interact with the endothelium. In this final chapter, I briefly summarize the findings 
presented in the previous chapters and discuss their potential clinical relevance. Finally, 
some implications for the direction of future research are proposed. 
 
Brachial artery Flow Mediated Dilation – a useful tool if applied correctly. 
Brachial artery FMD is considered by many as the de-facto research tool for the non-invasive 
assessment of vascular endothelial function in vivo and its use as a surrogate end-point in 
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research studies has become increasingly popular in the decades following its introduction 
(Figure 1). This is likely due to the measurements’ non-invasive and seemingly simple 
methodology, independent predictive value for CVD risk and the ability to induce changes 
therein across a relatively short timeframe. Despite its apparently easy use, several 
methodological and physiological issues can impact the validity, reproducibility, and 
interpretation of FMD studies. These limitations were recognised and highlighted in early 
studies focusing on the physiological principles underlying the FMD. At the same time, 
efforts were made to provide guidance and consensus on methodology in order to provide 
minimum standard requirements for FMD measurement. 4, 5 These expert consensus 
guidelines are, however, not always consistently applied across studies with FMD outcomes. 
The importance of adherence to these guidelines on the reproducibility of FMD 
measurements has never been systematically evaluated before. 
 
 
Figure 1. Medline search results detailing the number of studies including flow mediated dilation as 
a key outcome published during the past 20 years, with the count of the number of studies in 2016 
representing exactly 6 months (i.e. up to July 1st 2016). 
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In Chapter 2 we conducted a systematic review of studies reporting on the reproducibility of 
the FMD in order to determine the relation between adherence to current expert consensus 
guidelines for FMD measurement and its reproducibility. Amongst the 27 studies included 
in the analyses, we found that the level of adherence to expert consensus guidelines, 
quantified in the form of an “adherence score”, was indeed inversely correlated with FMD 
measurement reproducibility. Moreover, when adopting the guidelines, we found that 
continuous recording of brachial artery diameter over the cardiac cycle, use of operator-
independent edge-detection and wall-tracking software, and under some circumstances the 
use of a probe holder is crucial to improve reproducibility of the FMD measurement. This 
demonstrates that rigorous adherence to current expert consensus guidelines for 
measuring brachial artery FMD along with the use of contemporary techniques is critical to 
minimise measurement error and decrease chances for type II errors in studies that rely on 
FMD as their primary outcome parameter. 
Data from human intervention studies are frequently combined, summarized and compared 
by means of meta-analyses and-or systematic reviews in order to reach consensus 
regarding the totality of the available evidence for a given intervention, association or field 
of research. Whilst there are a number of tools that are commonly used to gauge the 
potential limitations and risk of bias in randomised trials e.g. the Cochrane Collaboration 
Risk of Bias tool, 6 Jadad score, 7 the Delphi list 8 etc., they do not specifically focus on the 
potential impact of measurement methodology. The findings presented in Chapter 2 
suggest that in cases where FMD is the outcome of interest, the level of adherence to expert 
consensus guidelines reported by studies considered for inclusion in a meta-analysis should 
be carefully evaluated. Studies’ level of adherence to expert consensus guidelines can be 
quantified e.g. by applying the “Adherence Score” tool presented in Chapter 2c which we 
developed for this purpose. 
A remarkable example recently appeared in the literature that demonstrates the 
importance of including such a measure of adherence to FMD guidelines. Ramos et. al. 
conducted a systematic review and meta-analysis to compare the impact of high-intensity 
interval training (HIIT) versus moderate-intensity continuous training (MICT) on FMD. 9 Seven 
randomised trials were included in the meta-analysis. 10-16 Four of the included studies 
demonstrated significantly larger improvements in FMD after HIIT compared to MICT 
whereas the remaining three found no difference. The pooled effect sizes, indicated that the 
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improvement in brachial artery FMD was on average 2.3% (P<0.05) greater following HIIT 
compared to MICT (Figure 2). The authors concluded that HIIT is more effective at improving 
brachial artery FMD than MICT. However, applying the adherence score tool to the studies 
included in this meta-analysis reveals two clusters with remarkable differences in the 
reported levels of adherence to expert consensus guidelines (Figure 2). It is of note that the 
cluster of studies with a good level of reported adherence found no difference in FMD 
improvement between the two training modalities, whilst the cluster with a poor level of 
reported adherence found a large difference. The latter cluster constituted ~60% of the 
overall weight of the meta-analysis and thus strongly influenced the overall outcome. This 
demonstrates that reported quality of measurements should be taken into account to validly 
perform meta-analyses on FMD.  
 
Figure 2. Forest plot depicting the outcome of a meta-analysis comparing the effects of high-intensity 
interval training versus moderate-intensity continuous training on brachial artery FMD. The grey 
shaded area represents the studies that have a reported level of adherence to expert consensus 
guidelines for FMD measurement which is considered to be below the acceptable threshold. Adapted 
from Ramos et. al. 2015. 9 
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According to the data presented in Chapter 2, it can also be concluded that the level of 
adherence to expert consensus guidelines only explains a portion of the variation typically 
seen in FMD measurements. I.e. even fully adopting contemporary guidelines does not 
exclude presence of variation in FMD. In order to comprehensively explore factors 
contributing to the within-subject variability of brachial artery FMD, we compiled a dataset 
of 672 repeated FMD measurements, performed by different research laboratories adopting 
current expert consensus guidelines (Chapter 3). Several factors were identified that 
independently contributed to increased FMD measurement variability. These can be divided 
into two distinct groups: 
Subject-related factors: The presence of a lower baseline FMD and aspects typically 
associated with it i.e. older age, dyslipidaemia, hypertension and a higher baseline brachial 
artery diameter were related to larger variation in FMD%. In agreement with previous work, 
this indicates that FMD reproducibility may be lower in populations with increased CVD risk 
compared to healthy, young subjects. 17 
Methodology-related factors: Despite the level of standardization that adoption of expert 
consensus guidelines affords, some methodological variation can still occur between 
studies. The time between measurements emerged as a strong independent determinant of 
the variation in FMD. Our findings concur with data from a recent large reproducibility study 
which reported variation when comparing long (9 months) with medium (3 months) and 
short (2 days) timeframes between repeated measurements (Figure 3). 18 This is logical 
since a longer time between repeated measures will likely result in increased variability due 
to subtle methodological variations. Additionally it is also likely that true biological variability 
is greater under circumstances where the repeated measure is more distant in time. 
Lastly, a greater level of experience of a laboratory with the FMD technique was associated 
with smaller variation between repeated FMD measurements. Although this is a somewhat 
self-evident finding, it is nonetheless important, as it should guide laboratories who adopt 
the technique in attaining the level of practice and experience required before robust 
measures can be assumed. 
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Figure 3. Bland–Altman plot showing greater variability for long-term (A, within 9 months) compared 
with short-term (B, within 48 h) assessment of flow-mediated dilatation. Adapted from Charakida et. 
al. 2013. 18 
An important practical implication of these associations relates to the estimations of sample 
size and statistical power in studies. It is often the case that sample size calculations 
involving FMD are determined by means of a “one-size-fits-all” approach, using the 
generally available FMD measurement reproducibility data of the laboratory in question. The 
findings presented in Chapter 3 however suggest that sample size calculations should be 
based on estimates of FMD measurement reproducibility obtained under the same 
methodological conditions and in the specific study population one intends to study. 
Additionally, it should not be assumed that less experienced sonographers will attain the 
same level of reproducibility as their more experienced peers. These issues will likely be 
taken into account in well-experienced laboratories with dedicated sonographers and 
reproducibility data from diverse study populations at their disposal. Thus, FMD 
measurement methodology should not be seen as a “plug and play” measurement in 
settings where it is newly established. In these cases, appropriate investment should be 
made in training and quality improvement as outlined in expert consensus guidelines. 4, 5 
Additionally, in the absence of reproducibility data for a given sonographer in the study 
population in question, studies should be preceded by a reproducibility pilot in order to 
inform sample size calculations. 
Considering the widespread use of FMD, the abovementioned findings indicate that specific 
recommendations regarding the application of brachial artery FMD measurements in 
different research settings are warranted: 
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Meta-analyses with FMD as the outcome measure of interest:  
 The level of adherence to expert consensus guidelines for FMD measurement should 
be included in analyses in order to highlight potential effects on estimated outcomes, 
between study heterogeneity, and risk of bias.  
 Ideally, the adherence score should inform the decision on the in- or exclusion of 
studies of interest in meta-analyses, since inclusion of studies with low adherence 
to guidelines could potentially lead to spurious conclusions. 
Intervention and observational studies with FMD as the outcome measure of interest: 
 Measures of brachial artery diameter should be exclusively done by means of 
(semi)automated edge-detection and wall-tracking software; Manual techniques for 
measurement of artery diameter should be considered as unacceptable. 
 Sample size calculations should be based on estimates of FMD measurement 
reproducibility obtained under the same methodological conditions and the specific 
population one intends to study. 
 Journals should adopt specific reporting requirements for FMD methodology to 
allow for accurate estimation of studies’ level of adherence to guidelines; a citation 
and simple statement of adherence should be considered as insufficient. 
Finally, it is suggested that adherence to expert consensus guidelines and where applicable, 
adherence to the abovementioned recommendations should be seen as prerequisites for 
journals to accept FMD related studies for publication. 
To conclude, the findings presented in Chapters 2 and 3 of this thesis suggests that brachial 
artery FMD data generated in accordance with current expert consensus guidelines on 
measurement can be confidently compared across different studies. This knowledge can 
inform the pooling of subject-level data from many different laboratories for the purpose of 
establishing age-, sex- and CVD risk-factor specific reference values for brachial artery 
FMD. Such data will greatly aid in the appropriate interpretation of FMD-related data in the 
future.  
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The interaction between diet and endothelial function – a prime candidate for 
modulating cardiovascular disease risk? 
Diet is an important determinant of CVD risk through direct effects on traditional CV risk 
factors (e.g. dyslipidaemia, hyperglycaemia, hypertension & obesity), with the endothelium 
being affected either as a cause, a consequence or both. Moreover, with the endothelium 
situated at the interface of the blood and vessel wall, it is acutely affected by changes in 
blood associated with the post-prandial state. In Chapter 4 we demonstrated that 
hyperglycaemia, typically present after a carbohydrate-rich meal, results in a transient 
period of endothelial dysfunction. This phenomenon is well known 19 and likely mediated 
through reduced NO bioavailability as a result of hyperglycaemia-induced inhibition of eNOS 
and damage to the endothelial glycocalyx as well as increased production of vasoconstrictor 
prostanoids such as prostaglandin H2 and thromboxane A2. 20-23 In contrast, increases in 
blood flow and shear stress results in marked improvements in NO-mediated vasodilator 
function, likely as a result of shear stress-induced Akt-dependent phosphorylation of 
endothelial NO synthase (eNOS). 24 
One may speculate that repeated exposure to transient periods of endothelial dysfunction 
as a result of postprandial challenges contributes to the development of atherosclerosis, 
whereas repeated exposure to periods of increased blood flow and shear stress could 
counteract this process. In Chapter 4 we utilised a model involving unilateral forearm 
heating to demonstrate that non-metabolically driven increases in blood flow and shear 
stress can prevent a hyperglycaemia-induced decrease in FMD (Figure 4A). These findings 
suggest that interventions which are aimed at elevating blood flow or shear rate can prevent 
the hyperglycaemia-induced decline in conduit artery endothelial function which typically 
occurs after a meal. Indeed physical exercise, a strong stimulus for elevation in blood flow, 
performed after consumption of a meal has been found to confer a similar level of protection 
against the postprandial decline in endothelial function (Figure 4B). 25 
The concept of improving endothelial health via interventions that increase blood flow is 
further strengthened by recent studies demonstrating the detrimental effects of extended 
bouts of physical inactivity. An example of this is prolonged sitting which results in 
reductions in lower extremity blood flow, adversely affecting endothelial function in the 
process. 26-29 However, in accordance to the effects we observed in the upper extremities, 
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Restaino et. al. 27 found that increasing leg blood flow through local heating (Figure 4C) 
prevented the sitting-induced decline in popliteal artery FMD. Interestingly, and perhaps 
more applicably, also the simple behaviour of fidgeting (e.g. tapping of the heel at a natural 
cadence) is sufficient to induce a marked increase in blood flow and counteract the 
detrimental effects of prolonged sitting on leg endothelial function (Figure 4D). 26 
 
 
Figure 4. The effect of increasing blood flow via different interventions on ameliorating peripheral 
endothelial dysfunction induced by postprandial hyperglycaemia and prolonged sitting. Panel A & B: 
Brachial artery FMD before (0) and after 75g oral glucose (1, 2 and 3 hours) in the presence (open 
symbol) and absence (solid symbol) of local heating (A, Chapter 4) or a bout of aerobic exercise (B). 
Panel C & D: Popliteal artery FMD before (0) and after (3 hours) prolonged sitting in the presence 
(open symbol) and absence (solid symbol) of local heating (C) or intermittent fidgeting (D). Data are 
presented as mean ± SE. EX, exercise; FMD, flow mediated dilation; OGTT, oral glucose tolerance 
test. Adapted from Zhu et al 2007 (B, 25), Restaino et al 2016 (C, 27) & Morishima et al 2016 (D, 26). 
 
Considering that most humans (in Western society at least) spend the majority of their 
waking hours in a sedentary postprandial state, identifying interventions that can mitigate 
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its effects on the endothelium is of particular interest. The abovementioned observations 
warrant future studies to explore whether the immediate benefits of physical activity to 
prevent post-prandial endothelial dysfunction also relate to actual improvements in CVD 
risk. Additionally, it is needed to establish whether different dietary interventions could 
confer similar beneficial increases in blood flow through e.g. peripheral vasodilation and 
whether the combination with physical activity has additional beneficial effects. 
 
The effect of tea flavonoids on endothelial function – a mediator of other 
cardiovascular health benefits? 
Improvements in endothelial function and NO-mediated vasodilator capacity may also 
mediate changes in other CVD risk factors in addition to its direct benefit for cardiovascular 
health. One of the most extensively studied dietary components in this respect are 
flavonoids: secondary plant metabolites purported to have beneficial effects on human 
health. Epidemiological data suggest the presence of an inverse association between 
consumption of tea beverages prepared from the leaves of Camellia Sinensis, a prominent 
source of flavonoids in the human diet, and the risk of stroke. An increase of three cups per 
day in tea consumption was found to be associated with an approximately 10% decreased 
risk of stroke. 30 A possible explanation for this association might relate to the 
abovementioned effects of tea consumption on blood pressure. In Chapter 5 we assessed 
the available evidence on the blood pressure lowering effects of black tea consumption by 
means of a systematic literature review and meta-analysis of controlled human intervention 
studies. We found that regular tea consumption resulted in statistically significant 
reductions in systolic- and diastolic blood pressure of 2 and 1 mmHg, respectively. Tea 
consumption is known to affect conduit artery endothelial function as well 31, suggesting that 
this mechanism may be responsible for the observed blood pressure lowering effects.  
Blood pressure is however primarily regulated at the resistance artery level. 32 Therefore, 
to better understand whether resistance artery endothelial function plays a role in the blood 
pressure, we examined the acute effects of tea consumption on forearm resistance artery 
endothelial function in healthy middle-aged subjects (Chapter 6). No indication of tea-
induced changes in endothelium-dependent vasodilation of forearm resistance arteries 
were apparent however. We hypothesized that the observed effects on conduit artery 
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endothelial function would also be present at the resistance artery level. It is, however, 
important to note that the endothelium is a paracrine organ, whose function/dysfunction can 
vary depending on which vascular district is explored or which stimulus is employed. 33 As 
such, changes in conduit and resistance artery endothelial function are not always 
correlated, 34, 35 suggesting that an intervention might elicit an effect in one vessel type but 
not in another.  
A potential limitation of this study that has to be noted is that we were only able to examine 
the acute (2h) effects of tea. Beneficial effects on resistance artery endothelial function 
might become apparent only after a more prolonged (several days/weeks) exposure. As 
such, sustained improvements in conduit artery endothelial function following longer-term 
tea intake have in some cases been accompanied by reductions in blood pressure and 
measures of small vessel tone 36-38.  
It is also likely that the blood pressure lowering effects of tea are mediated through other 
pathways. In vitro studies have suggested that some tea flavonoids and specific flavonoid 
metabolites might actually function as potent angiotensin converting enzyme (ACE) 
inhibitors, although these effects have yet to be confirmed in human studies. 39 In any case, 
further studies are warranted with longer term durations in which changes in measures of 
resistance artery endothelial function can be related to changes in blood pressure as well 
as plasma ACE and NO activity. This should help to elucidate which specific mechanistic 
pathways are involved in the blood pressure lowering effects of tea. 
 
Shifting the bell-curve – how the small blood pressure-lowering effects of tea 
may matter at a population level. 
Although the reductions in blood pressure associated with tea consumption (Chapter 5) are 
modest from an individual's perspective, such reductions may translate to substantial 
reductions in CVD risk if applied on a population-wide scale. The potential impact of 
population-wide dietary interventions with similar small reductions in blood pressure have 
been previously illustrated. 40 van Mierlo et al estimated that increasing potassium intake, 
known to cause reductions in blood pressure in the same order of magnitude as tea, 41 could 
potentially shift population systolic blood pressure distributions to ~2-3 mmHg lower levels 
in different populations (Figure 5). This would result in a reclassification of ~2-8% of the 
General Discussion | 193 
 
population into the optimal systolic blood pressure range and ~2-5% of the population out 
of the hypertensive blood pressure range (Table 1). 
 
Table 1. Predicted percentage of Finnish (25-74 years), United Kingdom (19-64 years) and 
United States of America (≥20 years) males and females in systolic blood pressure 
categories before and after a theoretical increase in potassium intake and the expected 
change in percentage in the different systolic blood pressure categories. Adapted from 
van Mierlo et. al. 2010.40, 42 
  Prevalence in systolic blood pressure categories 
 
Systolic blood 
pressure (mmHg) 
Before potassium 
increase 
After potassium 
increase 
Change 
Finland     
Males <120 19% 20% +2% 
 120-139 41% 41% +1% 
 ≥140 41% 38% -2% 
Females < 120 30% 34% +4% 
 120-139 38% 38% 0% 
 ≥140 32% 28% -4% 
UK     
Males <120 25% 30% +5% 
 120-139 50% 50% 0% 
 ≥140 25% 20% -5% 
Females <120 45% 53% +8% 
 120-139 42% 37% -4% 
 ≥140 13% 9% -4% 
USA      
Males <120 44% 48% +5% 
 120-139 34% 33% -1% 
 ≥140 22% 19% -3% 
Females < 120 49% 55% +6% 
 120-139 28% 26% -2% 
 ≥140 23% 18% -4% 
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Globally roughly half of the incidence of cerebrovascular- and ischaemic heart disease are 
attributable to suboptimal blood pressure (systolic blood pressure >115 mmHg). 43, 44 
Moreover, data from the Prospective Studies Collaboration indicate that a 2 mmHg lower 
systolic blood pressure is associated with a 10% reduction in stroke mortality and about 7% 
lower mortality from ischemic heart disease or other vascular causes in middle aged 
subjects. 45 Considering that tea is a relatively cheap and easily accessible beverage, it would 
seem that promotion of tea consumption to the public can be an attractive strategy to 
improve population cardiovascular health. In fact, the Dutch Health Council included a 
recommendation for a daily intake of 2 to 3 cups of tea based on its effects on blood pressure 
and stroke risk. 46  
 
Figure 5. Potassium intakes (current intakes, g/d and differences from recommended level) and 
illustration of estimated impact on population systolic blood pressure after increasing potassium 
intake in Finland, United Kingdom and United States. *Assuming a linear 1 mmHg reduction in 
population systolic blood pressure per 0.6 g/d increase in intake up to a level of 4.7 g/d. Source: van 
Mierlo et. al. 2010. 40, 42 
 
Tea time – a simple intervention to reduce the population burden of 
cardiovascular disease? 
When considering recommendations on tea intake to improve cardiovascular health in the 
population, additional options should be explored. To further enhance the potential impact 
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of increasing tea intake, especially in a workplace environment, one could consider 
recommendations to break up the prolonged periods of sitting at the desk for a tea break. 
As mentioned earlier in this chapter, increased blood flow as a result of physical activity also 
has direct beneficial effects on endothelial health. 26, 28, 29 In addition to the interventions 
highlighted in Figure 4, it has also been demonstrated that relatively low intensity activity 
breaks (e.g. a 10 minute walk) is already able to restore endothelial dysfunction induced by 
prolonged sitting periods. 29 Both tea flavonoids and physical activity may affect conduit 
artery vasodilator capacity by improving NO bioavailability through stimulation of eNOS 
activity. 24, 47 How these interventions may interact and whether their combination could 
provide potential synergistic benefit with regard to cardiovascular health, is subject for 
future research. 
 
Assumption of population-wide effects – does one size fit all? 
An important assumption of the abovementioned population-wide recommendations is that 
all individuals will respond in the same way to an increase in tea intake, whilst this will likely 
not be the case due to a variety of different factors. For example, in our meta-analysis 
(Chapter 5) the magnitude of the blood pressure-lowering effect of tea ingestion seemed to 
be dependent on baseline blood pressure. We found that each 10 mmHg higher baseline 
systolic blood pressure was associated with a 1 mmHg larger effect size and a similar 
association was seen for diastolic blood pressure. Whilst this would imply that individuals 
with a higher resting blood pressure (and therefore higher risk for CVD) would potentially 
benefit more from tea consumption, the converse is also true, with individuals with lower 
blood pressure potentially seeing no added benefit (whilst we found no evidence for 
potentially detrimental effects of tea in those with low blood pressure). Other subject-
related factors such as use of blood pressure lowering medication may also contribute to 
variation in the blood pressure lowering response to increased tea intake. In Chapter 7 we 
demonstrated that supplementation with flavonoid-containing grape and wine extracts 
produced no additional beneficial effects on blood pressure or endothelial function in 
hypertensive patients already receiving antihypertensive medication. Although 
compositional differences preclude direct comparisons between the effects of tea- and 
grape-derived flavonoids, this study does suggest that the effects of tea on blood pressure 
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and CVD risk might differ according to antihypertensive treatment status. Alternatively, 
differences in effects may also be partly mediated through the route of ingestion, as direct 
tea exposure may have different effects than using components only. As such, larger studies 
to determine whether different population strata respond differently to increased tea intake 
and its polyphenols would provide useful input for future consideration of inclusion of tea in 
population-based dietary guidelines. 
 
Increasing tea intake – potential dual effects of replacing the not-so-good with 
something better. 
As already mentioned, intake of tea and other flavonoid rich foods show robust associations 
with reduced CVD risk in prospective follow-up studies. 48, 49 It is interesting to note that the 
majority of human intervention studies on cardiovascular health effects of tea and other 
sources of dietary flavonoids have focussed on intake on top of the usual diet. These studies 
therefore mainly addressed the effects of intake of additional supplemented flavonoids or 
flavonoid-rich foods (e.g. tea), but do not provide answers on the effects of replacement of 
foods with flavonoid-rich alternatives, which might be a more pertinent question. Taking tea 
as an example: Ferreira-Pêgo et. al. reported that the median fluid intake across different 
populations worldwide is approximately 2L per day. 50 Therefore, in a real-world context 
where a recommendation to drink 2 to 3 cups of tea is applied, it is likely that people will 
maintain a 2L intake per day and that increased tea ingestion will replace intake of other 
beverages. Tea consumed without additives is essentially a zero-calorie beverage. One 
could therefore speculate that the potential beneficial impact of tea might in part also be 
due to replacement of “less healthy” beverages in the diet (e.g. energy drinks, sugar-
sweetened soft-drinks, alcoholic- or specialty blended coffee beverages etc.) with tea. Such 
changes could explain a portion of the cardiovascular health effects traditionally ascribed to 
flavonoids. Whether this is indeed the case needs to be addressed in future research.  
 
Implications of the findings in this thesis for future research. 
This thesis examined 1) the importance of adherence to expert-consensus guidelines, and 
of methodological and subject-related factors for, the reproducibility of brachial artery FMD 
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and 2) the effects of dietary interventions (with specific interest in flavonoids) on endothelial 
function and pathways known to interact with the endothelium.  
Brachial artery FMD will likely remain to be seen as an important research tool in for 
studying the effects of diet and lifestyle interventions on cardiovascular health for the 
foreseeable future. We have demonstrated that it is possible to generate valid and 
reproducible data that can be compared across different laboratories and studies through 
strict adherence to current expert consensus guidelines and application of contemporary 
measurement techniques. A more tangible and quantifiable concept of the actual benefit of 
FMD changes for reducing CVD risk is still lacking though. In this regard, the development 
of age- and sex-standardised normative data for FMD will advance the utility of FMD as a 
biomarker of cardiovascular health. 
Normative data for brachial artery FMD will however only be a useful reference tool if data 
from different studies can be confidently compared. The findings presented in this thesis 
indicate that ignoring current expert-consensus guidelines causes significant variability of 
the FMD and, consequently, may lead to spurious conclusions. It is therefore proposed that 
journals should not publish research on FMD that does not comply with current guidelines 
for its measurement. In addition, current comparisons or meta-analyses of FMD data from 
different sources (e.g. to determine predictive capacity for future disease risk or to 
determine consensus on the effects of specific interventions) should only include studies 
with sufficient adherence to FMD guidelines.  
We found that consumption of tea has modest but significant effects on blood pressure 
which, when applied within a whole population context could potentially confer substantial 
reductions in CVD risk. 45 This idea is however based on an assumption that an increase in 
tea intake will be equally effective at lowering blood pressure across the entire population, 
which will likely not be the case. Indeed, we found that supplementation with grape extracts 
(another important source of dietary polyphenols) had no additional beneficial effect on 
blood pressure and endothelial function in hypertensive patients receiving blood pressure 
lowering medication. As such, future studies should determine whether different population 
groups respond differently to increased tea intake. This will help to determine the actual 
impact of increases in tea intake on cardiovascular health in the population. 
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English Summary 
In Chapter 1 the role of the endothelium as the central regulator of vascular homeostasis is 
discussed and an overview of the endothelium’s physiology and function is provided. 
Additionally the pathological processes which affect the endothelium along with how 
important cardiovascular risk factors upset the balance of its various functions to ultimately 
facilitate the process of atherosclerosis is discussed. Finally the main hypotheses and 
questions of this thesis are presented along with the studies and research methods 
employed to answer these questions. 
Currently, the most popular technique utilised for studying endothelial function in vivo is 
flow-mediated dilation (FMD) of the brachial artery. Minor changes in the methodology 
employed to measure FMD may critically impact variability and decrease reproducibility of 
the FMD response however. In Chapter 2 we investigated the importance of adherence to 
current expert consensus guidelines for FMD measurement in decreasing its measurement 
error by means of a systematic review of studies reporting on the reproducibility of the FMD. 
We found that the level of adherence to expert consensus guidelines, quantified in the form 
of an “adherence score”, was inversely correlated with FMD measurement reproducibility. 
Moreover, when adopting the guidelines, we found that continuous recording of brachial 
artery diameter over the cardiac cycle, use of operator-independent edge-detection and 
wall-tracking software, and under some circumstances the use of a probe holder is crucial 
to improve reproducibility of the FMD measurement. This demonstrates that rigorous 
adherence to current expert consensus guidelines for measuring brachial artery FMD along 
with the use of contemporary techniques is critical to minimise measurement error and 
decrease chances for type II errors in studies that rely on FMD as their primary outcome 
parameter. 
Some variation in FMD still remains even with full adoption of contemporary guidelines. In 
Chapter 3 we comprehensively explored factors contributing to the within-subject variability 
of brachial artery FMD by compiling a dataset of 672 repeated FMD measurements, 
performed by different research laboratories adopting current expert consensus guidelines. 
Whilst FMD data showed good overall reproducibility, larger variation was observed in 
conditions with longer time between measurements and also in the presence of a lower 
baseline FMD and aspects typically associated with it i.e. older age, dyslipidaemia, 
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hypertension and a higher baseline brachial artery diameter. Conversely, a greater level of 
experience of a laboratory with the FMD technique was associated with smaller variation 
between repeated FMD measurements. Accounting for these factors will importantly 
decrease variability of the FMD and should be seen critical considerations when determining 
the sample size of studies that rely on FMD as their primary outcome parameter. 
With the endothelium situated at the interface of the blood and vessel wall, it is acutely 
affected by changes in blood associated with the post-prandial state. For example, 
hyperglycaemia, commonly present after a meal, causes a transient impairment in 
endothelial function. Therefore, diet can be seen as an important determinant of 
cardiovascular disease risk through its effects on endothelial function. In Chapter 4 we 
examined whether local increases in blood flow protect against the hyperglycaemia-
mediated decrease in brachial artery endothelial function in healthy subjects and patients 
with type 2 diabetes mellitus (T2DM). We demonstrated that a glucose load caused a 
transient decrease in FMD, whilst an increase in blood flow (mediated by local heating of the 
forearm) significantly prevented this decline in both healthy subjects and patients with 
T2DM. Thus, non-metabolically driven elevation in blood flow and shear rate can similarly 
prevent the hyperglycaemia-induced decline in conduit artery endothelial function in healthy 
volunteers and in patients with type 2 diabetes.  
One of the most extensively studied dietary components with regard to cardiovascular 
health are flavonoids. Epidemiological evidence has linked consumption of black tea, a 
prominent source of flavonoids in the human diet, with a reduced risk of cardiovascular 
diseases. A potential explanation for these associations relates to the effects of tea 
consumption on blood pressure. In Chapter 5 we assessed the available evidence on the 
blood pressure lowering effects of black tea consumption by means of a systematic 
literature review and meta-analysis of controlled human intervention studies. Eleven 
randomised controlled trials, including a total of 378 subjects, were included in the analysis. 
We found that regular tea consumption resulted in statistically significant reductions in 
systolic- and diastolic blood pressure of 2 and 1 mmHg, respectively. Although these 
reductions in blood pressure are modest from an individual's perspective, such reductions 
may translate to substantial reductions in cardiovascular disease risk if applied on a 
population-wide scale. 
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The blood pressure lowering effects of tea may be mediated through improvements in the 
endothelial function of resistance arteries. In Chapter 6 we examined the acute impact of 
black tea intake on forearm resistance artery endothelial function in healthy, middle-aged 
subjects. No evidence that acute intake of black tea significantly altered endothelium-
dependent vasodilation of forearm resistance arteries could however be found. These 
findings suggest that beneficial effects on resistance artery endothelial function might 
become apparent only after a more prolonged (several days/weeks) exposure or that the 
blood pressure lowering effects of tea intake might be mediated via mechanisms not related 
to resistance arteries.  
Red wine and grapes represent another source of dietary flavonoids, and increased intake 
of red wine and grapes has been linked with a reduced risk of CVD. Most previous studies 
on the blood pressure lowering effects of wine and/or grape extracts have been conducted 
in healthy participants or in non-medicated hypertensives making it difficult to translate the 
outcomes to the majority of hypertensive patients, who typically receive lifelong 
antihypertensive medication. In Chapter 7 we studied the effects of 8-week consumption of 
a grape-wine extract mix on ambulatory blood pressure, endothelial function and muscle 
sympathetic nerve activity in drug treated patients with essential hypertension. The 
intervention, did not result in changes in 24-hour ambulatory blood pressure, resistance- 
or conduit artery endothelial function, arterial stiffness or measures of resting sympathetic 
nervous system activity compared to placebo. However, we found an attenuated increase in 
muscle sympathetic nerve activity during sympathetic stimulation in those who received 
daily grape-wine polyphenol supplementation. These data suggest that neither blood 
pressure nor measures of vascular function or tone are affected by grape and wine 
polyphenol intake in patients receiving antihypertensive medication. Possible beneficial 
effects may however be present by attenuating increases in autonomic stress reactivity, 
which is a possible determinant of poor cardiovascular outcome. 
In Chapter 8 the outcomes of the studies presented in this thesis are summarised and 
discussed in the broader context of previous work. We reiterate the critical need for 
adherence to expert consensus guidelines for FMD measurement when using the technique 
to study endothelial function and make specific recommendations regarding the application 
of brachial artery FMD measurements in different research settings. We also address the 
potential importance of recommendations to increase the consumption of flavonoid-rich 
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foods like tea and the possible beneficial effects on population cardiovascular health. 
Finally, we highlight unanswered questions and attempt to give direction for future 
research.
208 | Samenvatting 
 
 
Nederlandse Samenvatting 
In Hoofdstuk 1 wordt de rol van de binnenbekleding van de bloedvaten, het endotheel, als 
de centrale regelgever van vasculaire homeostase uiteen gezet en verder wordt een 
overzicht van de fysiologie en de functies van het endotheel verstrekt. Tevens word diversen 
pathologische processen die van invloed zijn op het endotheel besproken, evenals hoe 
belangrijke cardiovasculaire risicofactoren het evenwicht van de verschillende endotheel 
functies verstoren om uiteindelijk het proces van atherosclerose te faciliteren. Tot slot 
worden de belangrijkste hypothesen en de vragen van dit proefschrift, en de gebruikte 
onderzoeksmethoden gepresenteerd.  
Momenteel is de meest populaire techniek voor het in vivo bestuderen van endotheelfunctie 
de flow-gemedieerde dilatatie (FMD) van de arteria brachialis. Kleine veranderingen in 
meetmethoden kunnen echter een grote invloed op het variabiliteit en reproduceerbaarheid 
van het FMD-respons hebben. In Hoofdstuk 2 onderzochten we daarom het belang van het 
naleven van de huidige expert richtlijnen voor FMD metingen met betrekking tot het 
verminderen van de meetfout. We deden dit door middel van een systematisch review van 
studies die de reproduceerbaarheid van FMD als methode onderzochten. We vonden dat de 
mate waarin de expert richtlijnen worden nageleefd, gekwantificeerd in de vorm van een 
'naleving score', een omgekeerde correlatie vertoonde met de reproduceerbaarheid van de 
FMD metingen in deze studies. Tevens vonden we dat bepaalde meet methoden, namelijk 
het continue meten van de arteria brachialis diameter over de cardiale cyclus, het gebruik 
van onderzoeker-onafhankelijke meetsoftware, en onder bepaalde omstandigheden, het 
gebruik van een sonde houder, van cruciaal belang zijn voor het verbeteren van de 
reproduceerbaarheid van FMD metingen. Dit toont aan dat het naleven van huidige expert 
richtlijnen voor het meten van FMD en het gebruik van hedendaagse technieken, essentieel 
zijn om meetfouten en de kans op type II fouten te minimaliseren in studies die afhankelijk 
zijn van FMD als hun primaire uitkomstmaat. 
Zelfs als we de huidige expert richtlijnen volledig naleven, blijft er enige meetvariatie in FMD 
uitkomsten. In Hoofdstuk 3 onderzocht we welke factoren bijdragen aan de binnen-persoon 
variabiliteit van FMD metingen. Voor dit doel werd een dataset van 672 herhaalde FMD 
metingen, uitgevoerd door verschillende onderzoekslaboratoria die huidige expert 
richtlijnen naleven, opgesteld. FMD data toonde in het algemeen goede 
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reproduceerbaarheid. Grotere variaties tussen herhaalde metingen werden waargenomen 
wanneer er langere tijd zat tussen de metingen, en ook in aanwezigheid van een lagere 
basale FMD en aspecten die doorgaans hiermee samenhangen, d.w.z. oudere leeftijd, 
dyslipidaemia, hypertensie en een hogere basale arterialis brachialis diameter. Omgekeerd, 
werd een hoger ervaringsniveau van een laboratorium met de FMD techniek geassocieerd 
met kleinere variatie tussen herhaalde metingen. Inachtneming van deze factoren kan dus 
de variabiliteit van FMD metingen verkleinen, en verdient daarom een kritische overweging 
bij het bepalen van de steekproefgrootte van studies met FMD als primaire uitkomst-
parameter. 
Het endotheel dient als een functionele interface tussen het bloed en de vaatwand en word 
direct beïnvloed door postprandiale veranderingen in het bloed. Zo veroorzaakt 
hyperglycemie, vaak aanwezig na een maaltijd, bijvoorbeeld een tijdelijke verslechtering van 
de endotheel functie. In Hoofdstuk 4 bestudeerden we het beschermende effect van een 
lokale verhoging van de doorbloeding in de arterialis brachialis op de endotheeldysfunctie 
veroorzaakt door hyperglycemie na een maaltijd in gezonde proefpersonen en in patiënten 
met type 2 diabetes mellitus (T2DM). Glucose inname veroorzaakte een tijdelijke afname in 
endotheel functie, terwijl een toename van de doorbloeding (in dit geval veroorzaakt door 
verwarming van de onderarm) deze afname voorkwam, en dus een beschermend effect had, 
in beide groepen. Dus, het bevordering van de doorbloeding kan endotheeldysfunctie 
veroorzaakt door hyperglycemie voorkomen bij gezonde vrijwilligers evenals bij patiënten 
met type 2 diabetes. 
Flavonoïden zijn stoffen in het dieet die vaak bestudeerd worden in relatie tot hart en 
vaatziekten. Zo hebben epidemiologische studies een link gelegd tussen consumptie van 
zwarte thee, een belangrijke bron van flavonoïden in het dieet, en een lagere risico op hart 
en vaatziekten. Deze relatie kan mogelijk verklaard worden door het effect van 
theeconsumptie op bloeddruk. In Hoofdstuk 5 bestudeerden we het effect van zwarte thee 
op bloeddruk in een meta-analyse van 11 gerandomiseerde, gecontroleerde studies. We 
toonden aan dat consumptie van zwarte thee de systolische en diastolische bloeddruk 
verlaagt met respectievelijk 2 en 1 mmHg. Alhoewel klein op individuele niveau, zijn dit soort 
effecten zeer relevant op bevolkingsniveau, met name in relatie tot een verlaagde risico op 
hart en vaatziekten. 
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De bloeddrukverlagende effecten van thee worden waarschijnlijk gemedieerd door een 
verbeterde endotheelfunctie van het weerstandsvaten. In Hoofdstuk 6 hebben we gekeken 
naar de acute effecten van zwarte thee inname op endotheelfunctie van het 
weerstandsvaten in gezonde personen van middelbare leeftijd. We vonden echter geen 
significante effecten van thee consumptie op de tonus van de weerstandsvaten in deze groep 
proefpersonen. Deze bevindingen wijzen er op dat de bloeddrukverlagende effecten van 
theeconsumptie waarschijnlijk niet gerelateerd zijn aan een verbeterde endotheelfunctie 
van de weerstandsvaten. 
Flavonoïden worden ook aangetroffen in druiven en daarmee ook in rode wijn, waarvan de 
consumptie ook geassocieerd wordt met een verlaagd risico op hart en vaatziekten. De 
meeste eerdere onderzoeken naar de bloeddrukverlagend effecten van wijn- en 
druivenextracten zijn echter uitgevoerd in gezonde personen of in mensen met hypertensie 
die geen bloeddrukverlagende medicatie gebruiken. Daardoor is het moeilijk om de effecten 
te vertalen naar hypertensieve patiënten, die meestal levenslang antihypertensieve 
medicatie gebruiken. In Hoofdstuk 7 bestuderen we de effecten van dagelijkse consumptie 
van een druiven-en-wijnextract durende 8-weken op bloeddruk, endotheel functie en de 
activiteit van het sympathische zenuwstelsel in hypertensieve patiënten die 
antihypertensieve medicatie gebruiken. In tegenstelling tot onze hypothese vonden wij in 
deze groep geen effecten op bloeddruk, endotheel functie, arteriële stijfheid of de basale 
activiteit van het sympathische zenuwstelsel. We vonden wel echter een verminderde 
stijging in sympathische activiteit tijdens sympathische stimulatie. Deze bevindingen wijzen 
erop dat consumptie van druiven-en-wijnpolyfenolen geen extra effect heeft op bloeddruk 
en vaatfunctie in patiënten die reeds antihypertensieve medicatie gebruiken. Er is echter 
wel mogelijke gunstige effecten op autonomen regulatie.  
In Hoofdstuk 8 vatten we de resultaten van de verschillende studies in dit proefschrift 
samen en bespreken we deze resultaten in de bredere context van eerdere werk. We 
beklemtonen het belang van het voldoende naleven van de expert richtlijnen voor FMD 
metingen en doen daarbij ook specifieke aanbevelingen wat betreft de toepassing van deze 
meettechniek bij verschillende soorten onderzoek. Tevens bespreken we het potentiële 
belang van aanbevelingen om flavonoïde-rijke voedsel zoals thee te consumeren, en de 
mogelijke gunstige effecten daarvan op de hart en vaatgezondheid van de algemene 
Samenvatting | 211 
 
 
bevolking. Tot slot, vestigen we de aandacht op een aantal onbeantwoorde vragen en doen 
we suggesties voor toekomstig onderzoek. 
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“I meant," said Ipslore bitterly, "what is there in this world that truly makes living worthwhile?" 
Death thought about it. 
CATS, he said eventually. CATS ARE NICE.”  
― Sir Terry Pratchett, Sourcery
  
  
 
